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Atherosclerosis 
Clinical implications 
The life expectancy and disease profile of human societies are known to be correlated 
with the level of their economic development and social organization. Upon 
industrialization, the major cause of death shifted from nutritional deficiencies and 
infectious diseases towards degenerative diseases including cardiovascular diseases 
(CVD), cancer and diabetes1. With 1.92 million people dying each year of coronary heart 
disease and 1.42 million of stroke, CVD include the first and the second most common 
cause of death in Europe2,3. Both diseases are characterized by the disturbance of blood 
flow in coronary or cerebral arteries respectively, in the majority of the cases a result of 
a progressing or rupturing atherosclerotic plaque. This makes the atherosclerotic 
plaque an extremely important phenomenon to study. 
Atherosclerosis literally means hardening of the arteries (“sclerosis”) due to the 
accumulation of lipids, cells and connective tissue (“atheroma”). It is a progressive 
disease characterized by the thickening and loss of elasticity of the walls of large and 
medium sized arteries. Most probably almost everyone in western society suffers from 
this disease but its progression usually occurs without clinical symptoms because the 
artery compensates for the narrowing lumen by remodeling and thereby enlarging its 
diameter4. Though a chronic disease, clinical symptoms are often acute and occur 
either upon (partial) occlusion of an artery by a growing atherosclerotic lesion beyond 
the ability to compensate for it or upon rupture of an instable lesion with the formation 
of a thrombus. Depending on the location of the plaque, blood flow in the downstream 
organ will be disturbed resulting in a wide variety of symptoms. Atherosclerosis in the 
coronary arteries can cause angina pectoris or myocardial infarction whereas in the 
carotid arteries it can result in transient cerebral events or stroke. In the peripheral 
circulation it might cause many different manifestations including acute limb ischemia, 
gangrene, ischemic renal failure, hypertension, mesenteric ischemia and bowel 
infarction5. 
Several risk factors determine the progression of an atherosclerotic plaque, most of 
them well-known like a Western-type diet, smoking, hypertension, obesity, a lack of 
physical exercise, diabetes and age, others less known like infectious agents and 
elevated homocysteine levels6-8. Up to now, therapy strategies focus on the reduction 
of these risk factors, managing lipid levels with statins9 or lowering blood pressure with 
ACE inhibitors and E-blockers10. A better knowledge of the cellular and molecular 
mechanisms involved in the atherogenesis and its development into a clinically relevant 
risk however might lead to more targeted and more efficient therapies. 
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Atherogenesis 
Atherosclerosis is a chronic inflammatory disease11-14 in which macrophages play a key 
role but also other cell types and immune mechanisms are involved12,15-17. It initiates 
when the permeability of the inner layer of the blood vessel is altered, for example by 
elevated levels of (modified) LDL, locally disturbed laminar blood flow or changes in 
shear stress. Because of this endothelial dysfunction, the vessel wall, that is only 
selectively permeable, suddenly becomes permeable for the LDL particles and they 
accumulate in the intima18, the matrix between the endothelial and the media layer of 
the blood vessel, where they are trapped by an interaction with the matrix 
proteoglycans19. Another consequence of the vessel wall damage is the activation of 
the endothelial cells, causing them to upregulate the expression and presentation of 
adhesion molecules, including E-selectin, vascular cell adhesion molecule (VCAM) and 
intercellular adhesion molecule (ICAM). In combination with the upregulation of 
chemokines such as monocyte chemoattractant protein-1 (MCP-1) they stimulate 
monocytes to adhere to and migrate through the endothelial layer, forming a so-called 
fatty streak. In this subendothelial space, the monocytes proliferate and differentiate 
into macrophages under the influence of monocyte colony stimulating factor (M-CSF), 
which is also produced by the activated endothelial cells. These macrophages use their 
scavenger  receptors,  such  as  CD36  and  scavenger  receptor  A  (SR-A),  to  take  up  the  
(modified) LDL particles20. Macrophages that are filled with lipids, called foam cells, get 
activated which induces them to start producing cytokines and chemokines, creating an 
inflammatory milieu and attracting more macrophages and other immune cells 
including T cells, dendritic cells and neutrophils to the vessel wall. This influx of new 
cells results in a complex atherosclerotic lesion that gains in size16,21.  
As the plaque progresses, the vascular smooth muscle cells (SMC) residing in the media 
underneath it will start to proliferate, triggered by foam cell produced growth factors. 
They migrate from the media to the endothelial layer that covers the luminal side of 
the plaque, where they will also produce extracellular matrix constituents such as 
collagen and proteoglycans. This results in a thick fibrous cap covering the plaque, 
which reduces the risk of plaque rupture and thus is a very important aspect in the 
concept of plaque stability16,21,22. 
Contrary to this plaque stabilization, other processes increase the risk of plaque 
rupture, the most important being the death of lipid-laden macrophages and the 
resulting necrotic core. Foam cell apoptosis in advanced atherosclerotic plaques can be 
explained through combinations of several mechanisms23,24. Besides a lack of sufficient 
growth factors, there is an abundance of cytotoxic agents such as oxygen radicals, 
modified lipids and specific cytokines25. They are all able to induce caspase activation 
and thereby apoptosis. Another mechanism however has gained in attention. Here, 
excessive lipoprotein-derived cholesterol accumulation in the cells and thus also in the 
membrane of the endoplasmic reticulum (ER) can induce an unfolded protein response 
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(UPR). This ER stress can, alone26 or in combination with a secondary signal such as 
pattern recognition receptor (PRR) signaling27,28,  lead to  a  release of  Ca2+ from the ER 
lumen26,29, a mechanism shown in vivo to  be  strongly  correlated  to  foam  cell  
apoptosis30.  The remains of the apoptotic cells  are cleared by the macrophages in the 
early stages of atherogenesis. In later stages however, the macrophages are already 
overfilled and unable to phagocytose these particles efficiently. The uncleared 
apoptotic bodies go into secondary necrosis, leading to the accumulation of cell debris 
and thereby the formation of a necrotic core20. While cell death in early lesions is 
considered beneficial, a growing necrotic core in more advanced plaques is associated 
with increased lesion instability and thus increased risk of clinical implications31. An 
additional risk comes from the tissue factor (TF) released by the necrotic cells, which 
can stimulate thrombus formation32. Other factors in the necrotic core induce 
neovascularization, branching microvessels from the vasa vasorum. This new 
microvasculature is often leaky and thereby initiator of yet another plaque destabilizing 
event, intraplaque hemorrhage33. 
In the end, the ratio of fibrosis over necrosis will be a strong determinant of plaque 
stability, so besides influencing plaque size, the shift of this ratio might be a second 
option for future therapeutic strategies22. 
Animal models of atherosclerosis 
History 
While experimental intervention possibilities in humans are limited and mostly ethically 
unacceptable, atherogenesis appears to be too complex for in vitro studies because of 
the many different interacting cell types in a confined, inflammatory and lipid-rich 
milieu. In vitro studies can never mimic the physiological situation accurately enough 
and can therefore merely be considered indicative. Therefore, the use of animal models 
is inevitable. During the early years, rabbits and to a lesser extend pigs and non-human 
primates were used to reveal the cellular background of atherogenesis34. Like in other 
biomedical research topics however, the use of mice gained in popularity35.  
Mouse models 
Mice have some undeniable advantages when used in atherosclerosis and other 
research. First of all, mice are small, easy to handle and quick to breed. Since 
atherosclerosis experiments have a relatively high variability they require large groups, 
making the ability to house them in relatively small facilities important. Second, the 
mice’ genetic background is well studied and many transgenic models with over-
expression or deletion of specific genes exist and continue being made, which can be 
applied in atherosclerosis studies36. 
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Mice however also have disadvantages. Because of their size, the amount of materials 
collected during the experiment and post-mortem, like blood and organs, are limited 
while the study of small tissues can be challenging. Second, however their lesions 
generally develop much like human lesions and contain the same cell types, some 
features of the human plaque still lack in mice. Since murine blood vessels are small, 
oxygen can diffuse more freely to all cells without the need of vasa vasorum. Therefore, 
their plaque hypoxia differs significantly from human lesions, also limiting its relevance 
in necrotic core formation and plaque neovasculogenesis37. Moreover, the shear stress 
within the vessel remains limited so reliable models for lesion rupture are not available 
yet38. Third and most important, mice don’t spontaneously develop 
hypercholesterolemia and therefore no atherosclerosis. To overcome this, mice were 
initially given an atherosclerosis inducing diet containing high saturated fat, cholesterol 
and cholic acid salts (cholate). This cholate however can induce an inflammatory 
response, an enormous drawback especially when studying the role of inflammation in 
atherosclerosis39. Therefore, transgenic mice have become the model of choice. 
Most transgenic atherosclerosis mouse models are developed in C57BL/6 mice because 
they have a relative high susceptibility for atherogenesis compared to other mouse 
strains40. The two most common models have a deletion of either the apoe gene 
encoding apolipoprotein E (ApoE) or the ldlr gene encoding the LDL receptor (LDLR), 
while other models have an overexpression of ApoB or mutant forms of ApoE, like 
human ApoE241 or ApoE*3-Leiden42,43. All these genetic modifications serve the 
purpose of raising the cholesterol levels in these mice and are most often combined 
with a period in which the mice are fed a diet containing high percentages of fat and 
cholesterol.  
In an effort to speed up atherogenesis for short-term experiments or for simulation of 
high shear-stress, arteries can be surgically narrowed. An example is the tightening of a 
small silastic collar around the carotid arteries, creating a turbulent blood flow that 
results in downstream plaque formation44.  
In order to combine atherosclerosis proneness with other gene deficiencies, these 
mouse models can be crossed with mice that lack the gene of interest, creating double 
KO mice. When specifically studying bone marrow derived cells however, a quicker 
method is the bone marrow transplantation. In this case, ldlr-/- mice are irradiated in 
order to deplete their bone marrow cells. Subsequently, their production of new blood 
cells is reconstituted by injection of bone marrow from a full or cell-type restricted KO 
model  for  the  gene  of  interest.  This  creates  a  hybrid  mouse  that  will  still  develop  
atherosclerotic  plaques  but  lacks  the  gene  of  interest  in  all  or  a  selection  of  its  bone  
marrow derived cells45. A different transplantation method can be used for studying 
changes in genetics of the vasculature during atherogenesis. Surgical transplantation of 
the aortic arch from a KO mouse model to an atherosclerosis prone mouse or vice versa 
creates hybrid mice in which the plaque and its surrounding vessel have a different 
genetic background from the blood and the newly infiltrating leukocytes46,47.  
 Even within one mouse model, there are different locations where 
be quantified (Figure 1.1).  In  one  very  common  method,  sections  are  cut  from  the  
aortic root. This is the location where the aorta leaves the left ventricle of the heart, 
immediately downstream of the tricuspid valves. Because of the ve
pulsatile blood flow in this part of the aorta, atherosclerotic plaques develop relatively 
rapid in this location. Therefore, it is the recommended location to study when 
performing short-term experiments. Moreover, the growth and phenotyp
plaques is well described in literature, making it easy to evaluate effects of the 
experiment on these criteria45,48.  In  a  similar  way,  sections  can be cut  from the aortic  
arch or the innominate artery, where advanced atherosclerotic plaques will appear 
after longer periods of high-fat diet49. Another common method is the 
atherosclerosis assessment, in which the complete aorta is isolated, stained and pinned 
down50. This provides a clear overview of plaque size and distribution throughout the 
aorta but should ideally be combined with aortic root analysis since it only provid
basic information on the composition of the plaques, as the immunohistochemical 
analysis that can be performed is limited. 
Figure 1.1: Different locations to study atherogenesis in mouse models. 
The innominate artery (HE). 3: The carotid artery, proximal of a collar (HE). 
descending aorta en face (Oil Red O, image © Charles River). 
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To study the gene expression within the atherosclerotic plaque, whole sections of the 
aorta can be lysed for RNA isolation. The results will however be disturbed by the 
abundant presence of RNA from the vessel wall, making the plaque-specific RNA levels 
in each sample dependent on the relative size of the plaque compared to the total 
section  size.  This  can  be  solved  by  correcting  each  sample  for  the  expression  of  a  
constant, plaque-specific gene, like the macrophage marker CD6851. A more precise and 
sensitive method however is laser capture microdissection, which makes it possible to 
isolate the plaques or even specific parts or cells in the plaques from histological 
sections, however providing a very limited RNA yield52. 
Recently, new methods emerged to study the atherosclerotic plaque composition in 
vivo, including intravital microscopy53,54, magnetic resonance imaging (MRI)55, 
fluorescence imaging (e.g. GFP or luciferase reporter systems)56, bioluminescence 
imaging57, ultrasound imaging58 and nuclear imaging (PET and SPECT)59. These methods 
are often non- to mildly invasive and can monitor the trends of several parameters over 
time. Their major drawback however remains the resolution, which is at present often 
still inadequate to fully characterize murine plaques60. 
Macrophages 
Macrophages are the most abundant and versatile cell type in atherosclerotic plaques. 
These immune cells with an unusual broad range of functions are formed when the 
bone marrow derived and in the blood circulating monocytes extravasate from the 
blood through the endothelial layer into the tissues, where they differentiate under the 
influence of macrophage- or granulocyte/macrophage colony stimulating factor (M-CSF 
or GM-CSF). Depending on the tissue the macrophage resides in, it may be known 
under a different name, with for example microglia in neural tissue, Kupffer cells in the 
liver, osteoclasts in the bone and sinusoidal cells in the spleen. However these 
macrophages usually preserve their broad range of functions independently of their 
location, they may as well exhibit a more specialized phenotype61,62. 
Probably the most important function of the macrophage is guarding and patrolling the 
tissues in search for pathogens. Once such a pathogen is detected, a series of actions 
follows in an attempt to clear them from the tissue. The macrophage will start to 
produce oxygen radicals to actively kill the pathogens and will engulf and digest the 
debris by phagocytosis, hence the name macrophage. At the same time, it will produce 
and secrete a set of cytokines and chemokines that bind to their respective receptors 
on the surrounding cells as a warning of the possible danger and as a trigger for the 
migration of other immune cells towards the site of infection. These cells include on the 
one hand myeloid “innate immune” cells (macrophages and granulocytes) that will 
assist in killing and digesting the intruders and on the other hand the antigen 
presenting cells (macrophages and dendritic cells) and lymphoid “adaptive immune” 
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cells  (T-  and B-cells)  that  will  create a  memory of  the pathogenic  patterns,  which will  
allow the host to react more quickly and adequately upon a next encounter with the 
same pathogen. Upon engulfment of the pathogen, the phagosome will fuse with the 
lysosomes in which the pathogen is digested and antigens are formed that can be 
presented through MHCII molecules to the adaptive immune cells63. 
Remarkably however, the macrophage not only induces the accumulation of immune 
cells and an inflammatory environment, it is also responsible for the resolution of this 
inflammation once the pathogens are cleared. Indeed, in a second wave of cell 
infiltration the macrophages secrete anti-inflammatory cytokines that neutralize the 
inflammatory milieu and inactivate the inflammatory cells in order to protect the tissue 
from damage and to avoid exaggerated, systemic inflammation. Both the inability of 
the macrophages to raise an inflammatory response upon infection or to neutralize this 
response once the infection is cleared can be detrimental to the host’s survival64, as 
explained in chapter 5. 
Similar to the phagocytosis of pathogens, also endogenous material like modified 
molecules, apoptotic bodies and debris of necrotic cells are cleared from the tissues by 
the macrophage. This way, it attempts to avoid the unnecessary inflammation that 
could be caused by the presence of mostly harmless agents63. 
Role of macrophages in atherosclerosis 
Due to their function as scavengers, macrophages play an important role in the first 
phase of atherogenesis. Although patrolling already the vascular wall of healthy blood 
vessels, additional macrophages infiltrate the subendothelial space upon the presence 
of modified LDL particles65, which they ingest using the scavenger receptors on their 
cell surface66. While this process is initially beneficial, the inability to process the 
particles results in lipid-laden foam cells11. As described above, these highly activated 
cells are responsible for the attraction of new macrophages and other cell types to the 
plaque through the production of chemokines and inflammatory cytokines but they 
also temper the local inflammation through the simultaneous production of anti-
inflammatory cytokines. The importance of macrophages in early atherogenesis is 
illustrated best by experiments with mice that lack the M-CSF growth factor. These 
mice developed virtually no atherosclerotic plaques, as described later in this chapter67. 
In the later phases of atherogenesis, apoptosis and secondary necrosis of foam cells is 
causing the formation of a plaque destabilizing necrotic core while the remaining foam 
cells rather induce plaque stabilizing factors such as the formation of extracellular 
matrix and smooth muscle cell proliferation and migration21. 
Both balances between pro- and anti-inflammatory cytokine production and between 
plaque stability and instability are therefore highly dependent on the stimulation of the 
macrophage by its local environment, as further discussed in chapter 562. This diversity 
in macrophage function however is not unique to atherosclerotic plaques but has also 
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been described in macrophages involved in other pathologies and physiological 
processes such as tumour associated macrophages (TAMs)68, adipose tissue 
macrophages (ATMs)69 and the earlier mentioned macrophages reacting to infectious 
diseases. It led to the concept of macrophage heterogeneity. 
Macrophage heterogeneity 
Recently, this macrophage heterogeneity gained a lot of attention and attempts were 
made to classify the different macrophage subsets into a comprehensive framework. 
The nomenclature makes a distinction between the pro-inflammatory, classically 
activated M1 and the alternatively activated, anti-inflammatory M2 phenotype, in 
analogy to the T helper cells which are also subdivided into Th1 and Th2 cells70,71. 
Macrophages are skewed towards an M1 phenotype by the Th1 cytokines IFNɶ, TNF 
and/or microbial molecules such as lipopolysaccharide (LPS). They are characterized by 
the production of pro-inflammatory cytokines and chemokines such as IL-1ɴ, IL-6 and 
TNF and anti-microbial effector molecules such as reactive oxygen and nitrogen 
intermediates (ROI and RNI). The M2 macrophages appeared in further study to be 
representing a collection of at least three different subtypes, dependent on the 
stimulus that induces them72. They are named M2a, which are induced by Th2 
cytokines such as IL-4 and IL-13, M2b which are skewed by immune complexes in 
combination with LPS or IL-1ɴ and M2c which are rather deactivated by cytokines such 
as IL-10 and transforming growth factor ɴ (TGF-ɴ) or by glucocorticoids. 
It has shown to be difficult to find appropriate markers to identify the different 
macrophages, mainly because most markers described so far are not exclusively 
expressed but rather overexpressed in a certain subtype. Moreover, this framework is 
merely an oversimplified model and actual macrophages rarely display these extreme 
 
Figure 1.2:  The IL-10/IL-12 and iNOS/arginase balances are two methods for determining 
the macrophage phenotype within a simplified model of heterogeneity. 
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differences in phenotype. To be able to make a quick and easy distinction between M1 
and M2 macrophages however, two different characterizations are described (Figure 
1.2). The first one is based on the inflammatory status of the macrophages and 
compares the expression of the pro-inflammatory cytokine IL-12, which is typically 
expressed in M1 macrophages, to that of the anti-inflammatory and thus M2 indicating 
IL-10. A second balance looks at the L-arginine metabolism and shows that this is tipped 
towards the expression and production of inducible nitric oxide synthase (iNOS) in M1 
macrophages while the differentiation towards M2’s correlates with an induction of 
arginase 1 (Arg-1)73. 
 
Different methods to induce macrophage heterogeneity in in vitro cell culture have 
been described. In the most common one, skewing cytokines (e.g. IFNJ for M1 and IL-4 
for M2) are added to the culture of a macrophage cell line or macrophages obtained 
through the differentiation of bone marrow cells or monocytes by M-CSF. Others 
however differentiate bone marrow cells into distinct phenotypes by culturing them 
either with M-CSF or GM-CSF74. 
Other leukocytes in the plaque 
While this thesis mainly focuses on macrophages, a range of other blood cell types are 
described to be present in the atherosclerotic plaque75,76. Most of them, and especially 
their numerous interactions, contribute to plaque progression, inflammatory 
phenotype and stability14. 
T lymphocytes 
T lymphocytes, or simply T cells, develop through strict selection procedures from bone 
marrow derived thymic and peripheral hematopoietic progenitor cells and are 
historically subdivided into two major subtypes, primarily based on the presence of 
cluster of differentiation molecules CD4 and CD8 on their cell membrane. More recent 
studies however revealed a far more complex subdivision, including T helper cells (TH), 
cytotoxic T cells (CTL), regulatory T cells (Treg), natural killer T cells (NKT), memory T cells 
and gamma delta T cells (ɶɷT). This extensive heterogeneity allows them, comparable 
to the different macrophage subsets, to possess both pro- and anti-atherogenic 
properties. Especially within the TH cell subtype, the most abundant subset within the 
atherosclerotic lesion which can be further subdivided into TH1  and  TH2 and other 
minor subtypes, this dual role is striking77. While TH1 cells promote atherogenesis by 
the production of the cytokine IFNɶ, stimulation of SMC proliferation and a stimulus for 
the antigen presenting cells to upregulate their major histocompatibility complex type 
II (MHC-II)17, the TH2 cells rather produce anti-atherogenic cytokines like IL-4 and IL-10 
and induce the production of antibodies directed against oxLDL78,79. Indeed, Th1 cells 
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account  for  most  of  the  T  lymphocytes  in  early  lesions80 and  the  absence  of  all  T  cell  
subsets through a Rag-1 KO mainly attenuates early atherogenesis81. In later phases of 
atherogenesis however, the TH1/ TH2 balance can be seen as a good indicator for T cell 
mediated plaque progression and stability82. 
Also the other T cell subsets are shown to be present in the atherosclerotic plaque and 
are overall believed to promote atherosclerosis. Their specific roles in plaque 
progression and stability remain however somewhat elusive and demand more focused 
and detailed research14,83,84. 
B lymphocytes 
B lymphocytes, or B cells, develop in the bone marrow and are mainly responsible for 
the production of antibodies. They constantly circulate the body and can therefore also 
be found in the vessel wall of healthy arteries. Upon atherogenesis however, they can 
start proliferating in the adventitia at the base of the plaque  and can migrate into the 
plaque from the there85-87. Their antibody production against oxLDL associated antigens 
seems to coincide with a reduction in atherogenesis and T cell infiltration into the 
plaque88. Indeed, B cell deficiency through bone marrow transplantation into ldlr-/- mice 
promotes atherogenesis89. Depletion of mature B cell by a CD20-specific monoclonal 
antibody however results in reduced atherosclerosis, indicating that B cells can not be 
simply regarded as athero-protective cells90. 
Granulocytes 
Granulocytes are also covering a collection of different cell types, all derived from 
myeloblast progenitor cells and characterized by the presence of cytoplasmic granules. 
While the role of eosinophils and basophils in atherogenesis is still quite unknown75, 
more information on the role of neutrophils emerges. They are constantly attracted to 
the inflammatory regions at the luminal side of the plaque and in the adventitia lining 
the  base  of  the  lesion  site91. Here they produce pro-inflammatory cytokines, which 
promote atherosclerosis and plaque instability, and myeloperoxidase (MPO), which 
might induce endothelial cell apoptosis91,92. Furthermore, they secrete mediators that 
promote the attraction of additional monocytes to the lesion93. 
At sites of plaque rupture, another type of granulocytes named mast cells can be 
found94. By degrading the athero-protective high-density lipoproteins (HDL) and 
impairing cholesterol efflux, these cells promote lipid accumulation and thereby plaque 
progression95. Moreover, they destabilize the plaque by apoptosis of the collagen-
secreting smooth muscle cells95 and by activation of matrix metalloproteinases 
(MMP)96,97. Furthermore, they are shown to be involved in angiotensin activation, 
intraplaque hemorrhage, macrophage apoptosis, vascular permeability and leukocyte 
recruitment to the plaques98,99. 
General introduction 
 
19 
Dendritic cells 
Dendritic cells (DC) are professional antigen presenting cells bridging the innate with 
the adaptive immunity. They are formed from myeloid precursors after which they 
circulate the body as immature cells and finally mature upon uptake of antigens, 
resulting in the migration towards a lymph node and subsequent presentation of these 
antigens to T cells.  
In atherosclerosis, vascular DC’s accumulate in a GM-CSF dependent way in the intima 
beneath the plaque and in the shoulder regions of the plaque itself100,101. Here they 
promote plaque growth, inflammation, the attraction of T cells and their activation 
through antigen presentation101,102. Upon uptake of an antigen, they may also migrate 
out of the plaque towards secondary lymph nodes, where they can activate antigen 
specific T cells103.  
Co-localizing with the conventional DCs, a second DC phenotype can be found in the 
plaque shoulder regions. These plasmacytoid DCs (pDC) are not as capable in antigen 
endocytosis and T cell stimulation but rather react to debris from apoptotic and 
necrotic cells in the plaque by secreting type I interferons and stimulating CD4+ T cells 
in an antigen independent manner to produce IFNɶ and TNF-related apoptosis-inducing 
ligand (TRAIL), which can induce smooth muscle cell apoptosis104-106. Moreover, they 
seem able to induce Treg differentiation
107. 
Signal transduction 
An atherosclerotic plaque is an actively changing and highly inflammatory region 
containing an abundance of triggers that can induce a response in the residing cells, 
including modified lipids, signaling molecules, oxygen radicals and debris of apoptotic 
and necrotic cells. The response of the cells to these changes in their environment 
ranges from proliferation to cell death, from lipid uptake to -efflux and from pro- to 
anti-inflammatory cytokine secretion, depending highly on the way the signals are 
transduced towards a gene expression pattern. Many different signal transduction 
pathways are known to be playing a role in atherogenesis and plaque stability, and their 
interplay offers the advantages of signal amplification, precise fine-tuning and effective 
feedback loops. Indeed, the availability, abundance and combination of different 
receptors and signaling molecules often determines the eventual response but differs 
between cell types or even within the heterogeneous cell types described above, 
explaining the multifunctionality of these cells within the plaque.  
Inflammatory signaling 
An interesting example of the complex signal transduction cascades that is also very 
relevant to this thesis is the way in which different signals within the plaque can induce 
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and modify an inflammatory response. In contrast to the inflammation usually seen as a 
reaction to pathogen-associated molecular patterns (PAMPs), atherosclerosis is 
considered an example of so-called sterile inflammation. Though reports of 
microbiological origins of atherosclerosis exist108,109, macrophage activation within the 
plaque is above all triggered by autologous damage-associated molecular patterns 
(DAMPs), including modified lipoproteins, cholesterol crystals, cytokines and debris of 
necrotic or apoptotic cells110-112.  
A key mediator that regulates the expression of several pro- and anti-inflammatory 
genes in atherosclerosis is NF-ʃB45,113,114. This transcription factor, which in fact 
represents a family of different homo- or heterodimeric combinations of five different 
NF-ʃB/Rel proteins, is shown to be activated in atherosclerotic plaques, while it is 
usually inactive in healthy blood vessels115,116. In order to induce the transcription of 
over 160 genes, NF-ʃB binds to a specific consensus DNA sequence. In non-activated 
cells however, this interaction is impeded through tight association of an inhibitor to 
cytoplasmic NF-ʃB, preventing it to enter the nucleus. The five different proteins that 
make up for the inhibitor of NF-ʃB (IʃB) family are Iʃɲ, Iʃɴ, Iʃɶ, Iʃɸ and Bcl-3. They 
are NF-ʃB target genes themselves, implicating a feedback loop of self-inactivation. 
Upon phosphorylation of the IʃB inhibitors by the IʃB kinase complex (IKK1, IKK2 and 
NEMO) followed by poly-ubiquitination and subsequent proteasomal degradation, NF-
ʃB can freely migrate to the nucleus and influence the gene expression117.  
Within an atherosclerotic plaque, several signals can result in the activation of NF-ʃB 
and thereby evoke an inflammatory response that influences the plaque progression. 
The CD36 scavenger receptor can, upon oxLDL binding, heterotrimerize with Toll-like 
receptors (TLR) 4 and 6, initiating the same NF-ʃB activating pathway that can be found 
upon detection of viral or bacterial components by the TLR receptors118,119. Besides 
oxLDL, also the heat-shock protein HSP60 and fragments of fibronectins are TLR 
activating factors present in the plaque, and a similar pathway can be found 
downstream of the receptor for the cytokine IL-1ɴ120. Indeed, deficiency of these 
receptors or their downstream adaptor molecule MyD88 attenuates plaque growth in 
murine atherosclerosis models121-123. Through a different signaling pathway, the binding 
of the inflammatory cytokine tumor necrosis factor (TNF) to its receptor (TNFR) 
converges with the above-mentioned pathways in the activation of the IKK complex 
and promotes atherosclerosis124-127. Also CD40, a receptor from the same family as 
TNFR, will bind CD40 ligand (CD40L), resulting in a similar pro-atherogenic effect128-131. 
Finally, the intracellular accumulation of cholesterol and subsequent ER stress response 
in foam cells was found to activate NF-ʃB132, while foam cells undergoing apoptosis can 
induce NF-ʃB activation in the neighboring phagocytes133,134.  
Worth mentioning here is the strong inflammatory and pro-atherogenic cytokine IL-1ɴ, 
which is produced upon NF-ʃB signaling in its inactive precursor form IL-1. Recently it 
was shown that accumulation of cholesterol crystals within the plaque macrophages 
stimulates the NLRP3 inflammasome complex and thereby promotes caspase-1 
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dependent IL-1 processing to IL-1ɴ135,136. Moreover, inflammasomal caspase activation 
might be yet another way in which NF-ʃB can be activated in plaque macrophages137. 
Cytokines and chemokines 
Cytokines are a family of proteins that can be produced and secreted by many different 
cell types upon their acute or chronic activation or are produced constitutively at low 
levels. The family can be divided into different classes: interleukins (IL), interferons 
(IFN), tumor necrosis factors (TNF), colony stimulating factors (CSF), transforming 
growth factors (TGF) and chemokines138. Unlike hormones, they mainly act autocrine 
and paracrine through binding to their specific receptors, which initiates signaling 
pathways that lead to the activation of factors including interferon regulatory factors 
(IRF), janus kinase & signal transducers and activators of transcription (JAK/STAT), 
mitogen-activated protein (MAP) and NF-NB. While chemokines regulate attraction of 
new cells by creating a gradient that affects the motility and adhesion capacity of their 
targets and colony stimulating factors initiate maturation and proliferation of specific 
cell types, the other cytokines are rather messengers of the inflammatory and immune 
responses. Noteworthy, there are both pro- and anti-inflammatory cytokines and their 
balance determines the net inflammatory status of the environment. This also 
implicates that the different TH- and macrophage phenotypes that have been described 
above can be discriminated through their profile of cytokine production. 
In an atherosclerotic plaque, the co-localization of many different immune cell types 
combined with the presence of several stimuli like modified lipoproteins, oxygen 
radicals and necrotic cell remnants can induce cytokine production in the foam cells as 
well  as  in  the  other  immune  cells,  the  endothelial  cells  and  the  smooth  muscle  cells.  
Thereby, these cells cooperate in the creation of an inflammatory milieu that attracts 
and activates even more cells from the blood stream and the adventitia.  
During the last 20 years, many animal experiments involving over-expression, inhibition 
or knock out of one of these cytokines or their receptors have proven their capital role 
in atherogenesis138. Their specific effects on atherogenesis range from altering the 
inflammatory and cellular balance of the lesion to plaque growth and alteration of 
plaque stability. These murine data can be assumed to be relevant in humans as well 
since similar cytokine production and cytokine receptor presence was also already 
shown in human atherosclerotic plaques. 
Inflammatory cytokines in atherosclerosis 
The inflammatory cytokine families can be sub-divided into members that mediate pro-
inflammatory or anti-inflammatory effects. Their production and secretion is mainly 
triggered by stimuli activating the cell and influenced by a pro- or anti-inflammatory 
skewing of the cell. They are able to mediate both the inflammatory reaction of the 
Chapter 1 
 
 
22 
cells as well as its resolution through binding to specific receptors, initiating a range of 
different signaling pathways. 
Because atherosclerosis is known to be a chronic inflammatory disease with many cell 
types mediating inflammation through the production and secretion of cytokines, their 
role in atherogenesis is well studied. Roughly, one could summarize that pro-
inflammatory cytokines promote atherogenesis (TNF126,139, IL-1140-142, IL-2143, IL-
12144,145,…) while anti-inflammatory cytokines are anti-atherogenic (IL-5146, IL-10147-149, 
IL-33150, TGFE151-155,…) and others have ambiguous effects (IL-4156-158, IL-6159-161). 
Therefore, their balance within the lesion, which is most probably dependent on the 
presence and activation of the different macrophage- and T helper cell subsets, is 
largely determining plaque growth and –stabilization. Knowledge on this balance and 
the specific roles of the cytokines in the plaque might reveal therapeutic possibilities, 
however site and/or cell type specific targeting of the therapy remains the biggest 
challenge. 
Chemokines in atherosclerosis 
Chemokines are small cytokines specialized in the chemotaxis of new cells to the site of 
inflammation. They share a typical three dimensional structure stabilized by disulfide 
bonds between two pairs of cysteines. These can be either adjacent (the CCL family) or 
separated  by  one  or  three  other  amino  acids  (the  CXCL  and  CX3CL family 
respectively)162. They play a role in the embryonic development and later in the 
homeostasis of tissues but their release is also often triggered by inflammatory stimuli, 
creating a concentration gradient able to attract specific cell subsets. Upon binding a 
family of G-protein coupled receptors, they induce the activation of phospholipase C 
(PLC). This results in the creation of the molecules inositol triphosphate (IP3) and 
diacylglycerol (DAG). These mediate the effects of the chemokine binding through 
activation of protein kinase C (PKC), the MAP kinase (MAPK) pathway and an altered 
intracellular Ca homeostasis. These effects include degranulation, an enhanced cell 
motility and a more efficient binding of the cell’s integrins to adhesion molecules162,163. 
Several interactions between chemokines and their receptors influence 
atherogenesis164,165,  the  first  one  discovered  being  the  CCL2-CCR2  axis166,167. Later 
however it was shown that the attraction of new cells to the site of plaque formation 
mainly depends on three different and non-redundant interactions. These are CCL2 
(MCP-1), CCL5 (RANTES) and CX3CL1 (Fractalkine) and their binding to the respective 
receptors CCR2, CCR5 and CX3CR1. Their importance was demonstrated by a 
simultaneous inhibition of CCL2 and the receptors CCR5 and CX3CR1, which almost 
completely abolished atherogenesis168, a far more pronounced effect than the 
inhibition of individual chemokines or other combinations169-172. 
More  recently,  the  focus  has  changed  from  a  net  effect  of  chemokines  on  
atherosclerosis to a more detailed image where chemokine production differs between 
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early and advanced lesions and chemokine receptors are often specific to monocyte or 
T cell subsets. This implicates that changes in chemokine production not only affects 
lesion size but can also affect the attracted cell types or –subsets and thereby the 
plaque composition and inflammatory status173,174. 
Interferons in atherosclerosis 
Interferons were the first known cytokines, discovered as the product of virus-infected 
cells that caused resistance to infection with the same or other viruses175. They are 
produced by lymphocytes upon contact with pathogens or tumor cells in order to alert 
neighbouring cells of the potential danger. Interferons are divided into two families, 
called type I interferons and type II interferons. They have distinct secretion profiles 
and functions, bind to different receptors but both signal through Jak/STAT pathways. 
Recent papers show a crosstalk between the two families through their effect on and 
use of STAT1176. 
Type I interferons include IFNɲ, IFNɴ, IFNɺ and IFNʘ, which all bind to a heterodimer of 
interferon-ɲ receptors IFNAR1 and IFNAR2177.  They are best  known for  their  ability  to  
“interfere” with viral infection. Because of this, they have been used for decades in the 
treatment of certain virus related diseases like Hepatitis C, often in combination with 
the antiviral ribavirin178,179. More recently however, their anti-proliferative and pro-
apoptotic effects proved to be useful in the treatment of certain tumors177,180 while 
their immunomodulatory properties made it the most commonly used treatment for 
the autoimmune disorder multiple sclerosis (MS)181,182. 
Type II interferons only include IFNɶ, which binds the heterodimeric interferon-ɶ 
receptor (IFNGR1 and IFNGR2). Next to limited antiviral and antitumoral effects they 
mainly activate leukocytes, contributing to an inflammatory milieu.  
While the pro-atherogenic role of IFNɶ is well studied183-186, type I interferons in 
atherosclerosis were yet poorly documented. Moreover, the few studies published 
failed to determine their effect on atherogenesis and clarify the mechanisms behind 
this104,187,188. Chapter 2 focuses on determining and further clarifying the effect of type I 
interferon signaling on mouse models for atherosclerosis and the possibility of 
translating these results to human atherosclerosis51. 
Colony stimulating factors in atherosclerosis 
Growth factors are a family of cytokines each responsible for the differentiation and 
proliferation of a certain cell type.  In the atherosclerotic setting, M-CSF is produced by 
the endothelial and smooth muscle cells and mainly ensures the differentiation of 
monocytes into macrophages and further macrophage proliferation189. Its importance 
in atherosclerosis was shown in mice with osteopetrotic (op) mutations. Both 
homozygous mice with the naturally occurring Csfmop/Csfmop (op/op) mutation, that 
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lack functional M-CSF, and mice with a heterozygous op mutation shown significantly 
reduced atherogenesis67,190-192. 
Another growth factor playing a role in atherosclerosis is GM-CSF, with both treatment 
and deletion approaches resulting in increased plaque size193,194. The exact mechanism 
however is yet to be revealed.  Besides recruiting endothelial progenitor cells to the 
plaque and promoting vasa vasorum neovascularization194-197, it regulates dendritic cell 
formation and proliferation in the lesions101,198 and reduces macrophage PPARɶ activity 
and ABCA1 expression193. 
Cell recruitment to the atherosclerotic plaque 
The growth of the early atherosclerotic plaque depends largely on the attraction of new 
immune cells199. In order to enter the plaque from the blood stream, these cells need to 
extravasate through the endothelial cell layer, a process called diapedesis, in a way that 
is similar to other, non-atherosclerotic sites of inflammation200,201.  This  is  typically  a  
three-step event where the cells initially roll over the vessel wall because of a low-
affinity binding to the selectins that are present on the activated endothelial cells202,203. 
Their enhanced affinity to endothelial adhesion molecules, mediated by chemokine-
dependent conformational changes in their integrins, then results in firm adhesion and 
leukocyte arrest204. In a third step, the arrested leukocytes secrete proteases that 
degrade the extracellular matrix between the endothelial cells so they can transmigrate 
through the vessel wall towards the site of inflammation205. 
Interference with this diapedesis cascade, for example by blocking antibodies against 
adhesion molecules or integrins, has been shown to reduce the nearby inflammatory 
burden206-208. Indeed, also in atherosclerosis, a reduced leukocyte attraction results in 
smaller lesions173,209-213 while an induction in recruitment promotes atherogenesis51,214. 
Quantification of new macrophages entering an atherosclerotic plaque has been 
challenging up to now due to a lack of good markers. In this thesis however, two novel 
markers are described that will facilitate the immunohistochemical detection of these 
cells.  
Monocytes entering the atherosclerotic plaque differentiate into macrophages under 
the influence of the M-CSF growth factor present within the plaque. As a result, newly 
recruited macrophages still express monocytic markers like the one recognized by the 
ER-MP58 antibody215-217. This myeloid precursor marker has been proven useful in the 
detection of recently matured macrophages in several inflammatory diseases215,218,219 
and is introduced in chapter 3 as a novel marker for newly recruited macrophages in 
the atherosclerotic plaque.  
The M-CSF dependent expression of the inhibitor of apoptosis proteins (IAP) family 
member survivin was already described for macrophages entering the human 
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atherosclerotic lesion, while surrounding cells in the plaque and blood vessel were 
survivin-negative220.  In  chapter  4,  it  is  now  confirmed  as  a  novel  marker  for  newly  
recruited macrophages in murine atherosclerotic plaques as well. 
This thesis 
The macrophage and its recruitment to the atherosclerotic plaque is a returning theme 
throughout this thesis. In Chapter 2, we show that this recruitment is enhanced in a 
chemokine-dependent way by type I interferons, resulting in larger lesions upon 
interferon treatment and smaller lesions upon defective myeloid interferon signaling. 
Hereby we identify the type I  interferons as a novel  cytokine family with a key role in 
atherogenesis. Also in Chapter 3, enhanced macrophage recruitment explains the 
larger plaques in mice with a myeloid deficiency of Iʃɲ, an inhibitor of NF-ʃB. In this 
chapter we also introduce ER-MP58 as a novel marker for newly recruited macrophages 
in the murine atherosclerotic plaque. In Chapter 4, we identify another protein that is 
specifically expressed in macrophages entering the murine atherosclerotic plaque, 
survivin. Subsequently, we target it with a lentiviral based immune therapy. We show 
that this immunization is indeed able to reduce the lesion size, opening new 
possibilities for future therapies. Finally, Chapter 5 gives an overview of the current 
knowledge on the different macrophage subsets and hypothesizes how this 
heterogeneity might affect atherogenesis. 
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Abstract 
Inflammatory cytokines are well-recognized mediators of atherosclerosis. Depending 
on the pathological context, type I interferons (IFNs; IFNɲ and IFNE) exert either pro- or 
anti-inflammatory immune functions but their exact role in atherogenesis has not been 
clarified. Here we demonstrate that IFNE enhances macrophage-endothelial cell 
adhesion and promotes leukocyte attraction to atherosclerosis prone sites in mice in a 
chemokine-dependent manner. Moreover, IFNE treatment accelerates lesion formation 
in two different mouse models of atherosclerosis and increases macrophage 
accumulation in the plaques. Concomitantly, absence of endogenous type I IFN 
signaling in myeloid cells inhibits lesion development, protects against lesional 
accumulation of macrophages and prevents necrotic core formation. Finally, we show 
that type I IFN signaling is upregulated in ruptured human atherosclerotic plaques. 
Hereby, we identify type I IFNs as novel pro-atherosclerotic cytokines, which may serve 
as additional targets for prevention or treatment. 
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Introduction 
The important contribution of inflammatory cytokines to atherosclerosis development 
is well recognized1-3.  The  macrophage  is  both  an  important  source  as  well  as  a  major  
target of these inflammatory mediators. Specific cytokines influence macrophage 
effector functions and thereby affect plaque initiation, progression and cellular 
composition. Ultimately, macrophages hereby alter important plaque stability factors 
such as necrotic core formation and inflammatory cell content. Hence, the macrophage 
is a very attractive target for designing therapeutic interventions4, making it crucial to 
understand how cytokines regulate macrophage function in atherogenesis. 
Cytokines of the type I interferon (IFN) family (IFNɲ and IFNɴ) are produced by immune 
cells in response to pathogenic challenges such as viruses, bacteria and tumor cells. 
They induce antiviral responses5,6, have immunomodulating activities and are clinically 
used to treat viral diseases, multiple sclerosis and certain tumors5,7,8. Recent data 
indicate that IFNɴ is also necessary for sustaining TNF driven inflammation9, promotes 
TNF-induced lethal shock10 and mediates MHC-I induction by TNF11. In addition, 
constitutive  low  levels  of  type  I  IFN  amplify  IFNJ and interleukin-6 (IL-6) driven 
inflammatory responses12,13. Thus, type I IFNs also modulate immune responses that 
are not directly induced by pathogens. In sharp contrast to the clinical application of 
IFNɴ as  treatment  for  the  pathologies  mentioned  above,  type  I  IFNs  have  also  been  
shown to promote disease in systemic lupus erythematosus (SLE), where inhibition 
strategies are being considered for therapy14. Interestingly, it was recently postulated 
that the increased risk of cardiovascular mortality in SLE patients15 is  linked  to  their  
elevated  levels  of  type  I  IFNs16. Thus, depending on the context, type I IFN may have 
either disease promoting or disease inhibiting properties. 
The important immunomodulatory activities of type I IFNs prompted us to hypothesize 
that  they  also  have  a  role  in  atherogenesis.  We  show  that  IFNE treatment induces 
chemokine dependent adhesion and migration of leukocytes and promotes 
atherosclerosis development in vivo. Consequently, we show that inhibition of type I 
IFN signaling in myeloid cells hampers cellular recruitment to lesions and thus 
atherosclerosis development. Finally, we found that type I IFN signaling is an integral 
feature of human atherosclerosis as well and is upregulated in plaque instability.  
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Results 
IFNɴ treatment of macrophages induces chemotactic mediators.  
To study the effect of type I IFN on macrophages we first performed in vitro studies 
with cultured bone marrow derived macrophages (BMM) and analyzed cytokine 
secretion, uptake pathways and factors mediating adhesion and migration. While TNF 
and IL-12 were not induced by IFNɴ, treatment did induce the production of the anti-
inflammatory cytokine IL-10 (Figure 2.1A). Next, we analyzed uptake pathways by BMM 
that had been pretreated with IFNɴ. Neither endocytosis of oxidatively modified LDL 
(oxLDL) nor phagocytosis of fluorescently labeled latex beads was affected by 
treatment  of  cells  with  IFNɴ (Figure  2.1B  and  C).  We  further  focused  on  molecules  
mediating attraction of cells to atherosclerotic lesions. FACS analysis of IFNE treated 
macrophages showed no differences for any of the major integrins necessary for rolling 
and arrest at inflammatory sites (Figure 2.1D). Interestingly, gene expression of the 
chemokine and chemokine receptors (Figure 2.1E and F) CCL5 (RANTES) and its 
receptor CCR5, as well as CCR2 were upregulated in macrophages activated with IFNɴ. 
However, further FACS analysis showed no significant upregulation of surface 
expression of both CCR2 and CCR5 (Figure 2.1G). In contrast, CCL5 secretion was 
strongly increased by activation of macrophages with IFNɴ (Figure 2.1H). Next, we 
studied  the  role  of  the  main  receptor  for  type  I  IFN,  IFNAR1,  and  therefore  
macrophages from mice with a myeloid specific deletion of IFNAR117 were used. 
Quantitative-PCR showed a deletion efficiency of IFNAR1 of 73.2% ± 1.4, and CCL5 
induction by IFNɴ was reduced to a similar extent in IFNAR1 deleted cells (IFNAR1del) 
compared to control cells (IFNAR1wt) (Figure 2.1I). Ablation of signal transducer and 
activator of transcription 1 (STAT1) signaling, as a key downstream transcription factor 
of type I IFN signaling, almost completely abolished induction of CCL5 by IFNɴ (Figure 
2.1J). CCL5 ELISA showed similar reduction in secreted CCL5 for IFNAR1del and STAT1-/- 
cells (data not shown). Treatment of macrophages with another type I IFN, IFND 
showed similar effects on CCR5 and CCL5 (Supplemental figure S2.1). Thus, in addition 
to inducing IL-10, type I IFN treatment of primary macrophages induces chemotactic 
factors, which may influence leukocyte attraction and atherosclerosis development.  
 
IFNE treatment of macrophages enhances in vitro adhesion to endothelial cells and 
promotes leukocyte arrest at atherosclerosis prone sites in vivo.  
In line with our data described above, we found that static adhesion of IFNɴ treated 
macrophages to endothelial cells was enhanced (Figure 2.2A). Endothelial adhesion of 
macrophages lacking IFNAR1 or STAT1 was not inducible by IFNɴ (Figure 2.2B and C). In 
line with a major role for CCL5-CCR5 signaling, we found that IFNɴ-induced adhesion 
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was not affected in CCR1 deficient macrophages, but completely blunted in 
macrophages lacking CCR5 (Figure 2.2D). Absence of CCR2 showed an intermediate 
phenotype,  with  a  moderate  effect  of  IFNɴ.  In vivo,  4  days  treatment  of  high  fat  fed  
apolipoprotein E deficient (apoe-/-) mice with IFNɴ led to a strong increase of leukocyte  
Figure 2.1: The effect of IFNE on cultured bone marrow derived macrophages. (A) Treatment of 
macrophages with IFNE induces IL-10 expression, without affecting TNF or IL-12. (B) Uptake of DiI-labelled 
oxLDL  by  control  (ctrl)  or  IFNE treated macrophages. (C) Uptake of fluorescent latex beads by control or 
IFNE treated macrophages. (D) Surface expression of VLA-4, Mac1, LFA-1 and PSGL1 in control (ctrl) or IFNE 
treated macrophages. (E) Relative gene expression of chemokine receptors in control or IFNE treated 
macrophages. (F) Chemokine expression after IFNE treatment of macrophages. (G) FACS analysis of CCR2 
and CCR5 after treatment with IFNE. (H) CCL5 secretion by macrophages after treatment with IFNɴ. (I) CCL5 
expression in ctrl and IFNE stimulated IFNAR1wt and IFNAR1del macrophages. (J) CCL5 expression in ctrl or 
IFNE treated wildtype and STAT1-/- macrophages. Graphs are representative for at least two independent 
experiments. Bars represent mean of triplicate wells ± SEM (*P<0.05, **P<0.01). 
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arrest in the carotid arteries of these animals (Figure 2.2E). Co-treatment of mice with 
the CCL5 antagonist Met-RANTES, just prior to analyzing leukocyte arrest, reduced 
leukocyte arrest in untreated mice and fully restored leukocyte adhesion to control 
levels in IFNɴ treated animals (Figure 2.2E). Thus, IFNE treatment in vitro and in vivo 
promotes leukocyte adhesion and attraction to the endothelium through CCL5-CCR5 
dependent mechanisms.  
IFNE treatment of mice accelerates atherogenesis in apoe-/- and ldlr-/- mice.  
Next,  we analyzed the effect  of  IFNɴ on atherogenesis  in  two well-established mouse 
models of atherosclerosis. Daily injections of IFNɴ in a collar-induced atherosclerosis 
model in apoe-/- mice18 did not alter plasma cholesterol levels (27.89±2.10 and 
26.98±2.04 mM; for the ctrl and IFNɴ treated, respectively) but increased plasma levels 
of IL-10 (3.90±2.1 and 19.21±5.8 pg/ml, p<0.05; for the ctrl and IFNɴ treated,  
 
Figure 2.2: IFN affects static in vitro adhesion and in vivo leukocyte arrest. (A) Adhesion of untreated 
macrophages (ctrl) to endothelial cells compared to IFNE treated macrophages (** P<0.01). (B) Adhesion of 
ctrl or IFNE treated IFNAR1wt and IFNAR1del macrophages (* P<0.05). (C) Adhesion of ctrl or IFNE treated 
wildtype or STAT1-/- macrophages (** P<0.01). (D) Adhesion of macrophages in ctrl or IFNE treated CCR1-/-, 
CCR2-/- or CCR5-/- macrophages, all on an apoe-/- background (* P<0.05, ** P<0.01). All bars for in vitro 
adhesion represent mean of triplicate wells ± SEM, stars indicate significant differences compared to ctrl 
treated cells of the same genotype.  (E) Leukocyte arrest in the carotid artery of apoe-/- mice (ctrl), after 
treatment with Met-Rantes, after 4-days IFNɴ treatment, or 4-days IFNɴ treatment combined with Met-
RANTES treatment (n=8, 4, 7 and 5 for the four groups respectively, error bars indicate SEM; *P<0.05 or 
**P<0.01 compared to control (ctrl), # P<0.01 compared to IFNE). 
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respectively). Atherosclerotic lesion analysis (Figure 2.3A and B) showed a strong 
increase in lesion formation in mice that had been treated with IFNɴ.  The same effect 
 
Figure 2.3: IFNE treatment accelerates atherosclerosis in apoe-/- and ldlr-/- mice. (A) Representative lesions of 
control (ctrl) or IFNE treated mice of collar induced atherosclerosis in apoe-/- mice. Scale bar indicates 50 
Pm. (B) Lesion area measured at six sequential locations proximal from the collar in apoe-/- mice which were 
control or IFNE treated (** P<0.01 by two-way ANOVA; n=9/12). (C) Representative lesions in the aortic root 
of control (ctrl) or IFNE treated ldlr-/- mice. Scale bar indicates 200 Pm. (D) Lesion area at the aortic root of 
control or IFNE treated ldlr-/- mice (*p<0.05; n=12/14). (E) Representative MOMA-2 stained lesions from 
control and IFNE treated ldlr-/- mice. Scale bar indicates 100 Pm. (F) Absolute macrophage area in lesions 
from control or IFNE treated ldlr-/- mice (* P<0.05; n=12/14). (G) CD68 expression in aortic arches from 
control or IFNE treated ldlr-/- mice (**p<0.01; n=11/14). (H) CCL5 levels in plasma from ctrl- or IFNE-treated 
ldlr-/- mice (**p < 0.01; n=9/11). Shown are mean ± SEM. 
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was seen in low-density lipoprotein receptor deficient (ldlr-/-) mice where IFNɴ 
treatment increased aortic root atherosclerotic lesion size by almost 2-fold (Figure 2.3C 
and D) without any effects on plasma cholesterol (26.30±1.78 and 26.86±1.66; for the 
ctrl and IFNɴ treated, respectively) or blood leukocyte levels (B220+ B-cells, CD3+ T-cells, 
Gr1hiCD11b+ neutrophils and Gr1int/-CD11b+ monocytes; data not shown). Staining for 
macrophage content showed an approximate two-fold increase in absolute 
macrophage area in IFNɴ-treated mice (Figure 2.3E and F). Gene expression analysis of 
aortic arches from these mice also showed increased expression of the macrophage 
marker CD68 (Figure 2.3G), further indicating increased macrophage accumulation in 
atherosclerotic lesions. More extensive immunohistochemical analysis of the aortic 
root lesions did not show any significant difference with respect to neutrophil or T-cell 
accumulation, TUNEL positive cells or necrotic core formation (data not shown). Of 
interest, we did find an induction of circulating CCL5 levels in IFNɴ-treated mice (Figure 
2.3H). Thus, IFNE treatment enhances atherosclerosis development, despite the 
induction of IL-10. 
Myeloid deletion of IFNAR1 reduces atherosclerosis development and prevents 
macrophage and neutrophil accumulation in lesions.  
Subsequently, we investigated whether endogenous production of type I IFN also 
contributes to atherosclerosis development. We first analyzed whether typical type I 
IFN signature genes were expressed in lesions of atherosclerotic mice. Indeed, 
expression of OAS1, OAS2, MX2 and IRF9 could be readily detected in aortic arches 
from ldlr-/- mice that had been fed a high fat diet for 6 or 9 weeks (supplemental figure 
S2.2), indicating that endogenous type I IFN signaling is present. We then performed a 
transplantation using bone marrow from IFNAR1wt and IFNAR1del mice, specifically 
lacking IFNAR1 in their myeloid lineage, to ldlr-/- mice to yield atherosclerosis 
susceptible mice that were either wildtype (IFNAR1wt) or deleted (IFNAR1del) for IFNAR1 
in their myeloid cells. Compared with IFNAR1wt mice, mice lacking myeloid IFNAR1 
showed a strong reduction in atherosclerotic lesion size (-34%) (Figure 2.4A and 4B) 
after 11 weeks of high fat diet. Lesions were mainly composed of macrophages (Figure 
2.4C) and absolute macrophage area in the lesions was reduced in the IFNAR1del mice 
(Figure 2.4D). Furthermore, the lesions were of intermediate phenotype, consisting 
mainly  of  macrophage  derived  foam  cells  with  a  fibrotic  cap  and  some  necrosis.  
IFNAR1del mice showed reduced numbers of advanced lesions and increased moderate 
and early lesions (Figure 2.4E). 
Plasma cholesterol levels did not differ between groups just before the start of the diet 
and after high fat feeding (Figure 2.4F). In addition, total leukocyte counts (Figure 2.4G) 
and blood levels of leukocyte subsets (Figure 2.4H) did not differ between IFNAR1wt and 
IFNAR1del mice. Plasma cytokine levels were reduced, with a strong reduction (-70%) of 
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circulating IL-6 (supplemental figure S2.2) and a borderline (P=0.05) reduction of the 
chemokine CCL2 (MCP-1) in IFNAR1del mice.  
 
Further examination of the lesions showed the neutrophil content to be decreased in 
atherosclerotic lesions of IFNAR1del mice (Figure 2.5A and B), while T-cell content did 
 
Figure 2.4: Absence of myeloid IFNAR1 reduces atherosclerosis development. Bone marrow from conditional 
mice devoid of IFNAR1 only on myeloid cells was transplanted to ldlr-/- mice to yield atherosclerosis 
susceptible mice that were either wildtype (IFNAR1wt) or deleted (IFNAR1del) for IFNAR1 in their myeloid 
cells. (A) Representative toluidin blue stained lesions from IFNAR1wt and IFNAR1del mice. Scale bar indicates 
200 Pm.  (B) Lesion area at the aortic root of IFNAR1wt and IFNAR1del mice (** P<0.01; n=19/15). (C) 
Representative MOMA-2 stained lesions from IFNAR1wt and IFNAR1del mice. Scale bar indicates 100 Pm. (D) 
Absolute macrophage area in lesions from IFNAR1wt and IFNAR1del mice (* P<0.05; n=17/14). (E) Lesion 
severity in IFNAR1wt and IFNAR1del mice (P<0.05 by Chi-square test; n=19/15). (F) Plasma cholesterol levels 
before (chow) and after 8 weeks of high fat diet (HFD) in IFNAR1wt and IFNAR1del transplanted mice. (G, H) 
Total leukocyte counts and relative levels of leukocyte subsets. Shown are mean ± SEM. 
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not differ (Figure 2.5C). Since type I IFNs have been implicated in the regulation of cell 
survival and proliferation5, cell proliferation and apoptosis were assessed by Ki-67 and 
TUNEL staining, but no differences were observed between the two groups (Figure 2.5D 
and E). We did however find a strong (>70%) reduction of necrosis in the lesions of 
IFNAR1del mice (Figure 2.5F and G), which is often considered a plaque destabilizing 
consequence of impaired efferocytosis in the lesions19. Thus, endogenously produced 
type I IFNs activate myeloid cells, increase lesional accumulation of macrophages and 
neutrophils, promote necrotic core formation, and thereby promote atherosclerosis 
development. 
 
Figure 2.5: Absence of myeloid IFNAR1 influences the phenotype of atherosclerotic lesions. (A) 
Representative NIMP stainings of lesions from IFNAR1wt and IFNAR1del mice. Scale bar indicates 50 Pm.  (B) 
Neutrophil influx in lesions from IFNAR1wt and IFNAR1del mice (*P<0.05). (C, D, E) T-cells, proliferation and 
apoptosis in lesions from IFNAR1wt and IFNAR1del mice.  (F) Representative examples of necrotic core in 
lesions from IFNAR1wt and IFNAR1del mice. Scale bar indicates 50 Pm.  (G) Necrosis in lesions from IFNAR1wt 
and IFNAR1del mice (** P<0.001). For all analyses, n=19 and 15 for IFNAR1wt and IFNAR1del mice 
respectively. Shown are mean ± SEM. 
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Type I IFN induces chemotactic mediators in human macrophages and type I IFN 
signaling is associated with plaque instability in human atherosclerotic lesions.  
To investigate whether type I IFNs also play a role in the pathogenesis of human 
atherosclerosis, we first analyzed the effect of IFNɴ on primary human macrophages. 
Although IFNɴ did not induce CCR2 (Figure 2.6A), it did increase expression of both 
CCR5 and CCL5 (Figure 2.6B and C), and induced secretion of CCL5 as analyzed by ELISA 
(Supplemental Figure S2.3), confirming our mouse data. Next, Ingenuity Pathway 
Analysis was performed on an expression database of human atherosclerotic lesions. 
 
Figure 2.6: IFNE induces chemotactic factors in human primary macrophages and type I IFN signaling is 
upregulated in unstable regions of human atherosclerotic lesions. (A) CCR2 expression in macrophages 
from two independent donors after IFNE treatment. (B) CCR5 expression in macrophages from two 
independent donors after IFNE treatment (*P<0.05; **P<0.01). (C) CCL5 expression in macrophages from 
two independent donors after IFNE treatment (**P<0.01). Bars indicate mean of triplicate wells ± SEM. (D) 
Ingenuity Pathway Analysis of the differentially expressed genes in stable sections compared to ruptured 
sections of carotid endarterectomy specimens. Red signals indicate upregulation and the pathway showed 
a strongly significant (P=2.36*10-6, ratio 16/23 (0.696)) upregulation of type I IFN signalling. Indicated are 
the fold-changes (FC) of the respective genes. 
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We compared data from stable carotid endarterectomy specimens and ruptured 
specimens, which had been classified according to the Virmani-classification20. 
Interestingly the type I IFN pathway showed a highly significant upregulation in 
ruptured lesions when compared to stable lesions (Figure 2.6D). In addition to the 
upregulation of the type I IFN pathway, also several chemotactic factors including CCR5 
and CCL5 were upregulated in ruptured atherosclerotic lesions (Supplemental Table 
ST2.1). These data show that type I IFN signaling correlates with plaque rupture in 
human atherosclerosis.  
Discussion 
In this paper we show that treatment with IFNɴ enhances atherogenesis in different 
models and that myeloid specific inhibition of type I IFN signaling reduces 
atherosclerosis development. We demonstrate that IFNɴ treatment induces 
chemotactic factors and thereby promotes leukocyte attraction to atherosclerosis 
prone sites. Accordingly, absence of endogenous myeloid type I IFN signaling reduced 
accumulation of cells from the myeloid lineage in the lesions. Thus, type I IFNs are pro-
atherosclerotic cytokines that act by promoting chemokine dependent leukocyte 
recruitment to atherosclerotic lesions. Interestingly, upregulation of type I IFN signaling 
is also associated with plaque instability in human atherosclerotic lesions. 
The family of type I IFNs consists of many members with IFND and IFNɴ being the most 
abundant and best studied. It was previously shown that IFND treatment promotes 
atherosclerosis in ldlr-/- mice. However, this effect was accompanied by elevated plasma 
levels of triglycerides and cholesterol21, which complicates the  interpretation of these 
data. Therefore, we chose to use IFNɴ in our treatment studies, although we found that 
IFND had similar in vitro effects on chemotactic factors. Zhang et al. describe that IFNɴ 
administration attenuates lesion formation induced by carotid artery ligation in 
angiotensin-II infused apoe-/- mice 22, which is in contrast to our findings. Thus, 
angiotensin acceleration of atherosclerosis depends on other inflammatory factors than 
our models. We now show, using two different models of atherosclerosis, that IFNɴ 
treatment promotes atherosclerosis in high fat fed mice. In both a collar-accelerated 
model (in the apoe-/- mice) and a solely hyperlipidemia-driven model (in the ldlr-/- mice), 
atherogenesis was enhanced by IFNɴ, without influencing plasma lipid parameters.  
We found that IFNɴ treatment of isolated primary macrophages induced IL-10. In 
addition, IFNE treatment of mice led to increased levels of circulating IL-10, similarly as 
is observed in MS patients and mouse models for MS23. IL-10 is a classical anti-
inflammatory cytokine and the beneficial effects of IFNE treatment in relapsing 
remitting MS patients is at least partly attributed to anti-inflammatory factors it 
induces24. The induction of this anti-atherogenic25 cytokine contrasts with the 
atherosclerosis promoting effect that we observe for IFNE.  However, we did find IFNE 
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to specifically elicit chemotactic factors with a reported pro-atherogenic function. CCL2 
(MCP-1) and CCL5 (RANTES) and their receptors (CCR2 and CCR5, respectively) are 
important in regulating attraction of cells to atherosclerotic lesions and thereby control 
atherosclerosis development26-28. We found that especially CCL5 was strongly 
upregulated after IFNɴ treatment of macrophages, coinciding with a modest induction 
of CCR5 and CCR2. CCL5 expression after IFNɴ was reduced in macrophages lacking 
either IFNAR1 or STAT1, indicating that CCL5 is either a direct target of IFNAR1-STAT1 
signaling or regulated by interferon regulatory factors (IRFs) induced by STAT1 
activation29-31. We could also show that IFNɴ increased static adhesion of macrophages 
to endothelial cells, again in an IFNAR1 and STAT1 dependent manner, which was 
abolished by macrophage CCR5 deficiency, but not by deficiency for CCR1, the other 
major receptor for CCL5. CCR2 deficiency had a modest effect on IFNɴ induced 
macrophage adhesion. Furthermore, enhanced leukocyte arrest induced by IFNE in 
apoe-/- mice could be completely blocked by co-treatment with the CCL5-receptor 
inhibitor, Met-RANTES. Therefore we think that despite the induction of IL-10 by IFNE, 
the atherosclerotic process is actually enhanced through the induction of especially the 
CCL5-CCR5 axis, thereby promoting attraction of leukocytes to lesions. 
Type I interferons are massively produced by various cell types in response to viruses 
and other microbial stimuli, through engagement of toll-like receptors such as TLR3, 
TLR4 and TLR9. Major in vivo sources of type I IFN are plasmacytoid dendritic cells 
(pDCs). Interestingly, DCs and more specifically pDCs have been identified in human 
atherosclerotic lesions and have been associated with rupture prone areas of the 
lesions32-34. Using datasets from stable and ruptured human endarterectomy segments 
we now show that segments of ruptured plaque have an upregulation of the type I IFN 
signaling pathway, when compared to stable segments. Thus, ruptured sections of 
atherosclerotic lesions show induction of type I IFN signaling. This may consequently 
increase attraction of inflammatory cells, further contributing to matrix degradation 
and plaque destabilization. 
Using conditional knockouts we demonstrate that myeloid cells are important targets 
for endogenously produced type I IFN in atherosclerosis. Through induction of 
chemotactic factors, type I IFN signaling promotes macrophage adhesion to endothelial 
cells. As such, deletion of IFNAR1 in myeloid cells ultimately leads to reduced 
accumulation of macrophages in atherosclerotic lesions and thereby reduces 
atherosclerosis development. We determined deletion efficiency to be approximately 
70% in our bone marrow cultures, indicating some remaining type I IFN signaling. In 
addition, it was previously shown that circulating monocytes from LysMCre-IFNAR1floxed 
mice show severely hampered but not fully absent type I IFN signaling17. Thus, the 
phenotype we observe is the likely result of reduced but not completely absent myeloid 
type I signaling. Whether this merely means an underestimation of the contribution of 
endogenous type I signaling in atherosclerosis or whether additional function are 
therefore undetectable remains to be discovered.  
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In addition to affecting macrophages, myeloid IFNAR1 deficiency also reduces 
accumulation of neutrophils in the lesions, which have recently been found to 
contribute to atherosclerosis35,36. Disturbed macrophage CCL5 production may impair 
lesional recruitment of neutrophils, which use CCR1 to respond to CCL537. Alternatively, 
IFNAR1 deficiency may have unexplored direct effects on neutrophils influencing 
migration to inflammatory sites. However, in our treatment approach with ldlr-/- mice, 
neutrophil accumulation in the lesions was not affected (data not shown), indicating 
that IFNE treatment does not affect neutrophils in these studies. In addition, although 
we clearly identify that myeloid IFNAR1 signaling highly controls lesion development, 
we  cannot  exclude  that  other  targets  of  type  I  IFN,  such  as  endothelial  cells  or  
fibroblasts, will contribute to the effects that we observe upon treatment of the mice 
with IFNɴ.  
We found that inhibition of endogenous myeloid type I IFN signaling reduces necrotic 
core formation and thus directly affects plaque stability. Reduced necrosis paralleled 
impaired progression of the lesions. However, upon analysis of a subset of lesions from 
both groups with similar size (84.5±4.8 and 81.4±4.2 x1000 Pm2 for  the IFNAR1wt and 
IFNAR1del groups) and severity (moderate lesions), we found that necrotic core 
formation was still reduced in the IFNAR1del group (12.6±2.4% and 4.0±1.3% for the 
IFNAR1wt and IFNAR1del groups). Thus, inhibition of myeloid IFNAR1 function directly 
inhibits necrotic core formation independent of lesion size and severity and without 
any clear effects on endocytosis or phagocytosis. Depending on the experimental 
context, both pro- and anti-cell death functions have been attributed to type I IFN. The 
antitumor effects of type I IFN are at least partly attributed to the induction of cell 
death by type I IFN5, in which IFNs and interferon stimulated genes are both sensitizing 
tumor cells to immune cell mediated cytotoxicity and are augmenting lytic activity of 
immune cells. In line, several groups have reported that endogenous type I interferon 
signaling sensitizes cells to pathogen induced cell death38,39 or apoptosis induced by 
serum deprivation40. In addition, treatment of MS patients with IFNE was  shown  to  
prime monocyte derived macrophages for apoptotic cell death41. We show that 
inhibition of myeloid type I IFN signaling reduces necrosis, but treatment of ldlr-/- mice 
with IFNɴ did not enhance necrotic core formation. Thus, in atherogenesis the necrosis 
promoting effect of endogenous type I IFN is apparently already maximal and not 
further promoted by exogenously added IFNɴ.  
Our findings are supported by previous studies demonstrating that type I IFNs are 
important inducers of cellular migration. The attraction of inflammatory cells is an 
important feature of type I IFN action in fighting microbial infections5. In addition, it 
was recently shown that type I IFNs are also essential mediators of TNF-induced lethal 
inflammatory shock by enhancing cell death and promoting white blood cell influx in 
tissues through induction of a set of chemokines10. Moreover, in search of IFNE related 
adverse side effects in MS patients several groups performed gene expression studies 
on peripheral blood mononuclear cells and demonstrated induction of chemotactic 
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factors in response to IFNE treatment42,43. In line with this it was recently shown that a 
group  of  chemotactic  genes,  including  CCL5  and  CCL2,  was  among  the  most  
prominently upregulated ones in brain macrophages (microglia) treated with IFNɴ 17. 
We focused on the major chemokines and chemokine receptors with a demonstrated 
role in atherogenesis and found that especially the CCL5-CCR5 axis may be very 
important in mediating the pro-atherogenic function of IFNE. 
In conclusion, we show that type I IFNs promote atherosclerosis development. Contrary 
to the antiviral effect of type I IFN acting on a multitude of cell types, we report that the 
specific interaction of endogenous type I IFN with myeloid cells enhances the 
recruitment of these cells to atherosclerotic lesions. This effect is in accordance with an 
observed type I IFN induced macrophage adhesion mediated by upregulation of specific 
chemokines and their receptors, mainly involving the CCL5-CCR5 axis. Furthermore, we 
present plaque instability as a direct consequence of myeloid IFN signaling. Collectively, 
these data raise the demand for further detailed analyses of cardiovascular risk in 
patients treated with type I IFN and may even imply that caution should be taken in 
using type I IFN as a therapeutic option. In contrast, targeting of type I IFN signaling 
may be an attractive target for prevention and treatment of atherosclerosis. 
Experimental Procedures 
Mice 
C57BL/6 mice and ldlr-/- mice on a C57BL/6 background were obtained from Jackson 
Laboratory (Bar Harbor, ME), apoe-/- mice on a C57BL/6 background were obtained 
from  Iffa  Credo  (Lyon,  France).  IFNAR1fl/fl, LysMCre-IFNAR1fl/fl, apoe-/-, apoe-/-CCR1-/-, 
apoe-/-CCR2-/-, apoe-/-CCR5-/- and STAT1-/- mice were all on a C57BL/6 background and 
have been described before17,44-46. All animal experiments were approved by the 
Committee for Animal Welfare of the Maastricht University or complied with German 
animal protection law. 
Interferons 
Recombinant murine IFND or IFNE were  obtained  from  Hycult  Biotec  (Uden,  The  
Netherlands). Human IFNE was obtained from Peprotech (Rocky Hill, NJ, USA). 
In vitro murine macrophage culture 
Bone marrow cells were isolated from femurs and tibiae of wildtype mice (C57BL/6), 
IFNAR1fl/fl, LysMCre-IFNAR1fl/fl, apoe-/-, apoe-/-CCR1-/-, apoe-/-CCR2-/-, apoe-/-CCR5-/- or 
STAT1-/- mice. Cells were cultured in RPMI-1640 (Gibco Invitrogen, Breda, The 
Netherlands) with 10% heat inactivated fetal calf serum (Bodinco B.V., Alkmaar, The 
Netherlands), penicillin (100 U/ml), streptomycin (100 ug/ml), L-glutamine 2 mM (all 
Gibco Invitrogen, Breda, The Netherlands) (R10) supplemented with 15% L929-
Chapter 2 
 
 
54 
conditioned medium (LCM) for 8-9 days to generate bone marrow derived 
macrophages (BMM), as described previously47. Cells were treated for 24h with 
100U/ml IFND or IFNE.  
In vitro human macrophage culture 
Human mononuclear cells were obtained by apheresis of 2x the blood volume from 
healthy volunteers using a Cobe® Spectra (CaridianBCT Europe, Zaventhem, Belgium). 
Monocytes were subsequently enriched by counter flow centrifugation using the Elutra 
Cell Separation System (CaridianBCT) and were cultured in R10 supplemented with 
5ng/ml  M-CSF  (Peprotech)  for  8  days  to  generate  human  macrophages.  Cells  were  
treated for 24h with 100U/ml human IFNE. 
Gene expression 
RNA was isolated from BMM or human macrophages with the High Pure RNA Isolation 
Kit (Roche, Basel, Switzerland). 500 ng total RNA was reverse transcribed using the 
iScript cDNA Synthesis Kit (BioRad, Veenendaal, The Netherlands). Quantitative PCR 
was performed using 10 ng cDNA, 300nM of each primer, IQ SYBR Green Supermix 
(BioRad) in a total volume of 20 ʅl. Deletion efficiency in BMM of the LysMCre-
IFNAR1fl/fl mice  was  measured  by  Q-PCR  on  25ng  DNA  as  described  before47, using 
primers specifically detecting the floxed and not the deleted or wildtype IFNAR1 allele. 
All gene expression levels were corrected for cyclophilin A as house keeping gene and 
primer sequences are available upon request. 
In vitro oxLDL and bead uptake 
BMM untreated or treated for 24h with 100U/ml IFNE were  incubated  for  3h  in  
Optimem-1 with fluorescently labeled latex beads or 25 Pg/ml DiI labeled oxLDL, 
generated through copper oxidation, as described previously47. Uptake was assessed by 
flow cytometry after residual beads or oxLDL were washed away. 
Flow cytometry 
BMM (+/- 100U/ml IFNE for 24h) were stained with antibodies against VLA-4 
(Cedarlane, Burlington, Ontario, Canada), Mac1, LFA-1, PSGL1 (all BD Pharmingen, 
Erembodegem, Belgium), CCR2 (Epitomics, Burlingame, CA, USA) or CCR5 (BD 
Pharmingen) and their mean fluorescence was measured by FACS analysis. For the 
CCR2 staining, cells were permeabilized using CytopermTM Plus Permeabilization Buffer 
and Perm/WashTM Buffer (both BD Pharmingen). 
ELISA 
Murine CCL5 secretion from BMM (+/- 100U/ml IFNE for 24h) was measured by ELISA 
using anti-mouse CCL5 (R&D Systems, Abigndon, UK) as coating antibody and 
biotinylated anti-mouse CCL5 (R&D Systems) as detection antibody with mouse CCL5 
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(Peprotech) as standard. Human CCL5 secretion in the supernatants from human 
macrophages (+/- 100U/ml IFNE for  24h)   was  measured  by  commercial  ELISA  (PBL  
Interferon Source, New Brunswick, NJ, USA). Absorbance was measured at 450nm using 
a microtiterplate reader (BioRad, Hercules, CA, USA). 
In vitro adhesion assay 
A confluent monolayer of bEND5 endothelial cells was grown in fluorescence 96 wells 
microplates (Greiner Bio-one, Frickenhausen, Germany). Triplicate wells were 
incubated for 30 min with 105 BMM (+/- 100U/ml IFNE for 24h) that had been 
fluorescently labeled with a PKH dye according to the manufacturer’s instructions 
(Sigma Aldrich, Zwijndrecht, The Netherlands). Subsequently, the wells were washed 
three times with R10 and adherent cells were measured by fluorometry in a Synergy HT 
microtiter plate reader (BioTek, Bad Friedrichshall, Germany) at an excitation of 485nm 
and an emission of 520nm. 
In vivo leukocyte adhesion 
Apoe-/- mice were put on a high fat diet (0.15% cholesterol, 21% fat, Altromin) for 6 
weeks and during the last 4 days daily injected subcutenously with either saline or IFNE 
(5000U). Four mice receiving saline injections and five receiving IFNE injections were 
co-treated with an intravenous Met-RANTES (50 ʅg/mouse) injection 30 min before the 
experiment. After sedation (intraperitoneal Ketamine/Xylazin) and intravenous 
rhodamin injection, the left carotid artery was exposed and 3 high power fields (hpf) 
near the carotid bifurcation were visualized by epifluorescence microscopy (Zeiss 
Axiotech, 20x water immersion objective) as described before48. Short movies were 
recorded for each hpf, in which the cells attaching to the vessel wall were counted by 
eye. 
Collar-induced atherosclerosis 
Seventeen-week-old male apoe-/- mice (n=21) were operated after 3 weeks of high fat 
diet (0.25% cholesterol, 16% fat) to introduce a 2mm long non-constrictive silastic tube 
around both carotid arteries, as described before18. During the 24 days post-operation, 
the high-fat diet was continued and the mice were treated by daily subcutaneous 
injection of either IFNE (5000U) or saline. Upon sacrifice the right carotid artery was 
isolated and embedded in paraffin. Sections of 5Pm were made and after every 100Pm, 
sections were stained with haematoxilin/eosin for lesion area analysis. 
IFNE treatment in ldlr-/- mice 
Twelve-week-old male ldlr-/- mice were fed a high fat diet (0.15% cholesterol, 16% fat, 
Arie Blok, The Netherlands) for 6 weeks in order to induce early atherogenesis. At this 
point, daily subcutaneous injections of either IFNɴ (5000U) or saline were started and 
continued for 3 weeks while the high fat diet was continued. Upon sacrifice the heart 
and aorta were taken out. The hearts were cut perpendicular to the heart axis just 
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below the atrial tips. Tissue was frozen in tissue-tec (Shandon, Veldhoven, The 
Netherlands) and cut into sections of 7Pm as described before47. Serial cross-sections 
from every 42Pm were stained with toluidin blue. All lesion areas were quantified using 
Adobe Photoshop software. The aortas were snap-frozen and RNA was isolated using 
the RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) including DNAse treatment. Gene 
expression was assessed by Q-PCR, similarly as described above. 
Bone marrow transplantation 
One week before transplantation, female ldlr-/- mice were housed in filter top cages and 
provided with acidified water containing neomycin (100mg/l; Gibco, Breda, The 
Netherlands) and polymyxin B sulphate (6x104 U/l;  Gibco).  The  animals  received  two  
times 6Gy total body irradiation on two consecutive days. On the second day, bone 
marrow was isolated from 6 LysMCre-IFNAR1fl/fl mice (IFNAR1del)  and  6  IFNAR1fl/fl 
littermates (IFNAR1wt)  and  107 cells/mouse were injected intravenously to rescue the 
hematopoietic system of the irradiated mice. Four weeks after the transplantation, 
mice were fed a high fat diet (0.15% cholesterol, 16% fat, Arie Blok, The Netherlands) 
for 11 weeks. After sacrifice, the hearts from the bone marrow transplanted mice were 
taken out and lesion size in the aortic root was measured as described above. The 
lesions were also typed according to severity as early, moderate and advanced as 
described before47. 
Mouse blood parameters 
At several time points during all in vivo atherosclerosis experiments, blood was drawn 
from the mice. Plasma lipid levels were monitored enzymatically (Sigma Aldrich, 
Zwijndrecht, The Netherlands) and plasma cytokine levels were measured by flow 
cytometry using a Cytometric Bead Array kit (BD-Pharmingen, San Diego). For the bone 
marrow transplanted mice, leukocytes were counted using a Coulter counter and blood 
cell distribution was quantified by flow cytometry after antibody staining with either 
Mac1-PE and Gr1-FITC for macrophages and granulocytes or 6B2-PE and KT3-FITC for B- 
and T-cells (BD-Pharmingen, Erembodegem, Belgium). 
Immunohistochemical staining 
Lesions from the aortic root were fixed in acetone and incubated with antibodies 
against macrophages (MOMA-2, a gift from G. Kraal), granulocytes (NIMP, directed 
against Ly6G, a gift from P. Heeringa), T-cells (KT3, directed against CD3, a gift from G. 
Kraal) and proliferating cells (Ki-67, Dako, Glostrup, Denmark). Apoptotic cells in the 
plaques were stained by the TUNEL staining (Roche Diagnostics, Mannheim, Germany), 
according to the manufacturer’s protocol. Necrotic areas were analyzed on toluidin 
blue stained sections and identified by the presence of pyknosis, karyorrhexis or 
complete absence of nuclei. 
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Human plaque transcriptomics 
Microarray analysis was performed on RNA isolated from 44 (22 stable and 22 
ruptured) human carotid plaque specimens using Illumina Human Sentrix-8 V2.0 
BeadChip® technology to detect differential expression. For pathway analysis we used 
the Ingenuity Pathway Analysis (Ingenuity® Systems, www.ingenuity.com) system. 
Statistical analysis 
The statistical analyses were performed using Graphpad Prism (Graphpad Software). 
Differences between 2 groups were evaluated using a t-test, unless stated otherwise. 
Values are represented as mean ± SEM. A P value of less than .05 was considered to be 
statistically significant. All mouse data passed a normality test. 
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Abstract 
Activation of the transcription factor NF-ʃB appears to be involved in different stages of 
atherogenesis. In this paper we investigate the role of NF-ʃB inhibitor Iʃɲ in 
atherosclerosis. Myeloid-specific deletion of Iʃɲ results in larger and more advanced 
lesions in LDL-R-deficient mice without affecting the compositional phenotype of the 
plaques or systemic inflammatory markers in the plasma. We show that Iʃɲ-deleted 
macrophages display enhanced adhesion to an in vitro endothelial cell layer, coinciding 
with an increased expression of the chemokine CCL5. Also, in vivo we found that Iʃɲdel 
mice had more leukocytes adhering to the luminal side of the endothelial cell layers 
that cover the atherosclerotic plaques. Moreover, we introduce ER-MP58 in this paper 
as a new immunohistochemical tool for quantifying newly recruited myeloid cells in the 
atherosclerotic lesion. This staining confirms that in Iʃɲdel mice more leukocytes are 
attracted to the plaques. In conclusion, we show that Iʃɲ deletion in myeloid cells 
promotes atherogenesis, probably through an induced leukocyte recruitment to 
plaques. 
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Introduction 
NF-ʃB is a transcription factor that translates the inflammatory stimuli from the 
environment into gene expression patterns regulating cell differentiation, activation, 
proliferation and apoptosis as well as the production of a set of inflammatory 
mediators. It is activated in response to pathogen detection by Toll-like receptor 
signaling or, in the inflammatory milieu, through different cytokine receptors such as 
the TNF receptor. Also, non-pathogen related activation, called “sterile inflammation”, 
including stimuli such as free radicals, radiation and modified lipoproteins, can trigger 
NF-ʃB1,2.  
Rather than one transcription factor, NF-ʃB is in fact a family of homo- and 
heterodimers, with different possible combinations of the Rel-domain containing 
proteins NF-ʃB1 (p50 and its precursor p105), NF-ʃB2 (p52 and its precursor p100), RelA 
(p65), RelB and c-Rel. In the absence of an activating stimulus, the NF-ʃB dimer is kept 
cytoplasmic because its nuclear localization signal is covered by an inhibitor belonging 
to the IʃB family3. The IʃB family consists of Iʃɲ, Iʃɴ, Iʃɶ, Iʃɸ and Bcl-34. Following 
a signaling cascade initiated by an inflammatory stimulus, IʃB is phosphorylated by a 
complex consisting of IʃB kinase 1 (IKK1 or IKKɲ), IKK2 (or IKKɴ) and NEMO (or IKKɶ). 
This phosphorylation leads to ubiquitination and subsequent proteasomal degradation 
of the IțB, leaving NF-ʃB free to translocate to the nucleus5. Being NF-ʃB target genes 
themselves, the IʃB family members are part of a negative feedback loop, retracting 
NF-ʃB from the nucleus back into the cytoplasm and thereby preventing excessive and 
irreversible NF-ʃB activation6.  
NF-ʃB activation is an important response in different infectious as well as non-
infectious pathologies. Also in the different stages of atherogenesis, from early 
endothelial activation to eventual plaque rupture, NF-ʃB has been described as a key 
regulator7,8. Atherosclerosis is a slowly progressing, chronic inflammatory disease of the 
large arteries representing the most common cause of death in western society9. This 
process is initiated when modified lipoproteins in the vessel wall activate the 
endothelial lining of the vessel, thereby attracting monocytes, which differentiate into 
macrophages upon migration through the endothelium. By taking up and storing the 
lipoproteins, these macrophages eventually become large foam cells and start secreting 
inflammatory mediators, cytokines and chemokines. The thereby created inflammatory 
environment attracts even more monocytes as well as other immune cells to the vessel 
wall, forming an atherosclerotic plaque10.  
In the atherosclerotic plaque, a wide variety of NF-ʃB inducers is present, ranging from 
modified lipoproteins to inflammatory mediators, free radicals and remnants of dead 
cells11-13. Therefore, activated NF-ʃB has been found in different cell types in the lesion, 
including macrophages, smooth muscle cells and endothelial cells8,14. To investigate the 
importance of this activation, we have previously studied models with either a 
Chapter 3 
 
 
64 
macrophage- 15 or endothelial cell-specific 16 ablation in NF-ʃB activation. While 
macrophage-specific deletion of IKK2 led to larger and more advanced lesions, 
endothelium-restricted NEMO deletion abrogated atherogenesis by impairing 
macrophage recruitment to the plaque. 
In this paper we aimed at investigating the role of the NF-ʃB inhibitor Iʃɲ in 
atherogenesis. Since full Iʃɲ knockout mice die neonatal of hypergranulopoiesis and 
severe dermatitis17-19, we used a conditional model with a myeloid specific deletion of 
/ʃɲ20. Bone marrow from these LysMCre-/ʃɲfl/fl mice was transplanted into 
atherosclerosis-susceptible ldlr-/- mice to study the effect of myeloid Iʃɲ deficiency on 
atherogenesis. We found that myeloid Iʃɲ deficiency promotes atherogenesis by 
causing increased attraction of myeloid cells to the developing plaques without 
affecting other phenotypical characteristics of the lesions. Quite surprisingly, 
macrophage Iʃɲ deficiency does not seem to affect the production of a number of NF-
ʃB target genes in vivo nor in vitro but appears to be involved in the adhesion and 
recruitment of these cells to the atherosclerotic plaque.  
Figure 3.1: Plasma values and body weight of mice transplanted with either INBDfl/fl or LysMCre-INBDfl/fl 
bone marrow:  
(A) Cholesterol levels, (B) triglyceride levels and (C) body weight measured before the start of the high fat 
diet  (0w  HFD),  after  4  weeks  of  diet  (4w  HFD)  and  upon  sacrifice  of  the  mice  (12w  HFD).  (D-I) Plasma 
cytokine concentrations at the end of the experiment, measured by a bead array. 
A B C 
D E F 
G H I 
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Results 
Myeloid Ițɲ deficiency promotes atherogenesis without altering plaque phenotype, 
body weight, plasma lipids and cytokines 
To  study  the  effect  of  myeloid  INBD deficiency on atherosclerosis, bone marrow was 
isolated from INBDfl/fl and  LysMCre-INBDfl/fl mice, the latter having a myeloid-specific 
deletion of the /ʃɲ gene20. This bone marrow was transplanted into irradiated ldlr-/- 
mice, resulting in atherosclerosis-susceptible mice that were either wildtype (INBDWT) 
or deleted (INBDdel) for INBD in their myeloid cells. Four weeks after transplantation, 
these mice were put on a high fat diet for 12 weeks in order to induce atherogenesis. 
The rise in plasma cholesterol, plasma triglycerides and body weight as a result of the 
diet was similar in both groups (Figures 3.1A, B and C). In addition, relative levels of 
circulating leukocyte populations (monocytes, granulocytes, T and B lymphocytes) after 
the transplantation did not differ between the groups (data not shown). After 12 weeks 
of diet, plasma levels of the NF-ʃB dependent pro-inflammatory cytokines IL-6, IL-12, 
 
Figure 3.2: Myeloid INBD deficiency promotes atherosclerosis in ldlr-/- mice:  
Representative pictures of toluidine blue-stained sections in the aortic root of (A)  INBDWT or  (B) myeloid-
specific INBDdel mice, original magnification x40. (C) Lesion area in the aortic root of INBDWT and INBDdel mice 
(** p<0.01; n=18/16). (D) Lesion severity in the aortic root of INBDWT and INBDdel mice (Chi square test; *** 
p<0.0001; n=54/48) was typed as absent (0), early (1+2), or advanced (4+5), as described before15. 
A B 
C 
D 
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TNF-ɲ and IFNɶ, the anti-inflammatory cytokine IL-10 and the chemokine MCP-1 (CCL2) 
were not influenced by the absence of myeloid INBD (Figures 3.1D - I). 
Upon sacrifice, atherosclerosis in the aortic root was analyzed. Interestingly, lesion area 
measurements using toluidine blue-stained sections (Figures 3.2A and B) showed a two-
fold, significant increase in plaque formation in Iʃɲdel mice compared to INBDWT mice 
(49740 ± 9142 ʅm² vs. 94330 ± 8803 ʅm² for IʃɲWT and myeloid-specific Iʃɲdel 
respectively; p=0.0014) (Figure 3.2C). Moreover, classification of the lesions according 
to their severity showed that Iʃɲdel mice had relatively more advanced and less early 
atherosclerotic lesions (Chi square test; p<0.0001) (Figure 3.2D).  
With additional analyses on sections of the aortic root, the phenotype of these plaques 
was further characterized. Plaque-stabilizing collagen was stained with Sirius Red but 
no significant differences were found in collagen content between the two groups 
(Figure 3.3A). Also analysis of T cell and neutrophil content revealed no significant 
differences (Figures 3.3B and C). Finally, both groups appeared to have the same 
number of proliferating and apoptotic cells in their plaques, as shown by Ki-67 and a 
TUNEL stainings (Figures 3.3D and E). Thus despite having larger and more advanced 
lesions, the Iʃɲdel lesions showed no other changes in their plaque characteristics. 
Next to the lesions in the aortic root, atherosclerotic plaque formation was also 
assessed in the aortic arch. In RNA isolated from this tissue, a 49.6% increase in the 
expression of macrophage marker CD68 was found (p=0.0384, data not shown), 
indicating enhanced macrophage accumulation in the vessel wall of Iʃɲdel-
transplanted mice. 
 
Figure 3.3: Myeloid INBD deficiency does not influence plaque phenotypic characteristics:  
(A) Collagen content is not different between INBDWT and INBDdel mice, as shown by a Sirius Red staining. 
Also the relative number of (B) T cells, (C) neutrophils, (D) proliferating and (E) apoptotic cells was similar in 
both groups. 
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Myeloid Ițɲ deficiency promotes in vitro macrophage adhesion  
To investigate the mechanism behind the enhanced atherogenesis in the Iʃɲdel mice, 
in vitro experiments were done. Surprisingly, the reduced production of Iʃɲ shown in 
Figure 3.4A and Supplemental Figure S3.1A did not result in an increased activation of 
the p65 NF-ʃB subunit (Supplemental Figure S3.1B-C), suggesting a potent 
compensatory mechanism operating in the absence of Iʃɲ. As a result, hardly any 
difference was found in the expression of some genes known to be NF-NB targets, NF-
ʃB inhibitors or inflammatory mediators when assessed in unstimulated as well as LPS 
stimulated bone marrow-derived macrophages from LysMCre-INBDfl/fl mice and 
compared to wild type cells (Figure 3.4A and Supplemental Figure S3.1D). However, the 
expression of the chemokine CCL5 (or RANTES) was significantly elevated 2.8 fold in 
macrophages lacking INBD. CCL5 was previously shown to be involved in the adhesion 
of macrophages to endothelial cells. In line with these findings, static adhesion of 
/ʃɲdel macrophages to a monolayer of the bEND.5 endothelial cell line was significantly 
enhanced compared to wild-type macrophages (14610 ± 1163 AU vs. 21720 ± 1810 AU 
for IʃɲWT and Iʃɲdel respectively; p=0.0298) (Figure 3.4B). 
 
Figure 3.4: Deletion of Iʃɲ in bone marrow-derived macrophages has limited effect on the expression of 
NF-ʃB-dependent and/or –regulating genes but enhances in vitro static macrophage adhesion:  
(A) Gene expression in triplicates of LysMCre-INBDfl/fl macrophages was compared to INBDfl/fl macrophages 
by Q-PCR. (B) Adhesion of fluorescently labeled macrophages to an endothelial monolayer (bars represent 
triplicate wells ± SEM; * p<0.05). Data shown are representative for at least 3 experiments. 
A 
B 
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Figure 3.5: Increased leukocyte adhesion and newly recruited myeloid cells in Iʃɲdel mice:  
(C)  In  INBDdel mice, more leukocytes adhere to the endothelial cell layer delineating the lesion (*** 
p<0.0001; n=17/17). Representative pictures from (A) INBDWT and (B) INBDdel lesions, original magnification 
x200. (F) Lesions from INBDdel mice contain more ER-MP58 positive cells, suggesting an increased attraction 
myeloid cells (** p<0.001; n=19/17). Representative pictures from (D) INBDWT and (E) INBDdel lesions, original 
magnification x200. 
A B 
C 
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Atherosclerotic lesions in mice lacking myeloid Iʃɲ show increased leukocyte 
adhesion and migration. 
To investigate whether the observed increased in vitro macrophage adhesion could also 
be observed in the in vivo atherosclerosis model, cells adhering to luminal side of the 
endothelial cells covering the atherosclerotic plaques were quantified in the toluidine 
blue-stained sections. Indeed, the INBDdel mice displayed a significantly higher number 
of adhering cells  compared to the INBDWT mice (7.8 ± 1.3 cells vs. 15.9  ± 1.8 cells for 
INBDWT and  INBDdel respectively; p=0.0009) (Figures 3.5A - C), suggesting enhanced 
recruitment of new cells to the plaque in mice lacking INBD in their myeloid cells. 
To further analyze this recruitment of monocytes to the lesions, we used a marker that 
is specifically expressed on circulating immature myeloid cells but that is lost upon 
differentiation to macrophages. This marker, detected by the antibody ER-MP58, has 
previously been used in other studies to analyze recruitment of cells from the 
circulation to tissues21-23. Sections from the aortic root were stained with ER-MP58 and 
positive cells were quantified. As expected, these cells were predominantly observed 
on the luminal side of the plaque. However, also on the adventitial side, some myeloid 
recruitment could be observed. Interestingly, ER-MP58-positive cells were also seen in 
inflammatory regions in the vicinity of the plaques. Quantification showed that IʃBDdel 
mice had significantly more newly recruited myeloid cells in their plaques compared to 
/ʃɲWT mice (15.890 ± 3.164 cells vs. 37.590 ± 5.568 cells; p=0.0014) (Figures 3.5D - F). 
These data indicate that atherosclerotic lesions in the aorta of ldlr-/- mice lacking 
myeloid Iʃɲ may be larger because of enhanced recruitment and infiltration of 
myeloid cells, suggesting that myeloid Iʃɲ is important in regulating the migratory 
phenotype of cells in atherogenesis. A possible role for CCL5 in this mechanism is 
illustrated by the observation that the expression of this chemokine was significantly 
elevated in the aforementioned aortic arch-derived RNA (40.7% increase, p=0.0270, 
data not shown). 
Discussion 
In this paper we show that myeloid-specific deletion of the inhibitor of NF-ʃB, Iʃɲ, in 
ldlr-/- mice results in larger atherosclerotic plaques without affecting the general plaque 
composition. Studying cell adhesion to the luminal side of the endothelial layer 
covering atherosclerotic plaques, we observed increased adhesion of leukocytes in the 
absence of myeloid Iʃɲ. Through a marker specific for circulating myelomonocytic 
cells that is lost upon maturation to macrophages, ER-MP58, we found that lesions 
from mice lacking myeloid Iʃɲ are characterized by more newly recruited leukocytes. 
Moreover, we found an increase in macrophage content in the vessel wall of the aorta. 
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These data suggest that Iʃɲ in myeloid cells may have a pivotal role in regulating the 
recruitment of cells to atherosclerotic lesions.  
Atherosclerosis is known to be driven by inflammation and aggravated by the 
production of pro-inflammatory cytokines24. Since cytokine expression is highly 
dependent on NF-NB, it can be expected that the atherosclerotic process is 
proportional to the activation level of this transcription factor. Indeed, Gareus et al. 
showed that endothelial-specific inhibition of NF-ʃB by NEMO deletion impaired 
macrophage recruitment to the plaque and hereby impaired atherogenesis16. Another 
paper, by Wolfrum et al., describes how haploinsufficiency for the NF-ʃB activation 
inhibitor A20 results in enhanced atherogenesis while A20 overexpression reduced 
plaque formation25.  Our  group  also  showed  that  the  role  of  NF-ʃB  in  macrophages  is  
not as straightforward. Myeloid-specific blocking of the canonical activation of NF-ʃB 
through deletion of IKK2 resulted in plaques that were not only larger but also more 
advanced and more necrotic, highlighting the fact that NF-ʃB also acts as an anti-
apoptotic transcription factor and is involved in regulating anti-inflammatory 
mechanisms15. In contrast, the present study demonstrates that deletion of myeloid 
/ʃɲ, aiming at myeloid-specific NF-ʃB activation, also induces larger and more 
advanced plaques but without affecting the plaque composition. 
Studying gene expression in LysMCre-/ʃɲfl/fl bone marrow-derived macrophages and 
comparing it to wildtype cells, we found an increase in the expression of the chemokine 
RANTES (Released upon Activation, Normal T-cell Expressed and Secreted, or CCL5). 
This molecule belongs to a relatively limited set of chemokines and adhesion molecules 
that are described to be influencing atherogenesis through the recruitment of new cells 
to the plaque26,27. In a recent publication, our group showed that IFNɴ-induced 
expression of CCL5 augments the static adhesion of macrophages to endothelial cells in 
vitro as well as the adhesion of leukocytes to the vessel wall at atherosclerosis-prone 
sites in vivo, thereby promoting the attraction of new cells to the plaques28. 
Macrophages from LysMCre-INBDfl/fl mice indeed adhered more efficiently to an 
endothelial cell layer in vitro, while in the atherosclerosis model, more monocytes were 
found adhering to the endothelial layer covering the plaques in the INBDdel mice 
compared to the INBDWT mice. 
To confirm the hypothesis that the lesions in the INBDdel mice were larger because of an 
increased attraction of leukocytes, we applied a staining detecting a marker specific for 
immature myeloid cells, ER-MP58. The target is an antigen with a yet unknown 
function, which is present on the bone marrow-derived, myeloid-committed progenitor 
cells. It continues to be expressed on neutrophils and monocytes but disappears 
progressively upon maturation of the M-CSF-responsive cells to macrophages21,29. Thus, 
both Ly-6C-high and Ly-6C-low subsets of circulating monocytes are positive for ER-
MP58 while tissue macrophages have lost the marker29,30. Previously, detection of this 
marker has been used to distinguish infiltrating immature myeloid cells from the 
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resident macrophages already present within the site of inflammation, both in 
thioglycollate elicited macrophage recruitment to the peritoneum21,22 and in the 
restoration of the Kupffer cell population in the liver, following injection with liposome-
entrapped dichloromethylene diphosphonate23. In this paper, we show that ER-MP58 is 
also a valid marker for newly recruited myeloid cells to the atherosclerotic plaque, with 
a positivity that is limited to small, recently infiltrated cells in the vicinity of the luminal 
plaque surface and inflammatory regions. 
Contrary to the upregulation of CCL5 expression in the LysMCre-/ʃɲfl/fl macrophages, 
many typical NF-ʃB-dependent genes were not influenced by the deletion of Iʃɲ. This 
suggests that in these cells, NF-ʃB is not continuously activated, but inhibited by other 
feedback mechanisms which, like Iʃɲ, prevent NF-ʃB translocation to the nucleus or 
terminate NF-ʃB activation by exporting it back to the cytoplasm. Indeed, studying the 
nuclear translocation of several NF-ʃB subunits, we found that the LysMCre-/ʃɲfl/fl 
macrophages had the same degree of translocation as wildtype cells (data not shown) 
and no increase in p65 phosphorylation was observed in the Iʃɲdel macrophages 
(Supplemental Figure S3.1B-C). In addition, only mild to no upregulation of other IʃB 
family members was detected by gene expression analysis, indicating alternative 
mechanisms of regulation of NF-ʃB dependent transcription. Recent studies indeed 
show that, besides IʃB inhibitors, also nuclear ubiquitin ligases can terminate chronic 
NF-NB activation by its nuclear degradation, a mechanism that might compensate the 
deletion of INBD31. 
In conclusion, we found that myeloid-specific deletion of Iʃɲ resulted in an 
upregulation of the chemokine CCL5 and enhanced static in vitro adhesion of 
macrophages to an endothelial cell layer. Moreover, this correlated in vivo with 
increased leukocyte adhesion to the activated endothelial lining of the blood vessel, 
enhanced recruitment of ER-MP58+ immature myeloid cells to the atherosclerotic 
plaque and increased atherosclerotic lesion formation in the aortic root and arch. 
Hereby we show that the role of myeloid Iʃɲ in the regulation of inflammation is 
complex but that it is involved in the recruitment of macrophages to the atherosclerotic 
plaque. 
Materials and methods 
Mice 
C57BL/6 mice and ldlr-/- mice on a C57BL/6 background were obtained from Jackson 
Laboratory (Bar Harbor, ME). /ʃɲfl/fl mice on a C57BL/6 background were described 
before32. All animal experiments were approved by the DierExperimenten Commissie 
(DEC) of the Maastricht University (permit numbers 2005-090 and 2009-168). 
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Bone marrow transplantation 
One week before transplantation, female ldlr-/- mice were housed in filter top cages and 
provided with acidified water containing neomycin (100mg/l; Gibco, Breda, The 
Netherlands) and polymyxin B sulphate (6x104 U/l; Gibco). The animals received 10Gy 
total body irradiation and on the following day, bone marrow was isolated from 6 
LysMCre-INBDfl/fl mice (INBDdel)  and 6  INBDfl/fl littermates (INBDwt)  and 107 cells/mouse 
were injected intravenously to rescue the hematopoietic system of the irradiated mice. 
Four weeks after the transplantation, mice were fed a high fat diet (0.15% cholesterol, 
16% fat, Arie Blok, The Netherlands) for 12 weeks.  
Mouse blood parameters 
At several time points during the in vivo atherosclerosis experiment, blood was drawn 
from the mice. Plasma lipid levels were monitored enzymatically (Sigma Aldrich, 
Zwijndrecht, the Netherlands) and plasma cytokine levels were measured by flow 
cytometry using a Cytometric Bead Array kit (BD-Pharmingen, San Diego, CA). 
Leukocytes were counted using a Coulter counter and blood cell distribution was 
quantified by flow cytometry after antibody staining with either Mac1-PE and Gr1-FITC 
for macrophages and granulocytes or 6B2-PE and KT3-FITC for B- and T-cells (BD-
Pharmingen, Erembodegem, Belgium). 
Atherosclerosis analysis 
Upon sacrifice, the hearts from the bone marrow transplanted mice were taken out and 
cut perpendicular to the heart axis just below the atrial tips. Tissue was frozen in tissue-
tec (Shandon, Veldhoven, The Netherlands) and cut into sections of 7 ʅm as described 
before15. Serial cross-sections from every 42 ʅm were stained with toluidine blue. All 
lesion areas were quantified using Adobe Photoshop software. The lesions were also 
typed according to severity as early, moderate and advanced, as described before15. 
Immunohistochemical staining 
Lesions from the aortic root were fixed in acetone and incubated with antibodies 
against neutrophils (1A8, BD-Pharmingen), T cells (KT3, directed against CD3, a gift from 
G. Kraal), proliferating cells (Ki-67, Dako, Glostrup, Denmark) and newly recruited 
macrophages (ER-MP58, P. Leenen), followed by detection with a biotin labeled rabbit 
anti-rat antibody and staining with the ABC kit (Vector Labs, Burlingame, CA). Apoptotic 
cells in the plaques were stained by the TUNEL staining (Roche Diagnostics, Mannheim, 
Germany) according to the manufacturer’s protocol. Collagen areas were analyzed on 
Sirius red stained sections. Adhering leukocytes were quantified on toluidine blue-
stained sections. 
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In vitro murine bone marrow macrophage culture 
Bone marrow cells were isolated from femurs and tibiae of either wild-type (Ițɲfl/fl) or 
deleted (LysMCre-Ițɲfl/fl) mice. Cells were cultured in RPMI-1640 (GIBCO Invitrogen, 
Breda, The Netherlands) with 10% heat-inactivated fetal calf serum (Bodinco B.V., 
Alkmaar, The Netherlands), penicillin (100 U/ml), streptomycin (100 ug/ml), and L-
glutamine 2mM (all GIBCO Invitrogen, Breda, The Netherlands) supplemented with 15% 
L929-conditioned medium (LCM) for 8–9 days to generate bone marrow-derived 
macrophages (BMM), as described previously15.  
Western blotting 
Protein was isolated from BMM with an SDS lysis buffer, supplemented with complete 
protease inhibitor cocktail (Roche Diagnostics) and PhosSTOP phosphatase inhibitor 
cocktail (Roche Diagnostics). After Western blotting, blots were incubated with P-p65 
antibody (1:500, Cell Signaling, Danvers, MA) in PBS with 0.05% Tween and 5% BSA 
(Sigma Aldrich). 
Gene expression 
RNA was isolated from BMM with the High Pure RNA Isolation Kit (Roche, Basel, 
Switzerland) or from snap-frozen aortic arches with the RNeasy Mini Kit (Qiagen, Venlo, 
The Netherlands). 500 ng total RNA was reverse transcribed using the iScript cDNA 
Synthesis Kit (BioRad, Veenendaal, The Netherlands). Quantitative PCR (Q-PCR) was 
performed using 10 ng cDNA, 300 nM of each primer, and SensiMix (Quantace-Bioline, 
London, UK) in a total volume of 20 ʅl. All gene expression levels were corrected for 
cyclophilin A as housekeeping gene. Primer sequences are available upon request. 
In vitro adhesion assay 
A confluent monolayer of bEND5 endothelial cells was grown in fluorescence 96-well 
microplates (Greiner Bio-one, Frickenhausen, Germany). Triplicate wells were 
incubated for 30 min with 105 BMM that had been fluorescently labeled with a PKH67 
dye according to the manufacturer’s instructions (Sigma Aldrich, Zwijndrecht, The 
Netherlands). Subsequently, the wells were washed three times with the 
aforementioned macrophage medium, and adherent cells were measured by 
fluorometry in a Synergy HT microtiter plate reader (BioTek, Bad Friedrichshall, 
Germany) at an excitation of 485 nm and an emission of 520 nm. 
Statistical analysis 
The statistical analyses were performed using Graphpad Prism (Graphpad Software). 
Differences between 2 groups were evaluated using a t-test, unless stated otherwise. 
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Values are represented as mean ± SEM. A P value of less than .05 was considered to be 
statistically significant. All mouse data passed a normality test. 
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Abstract 
Survivin is an inhibitor of apoptosis and is highly expressed in virtually all tumors but 
has low to undetectable levels in healthy cells. Therefore, survivin has been a target in 
cancer therapies, including immunotherapy against survivin-positive cells. Recently, 
survivin expression was observed in macrophages that infiltrate early human 
atherosclerotic lesions. In this paper, we confirmed the presence of survivin-positive 
cells in murine atherosclerotic plaques. Subsequently, we targeted atherosclerosis by 
inducing a cytotoxic T cell response against survivin-positive plaque macrophages. We 
immunized atherosclerosis-susceptible mice using a lentivirus-based vaccination 
strategy, which indeed reduced atherosclerotic lesion size and promoted the migration 
of CD3+ T  cells  and  CD8+ cytotoxic  T  cells  into  the  plaque.  These  experiments  are  the  
first to show the therapeutic potential of immunization against plaque-infiltrating 
macrophages and thereby offer a novel perspective for immunotherapy-based 
strategies in combating atherosclerosis. 
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Introduction 
Survivin (also known as baculoviral inhibitor of apoptosis repeat-containing 5, BIRC5) is 
a member of the Inhibitor of Apoptosis (IAP) family of proteins1 and is predominantly 
studied as a tumor-associated protein. While its expression in healthy cells is usually 
low to undetectable2 and restricted to the G2/M phase of mitosis with a rapid 
downregulation in the G1 phase, virtually all tumors exhibit an excessive and cell cycle-
independent expression, making survivin the fourth most upregulated gene in tumor 
transcriptomes3. 
 Survivin regulates two essential cellular processes that both contribute to 
tumor growth. As an IAP family member, survivin inhibits apoptosis. Indeed, its 
overexpression attenuates cell death, while inhibiting its function results in 
spontaneous cell death and a higher sensitivity to apoptotic stimuli4. It is, however, not 
a direct caspase inhibitor5, and the mechanism behind its effect on apoptosis is still 
unclear. In addition to blocking apoptosis, survivin also regulates mitosis through its 
effects on multiple spindle microtubule functions and mitotic checkpoints, promoting 
proliferation by facilitating accurate sister chromatid segregation and stabilization of 
microtubules in late mitosis6,7. Because cell cycle progression and resistance to cell 
death are two factors that are essential to tumor formation, survivin upregulation may 
be a key step in the initiation of tumorigenesis8. These properties make survivin an 
attractive universal target for anti-tumor drugs and therapies4. Several strategies, 
including small-molecule antagonists, dominant-negative mutants, small interfering 
RNA (siRNA), ribozymes, anti-sense oligonucleotides, immunotherapy and survivin 
promoter-induced TRAIL expression, have been tested in experimental models, and 
some strategies have advanced to human phase I or II clinical trials, all without 
significant cross-reactivity-related side effects9-12.  
 Interestingly, Blanc-Brude et al. described survivin to also be detectable in 
human atherosclerotic plaques13. Atherosclerosis is a chronic inflammatory disease of 
the vascular wall that gradually causes a variety of acute, life-threatening outcomes, 
such as myocardial infarction and stroke. It is initiated when low-density lipoproteins 
(LDL) accumulate in the subendothelial space and are chemically modified. This 
mobilizes circulating monocytes to the vessel wall to clear the modified LDL. The 
accumulation of these cells forms an early atherosclerotic plaque or fatty streak. 
Subsequently, the plaque evolves to a more advanced state by the attraction of more 
blood cells, the growth of a fibrous cap and the appearance of a necrotic core, a region 
in the plaque where the debris of inefficiently cleared apoptotic and necrotic cells 
gathers. The susceptibility of the plaque to rupture and cause acute symptoms is 
determined by the balance between stabilizing (e.g., cap thickness) and destabilizing 
(e.g., necrotic core size) factors. 
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In the aforementioned study, macrophage colony-stimulating factor (M-CSF) is able to 
upregulate survivin expression in macrophages in vitro13. M-CSF is abundantly present 
in atherosclerotic plaques where it promotes macrophage attraction and survival14. 
Prolonged in vitro exposure to oxidized LDL (oxLDL), however, abolishes survivin 
expression13. Indeed, immunohistochemical analysis of human atherosclerotic plaques 
revealed that CD68+ macrophages are positive for survivin at the luminal side of early 
fatty streaks, while in more advanced plaques, survivin-positive cells were rarely 
found13. This suggests that newly infiltrated macrophages in early atherosclerotic 
plaques express survivin under the influence of M-CSF, possibly as a protective 
mechanism against apoptosis provoked by radical oxygen species and lipid degradation 
products within the lesion15. Once the macrophages become foam cells, however, they 
lose their survivin expression. Thereby they become vulnerable to apoptosis, 
contributing to necrotic core formation. 
 In this paper, we identify survivin as a new specific immune target in 
atherosclerosis by showing that survivin-expressing cells are detectable in murine 
plaques. Analogous to cancer models, in which cellular immunity against survivin-
expressing cells selectively kills tumor cells without significant side effects16,17, we 
applied a lentiviral vaccination strategy to induce cellular immunity against newly 
infiltrating macrophages in the plaques. We show that such survivin-based 
immunotherapy effectively reduced atherosclerotic plaque size and was accompanied 
by an enhanced recruitment of CD3+ T cells and CD8+ cytotoxic T cells to the lesions. 
RESULTS 
Survivin is detected in murine atherosclerotic plaques and macrophages 
Cryosections of atherosclerotic lesions from LDLR-/- mice fed a high-fat diet for 12 
weeks were immunohistochemically stained for survivin. In the plaques, survivin-
positive cells were clearly detectable (Figure 1 A-B). Morphologically, these cells were 
identified as macrophages, and they were located predominantly on the luminal side of 
the plaque, similar to the survivin-positive cells found in human fatty streaks 13. No 
staining was observed in the media or in the adjacent aorta, indicating that survivin 
expression was specific to the plaque-infiltrating macrophages, in addition to its usually 
assumed restriction to tumor cells, apoptosis-related fetal tissues18, sites of vascular 
injury19 and a selection of self-renewing cells2. 
Analysis of microarray data generated by our group20 showed that treating murine 
bone marrow-derived macrophages in vitro with oxLDL, but not with acetylated LDL 
(acLDL) or unmodified LDL, reduced survivin expression by 48% (p=0.0068; Figure 1 C).  
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Validation of a survivin-specific cytotoxic T cell response upon lentiviral vaccination 
Inhibition of survivin expression and elimination of survivin-positive cells have been 
successfully applied as therapies in murine tumor models and cancer patients10. To 
evaluate whether survivin-positive cells in atherosclerotic plaques can be targeted in a 
similar way, we developed a lentiviral vector-based vaccination strategy aimed to skew 
the immune system toward autoreactivity against survivin-presenting cells. The murine 
survivin gene was cloned into a lentiviral vector containing a CMV promoter. Moreover, 
this vector encodes the non-functional truncated nerve growth factor receptor (tNGFR) 
as a marker gene21. Viruses generated from this vector (‘SURV’) or from the empty 
control vector (‘tNGFR’) were subsequently used for vaccination. 
To verify the ability of these viruses to induce a murine survivin-specific immune 
reaction, BALB/c mice were injected in the footpad with one of the viral vectors. Four 
days after immunization, splenocytes from the mice were isolated and re-stimulated in 
vitro with the survivin-expressing BALB/c-derived B cell lymphoma cell line A20. 
Subsequently, the induction of cytotoxic T cells was evaluated in a 51Cr-release assay. In 
this experiment, the splenocytes were co-cultured with radioactively labeled A20 cells 
 
Figure 4.1: Survivin expression in murine atherosclerotic plaques and macrophages:  
A-B: Murine atherosclerotic plaques were immunohistochemically stained without (A) or with (B) a survivin-
detecting antibody (original magnification x200). The survivin-expressing cells are indicated by arrows. C: 
Survivin gene expression in murine bone marrow-derived macrophages incubated for 24h with non-modified 
LDL, oxidized LDL or acetylated LDL.  
A B 
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at different effector/target (E/T) ratios, and specific cell lysis was analyzed. The results 
show that vaccination with a survivin-encoding lentivirus significantly induced cytolytic 
activity against A20 cells (two-way ANOVA, p=0.0141; Figure 2).  
LDLR-/- vaccination and general pathology 
To assess the effect of a survivin-targeted vaccination on atherosclerosis development, 
9-week-old LDLR-/- mice were injected with either ‘SURV’ (n=16) or ‘tNGFR’ (n=15) 
lentiviruses. They received additional boost injections after 1 and 4 weeks. One week 
after the first injection, the mice were placed on a high-fat diet to induce 
atherogenesis, which was maintained for 11 weeks (Supplemental Figure S4.1). During 
this period, both groups of mice gained equally in total body weight (Supplemental 
Figure S4.2A), and both groups had similarly raised plasma cholesterol and triglyceride 
levels (Supplemental Figure S4.2B-C). No mice died or showed any sign of discomfort 
during the experiment. Upon sacrifice, no macroscopic signs of pathology were visible 
in either of the vaccinated groups, and the microscopic examination of the small 
intestine, kidneys, liver and skin did not show any indication of tissue damage or 
immune cell aggregation. The plasma values and pathology of the lentivirus-injected 
groups did not differ from that of a group of PBS-injected control mice (n=15). 
Atherosclerotic plaque analysis 
After  11  weeks  on  a  high-fat  diet,  the  mice  were  sacrificed,  and  cryosections  of  the  
aortic root were obtained to analyze the effect of vaccination on atherosclerosis. 
Compared with the ‘tNGFR’ group, ‘SURV’-vaccinated mice had plaques that were 31% 
smaller (124,900 ± 6,472 ʅm² vs. 85,950 ± 10,250 ʅm², respectively, p=0.0080; Figure 3 
A-B). We observed no effect from the lentiviral treatment itself; lesions of the ‘tNGFR’-
vaccinated mice were equal in size compared with PBS-injected mice (data not shown).  
 
Figure 4.2: In vitro cytotoxicity assay: 
Splenocytes from mice that were vaccinated with either control (tNGFR) or survivin (SURV) lentiviruses 
were re-stimulated with survivin-expressing cells, after which they were co-cultured with 51Cr-labeled A20 
cells at different E/T ratios, and lysis was analyzed. 
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Both groups of vaccinated mice had equal percentages of plaque-stabilizing collagen in 
their lesions (7.002 ± 1.050% for ‘tNGFR’ vs. 6.340 ± 1.050% for ‘SURV’, p=0.6647; 
Supplemental Figure S4.2D), while the necrotic core area was remarkably yet 
insignificantly increased upon ‘SURV’ treatment (3.222 ± 0.6864% for ‘tNGFR’ vs. 5.705 
± 1.181% for ‘SURV’, p=0.0834; Supplemental Figure S4.2E).  
Because the lentiviral vaccination was designed to induce a cytotoxic response against 
survivin-expressing cells, the number of T cells within the plaque was assessed using 
CD3 staining. We observed an increase in CD3+ T  cells  in  the  plaques  of  ‘SURV’-
vaccinated mice (113.2 ± 21.65 T cells/mm² for ‘tNGFR’ vs. 611.7 ± 92.19 T cells/mm² 
for ‘SURV’, p=0.0001; Figure 3 C-D). Focusing further on cytotoxic T cells, we also found 
a higher lesion content of CD8+ cells in ‘SURV’-vaccinated mice (37.64 ± 8.472 CD8+ 
cells/mm² for ‘tNGFR’ vs. 84.68 ± 18.06 CD8+ cells/mm² for ‘SURV’, p=0.0306; Figure 3 
E-F), suggesting the recruitment of survivin-targeted cytotoxic T cells.  
 
Figure 4.3: Atherosclerotic plaque size and phenotype: 
A-B: Sections of the aortic root of mice treated with either control (tNGFR) (n=15) or survivin (SURV) (n=16) 
lentivirus were stained with toluidine blue to quantify the lesion size. C-D: The numbers of CD3+ T cells in the 
plaques of tNGFR or SURV treated mice with representative pictures. E-F: The numbers of CD8+ cytotoxic T 
cells in plaques of tNGFR or SURV treated mice with representative pictures. 
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DISCUSSION 
In chronic diseases where leukocyte recruitment to the site of inflammation has a 
detrimental effect on outcome22, knowledge of specific markers for the infiltrating cells 
can be very useful for both analysis and treatment purposes. While no survivin 
expression is present in healthy blood vessels18,19, the presence of survivin-positive cells 
has been demonstrated in human atherosclerotic lesions13. In this paper, we evaluated 
murine lesions for the presence of cells that express survivin and subsequently targeted 
them with a lentiviral vaccination strategy. 
Blanc-Brude et al. described how M-CSF induces the expression of survivin in 
macrophages entering the human plaque. However, these survivin-positive cells were 
absent in the adventitial region as well as in more advanced plaques, which was 
attributed to a downregulation of the expression evoked by long-term exposure to 
oxidized lipids within the plaque13. We confirmed the presence of survivin-positive cells 
in a confined region within murine plaques and identified them morphologically as 
newly recruited macrophages. Furthermore, we demonstrated in vitro that murine 
bone-marrow-derived macrophages cultured in the presence of M-CSF express survivin 
and lose this expression upon treatment with oxLDL, but not with acLDL or unmodified 
LDL. This indicates that the survivin downregulation in foam cells is specifically related 
to the oxidative modification of lipoproteins rather than the intracellular accumulation 
of cholesteryl esters. Taken together, these data indicate that survivin is a specific 
marker for newly recruited macrophages in murine atherosclerotic plaques that is lost 
upon foam cell formation. 
The specificity of this marker allows targeting of these cells through the induction of a 
cytotoxic immunity. A lentiviral vaccination strategy was designed in analogy to tumor 
cell-targeting vaccines, where it was shown previously that direct administration of 
similar lentiviral vectors to mice results in the induction of transgene-specific T cell 
responses23,24. In order to evaluate the potency of the lentiviral injections to induce 
cytotoxicity against survivin-expressing cells, we measured the level of cell death in a 
survivin-positive cell line co-cultured with splenocytes from vaccinated mice. The 
observed induction in cytotoxicity is comparable to results from earlier immunization 
studies using the same constructs with a different insert24.  
Until now, therapeutic options in atherosclerosis have been mainly restricted to plasma 
lipid lowering, either through dietary changes or pharmaceutical intervention. Recently, 
experimental immune modulation gained attention and has begun to be used in the 
clinic. To achieve a more targeted effect than systemic immune suppression, however, 
an immune response against atherosclerosis-specific antigens is needed. Active or 
passive immunization with oxLDL or with specific epitopes derived from oxidized 
phospholipids or apoB-100 has been shown to reduce plaque size25,26. Other immune 
therapies that successfully attenuated experimental atherosclerosis include promoting 
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regulatory T cells through oral HSP60 tolerance induction27, skewing the helper T cells 
towards a regulatory T cell or Th2 response28 and inducing cellular immunity against 
CD9929 or vascular endothelial growth factor receptor 2 (VEGFR2)30. 
Analysis of the atherosclerosis in LDLR-/- mice revealed that vaccination with the ‘SURV’ 
lentiviruses resulted in significantly smaller lesions containing more CD3+ T  cells  and  
CD8+ cytotoxic T cells, without affecting other tissues or the mice’ health. Moreover, 
their lesions displayed a trend towards an increase in necrotic core area, which may be 
a reflection of the lysis of survivin-expressing cells within the plaques and may suggest 
that ‘SURV’ vaccination provokes plaque instability over time, an important issue that 
should be further investigated in the future.  
In conclusion, the lentiviral vaccination strategy applied in this murine atherosclerosis 
model reduced the lesion size and induced the presence of intra-plaque T cells and 
cytotoxic T cells. This confirms the feasibility of this novel approach, which specifically 
targets cells in the atherosclerotic plaque with a survivin-specific immune response 
without significant side effects. This approach is analogous to existing cancer therapies 
that target survivin-expressing tumor cells. Future studies should further investigate the 
long-term effects of lentiviral vaccination on plaque size and composition and also 
study whether therapeutic and prophylactic vaccinations have similar outcomes. 
METHODS 
Mice 
BALB/c mice and ldlr-/- mice on a C57BL/6 background were obtained from Harlan 
(Horst, The Netherlands) and Jackson Laboratory (Bar Harbor, ME), respectively. All 
animal experiments were approved by the Leiden University and the Vrije Universiteit 
Brussel.  
Survivin expression 
Macrophage survivin expression was assessed by Affymetrix microarray, as described 
before20. 
Lentivirus production 
The murine survivin gene (a kind gift from Dr. E.M. Conway, Katholieke Universiteit 
Leuven, Belgium), was cloned into the pSINT vector, which was previously described 21. 
This transfer plasmid (‘SURV’) or the empty vector (‘tNGFR’) was co-transfected into the 
human embryonal kidney (HEK) 293T cell line together with the envelope (pMD.g) and 
packaging (pCMVȴR8.9) plasmids (a kind gift from Dr. Trono, University of Geneva, 
Switzerland), using the FuGENE® HD transfection reagent (Roche, Mannheim, 
Germany). Viruses were harvested from the supernatant on three consecutive days and 
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concentrated by ultracentrifugation, as previously described21. Virus titers were 
determined using the NucleoSpin RNA Virus kit (Macherey-Nagel, Düren, Germany) and 
the Lenti-X qRT-PCR Titration kit (Clontech, Mountain View, CA).  
Mouse immunization and cytotoxicity assay 
BALB/c mice were immunized by injection of 107 transducing units (TU) of the ‘SURV’ or 
‘tNGFR’ lentivirus in the footpad. The induction of survivin-specific T cells was analyzed 
by isolation of spleen cells and re-stimulation for 5 days by co-culture with mitomycin 
C-treated A20 cells at a responder/stimulator ratio of 1:2. Subsequently, splenocytes 
were co-cultured for 4 hours with 51Cr-labeled A20 cells at different effector/target 
(E/T) ratios. Cell lysis was measured by 51Cr-release in the supernatant with a ɴ counter 
as previously described21,24. 
Atherosclerosis analysis 
Ldlr-/- mice were immunized by injection of 107 TU of ‘SURV’ (n=16) or ‘tNGFR’ lentivirus 
(n=15) in the footpad. The effect of the virus injection was assessed by injecting a 
parallel group with PBS (n=15). The mice were fed a high fat diet (15% cocoa butter, 
0.25% cholesterol) for 11 weeks and subsequently sacrificed for analysis as described 
previously22. Survivin staining was performed using a rabbit polyclonal antibody (Novus 
Biologicals, Littleton, CO). 
Statistical analysis 
Statistical analyses were performed using Graphpad Prism (Graphpad Software). 
Differences between 2 groups were evaluated using a t-test, unless stated otherwise. 
Values are represented as mean ± SEM. A P value of less than .05 was considered to be 
statistically significant. All mouse data passed a normality test. 
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Abstract 
Atherosclerosis is a chronic inflammatory disease involving many cell types with a well-
accepted key role for macrophages. A wide array of different properties and functional 
characteristics are attributed to macrophages present in the atherosclerotic plaque. As 
an increasing body of evidence strengthens the consensus that macrophages comprise 
a heterogeneous population, several co-existing subtypes with diverse, even opposing 
specialties have already been described in fields like parasitology, tumour biology and 
metabolic disorders. However, macrophage heterogeneity within atherosclerotic 
lesions has not been studied in detail yet. In this review we will introduce the 
characteristics of macrophage subsets in other pathologies and address the presence 
and possible roles of distinct macrophage subtypes in the rapidly evolving field of 
atherosclerosis. Finally, we make an effort to relate these subtypes to disease 
progression and explore a number of opportunities for novel diagnostic and therapeutic 
approaches. 
  
Macrophage heterogeneity in atherosclerosis 
 
91 
Introduction 
Atherosclerosis is a multifactorial disease that afflicts the medium and large sized 
arteries of the body. Formerly perceived as a mere lipid storage disease, the treatment 
of atherosclerosis in patients has focused mainly on the lowering of plasma cholesterol. 
Although effective lipid lowering can be achieved pharmaceutically, cardiovascular 
disease (e.g. myocardial infarction, stroke) still constitutes the main cause of mortality 
in modern societies. Since these acute clinical events are largely attributable to 
complications of atherosclerotic lesions, novel strategies for prevention and 
management of atherosclerosis are in high demand. From this perspective, the 
fundamental role of inflammation as a mediator of all stages of atherogenesis is being 
appreciated to an ever increasing extent. Not only does the chronic inflammatory 
response associated with atherosclerosis act alongside well-known environmental and 
genetic risk factors to induce lesion initiation, it also promotes progression and 
ultimately leads to plaque rupture by reducing lesion stability1,2. Consequently, 
extensive scientific efforts have been made over the past decade to illuminate the 
inflammatory processes that underlie atherosclerosis development at the molecular 
and cellular level.  
Atherosclerosis, as an inflammatory condition, involves many cell types and mediators 
of the immune system. In this regard, monocyte-derived macrophages are imperative 
as these immune cells partake in innate and adaptive (Th1 and Th2-mediated) immune 
responses, which are both intricately engaged in atherogenesis2. Macrophages do not 
only form one of the main cellular constituents of the lesions (e.g. as foam cells), they 
also  serve  as  a  major  source  of  inflammatory  mediators.  Thereby  they  determine  the  
inflammatory equilibrium (i.e. the balance between pro- and anti-inflammatory factors) 
during atherogenesis, greatly impact the activation, migration and survival of other cells 
in the plaque and ultimately affect plaque stability. As such, macrophages are generally 
accepted as key players in the pathophysiology of atherosclerosis that profoundly 
shape atherosclerotic plaque development. The morphology of macrophages in 
atherosclerotic lesions can vary dramatically, from a large quiescent lipid-laden foam 
cell to a small active inflammatory cell. Recent work in the field of innate immunity has 
led to the identification of macrophage subsets based on their immune polarization. 
These subsets portray divergent characteristics and identification of specific markers 
and their functional role in vivo has recently gained strong interest in different fields of 
inflammatory disease. Knowledge on the in vivo contribution of different macrophage 
populations to the development of atherosclerosis however is scarce. Nevertheless, 
based on their distinct physiological roles, macrophage subsets are expected to highly 
determine plaque composition, stability and consequently clinical outcome. Taking 
approaches with experimental animal models as lead, in this review we will highlight 
the typical features of macrophage subsets and discuss their relevance and 
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contribution in a number of pathologies. Moreover, we speculate on the functional 
characteristics of macrophage subsets in atherosclerosis and address opportunities that 
may arise in using macrophage subsets for therapeutic targeting and the diagnosis of 
atherosclerosis. 
Macrophage heterogeneity 
Cells of the mononuclear phagocyte lineage (i.e. monocytes, macrophages) are 
characterized by a substantial degree of heterogeneity3,4. Especially macrophages are 
known to express functionally different phenotypes in response to tissue-derived 
signals and the immunological micro-environment, thus skewing them towards their 
many tasks in homeostasis, host defence and pathology4-9. Furthermore, macrophages 
display notable plasticity, as they are capable of rapidly switching between activation 
states in response to a specific incentive9-11. Accordingly, under inflammatory 
conditions, macrophage populations may initially partake in promoting inflammation 
and later contribute to its resolution12-14. Over the last decade, a conceptual framework 
has been devised and gradually expanded to account for the polarized functional 
properties of different macrophage populations. In reflection of the Th1 and Th2 
nomenclature in lymphocytes, polarized macrophage subsets are mostly referred to as 
M1 and M2 macrophages5,6,15.  
Classically activated or M1 macrophages are elicited through stimulation with the Th1-
cytokine interferon-ɶ (IFN-ɶ) alone, through a concomitant stimulus of IFN-ɶ with 
microbial products, such as lipopolysaccharide (LPS) or by activation with the Th1 
cytokine tumour necrosis factor (TNF). Although these cells show extensive 
morphological diversity based on their tissue localization, M1 cells share the ability to 
secrete large quantities of pro-inflammatory cytokines, such as TNF, interleukin (IL)-1ɴ, 
IL-6, IL-18 and IL-125,13. Additionally, they produce high levels of anti-microbial effector 
molecules (reactive oxygen and nitrogen species; ROS, RNS). These qualities allow M1 
macrophages to act as potent inducers and effectors of polarized type I immune 
responses, consequently associating them with resistance to pathogens and tumours as 
well as tissue destruction16-19. Recently, Martinez et al. have suggested a further 
subdivision of the M1 subset in M1a and M1b macrophages to distinguish between 
classical and innate activation types 13.  Whereas  the  latter  phenotype  is  said  to  be  
induced through ligation of for instance Toll-like receptors (TLR) by so-called Pathogen-
Associated Molecular Patterns (e.g. LPS) and somewhat resembles the classical 
activation profile, the different phagocytic properties and inability to produce 
functional amounts of IL-12, sets it apart from classically activated M1a 
macrophages20,21. However, in our view, macrophages derived through these activation 
pathways still need to be characterized more thoroughly. 
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In recent years, the term M2 has served as a generic name indicating the various forms 
of alternatively activated or anti-inflammatory macrophages4,22. As opposed to classical 
activation by IFN-ɶ, alternative activation of macrophages is induced by several 
different stimuli and a subdivision of M2 cells has been made accordingly. M2a cells are 
generated by stimulation with the Th2-cytokines IL-4 and IL-1323; M2b cells correspond 
to concomitant stimulation with immune complexes and either LPS or IL-1ɴ (initially 
termed type II activation)24,25, whereas M2c macrophages are triggered by IL-10 (and to 
some extent by transforming growth factor-ɴ (TGF-ɴ) or glucocorticoids). Functionally, 
M2 macrophages are integrated in type II immune responses, accounting for the 
attenuation of excessive Th1-mediated inflammation, tissue remodeling, allergy, 
tumour progression and host defence against extracellular parasites5,7,15,22. Although 
the diversity between M2 macrophages is apparent14,26,  usage of  this  term is  justified 
by the fact that various forms of M2 macrophages do share a number of phenotypical 
similarities4. Generally, M2 cells produce low amounts of pro-inflammatory factors (e.g. 
IL-12), in contrast to an increased production of anti-inflammatory mediators such as IL-
10 and the pro-fibrotic factor TGF-ɴ. However, in this regard the M2b subset stands out 
by the fact that it is characterized by a higher inflammatory cytokine production (e.g. 
TNF, IL-1 and IL-6) and does not show induction of arginase-1 (Arg-1) or TGF-ɴ. On the 
other hand, these cells still clearly portray a high IL-10 and low IL-12 profile, which 
warrants their M2 classification19. M2 macrophages additionally display high levels of 
scavenger receptor activity and express a chemokine repertoire that is dissimilar from 
 
Table 5.1: Simplified overview of the phenotypical characteristics of M1 and M2 macrophages. 
Abbreviations: IFN-ɶ, interferon-ɶ; LPS, lipopolysaccharide; TNF-ɲ, tumour necrosis factor-ɲ; IL, interleukin; 
IC, immune complexes; TGF-ɴ, transforming growth factor-ɴ; GC, glucocorticoids; NO, nitric oxide; ROS, 
reactive oxygen species; iNOS, inducible nitric oxide synthase; Arg-1, arginase-1; IL-1Ra, IL-1 receptor 
antagonist; CCL, chemokine C-C motif ligand; MHC-II, major histocompatibility complex class II; CD, cluster 
of differentiation; IL-1RI, IL-1 receptor I; MR, mannose receptor; SR, scavenger receptor. 
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that of M1 macrophages4,27. Finally, in M2a macrophages as opposed to M1 cells, the 
arginine metabolism is generally shifted to the production of proline and polyamines 
through activity of the profibrotic enzyme Arg-1. This shift inversely correlates with 
inducible nitric oxide synthase (iNOS)-mediated nitric oxide (NO) production28. A 
simplified summary of the characteristics of each respective phenotype is presented in 
Table 5.1.  
Macrophage heterogeneity in health and disease 
Although the contribution of different macrophage subsets to atherosclerosis is very 
scarcely studied29,30, the concept of macrophage heterogeneity has already been well 
explored in other pathologies with macrophage-related origins (i.e. infectious disease, 
cancer and metabolic disorders). Logically, knowledge from lessons learnt in other 
fields might be useful when applied to atherosclerosis research, provided that the 
underlying mechanism by which macrophage dysfunction causes morbidity is taken into 
account31. Often, when conditions manifest with a disturbed inflammatory balance, 
immune cells (e.g. macrophages) are either unable to react to environmental changes 
or by contrast exaggerate their response to such events. In these situations, one 
macrophage subset may be favoured over another. It is very likely that such an 
imbalance also plays a role in the pathogenesis of atherosclerosis, making it very 
relevant to study the dynamics in subset distribution throughout the course of this 
disease. Thereby, we might better appreciate  how each subset contributes to the 
many specialized macrophage functions in the atherosclerotic plaque. 
Macrophage heterogeneity in infectious disease 
Regulation of the delicate balance between M1 and M2 type polarization has been 
shown to be critical in host defence against many types of pathogens. Based on the 
analysis of host transcriptomes in several studies, Jenner et al. identified a set of genes 
that together comprise the ‘common host response’ of innate immune cells in reaction 
to a range of bacteria, viruses and fungi32. Especially monocyte-derived macrophages 
seem to develop a common pattern of gene expression when challenged by bacteria33. 
Interestingly, Benoit et al. reported more recently that this shared response to bacterial 
infection is mainly associated with increased expression of genes that are involved in 
polarization towards a functional M1 program. More specifically, these include the 
genes that encode for TNF, IL-6, IL-12, iNOS and monocyte chemotactic protein-1 (MCP-
1), also known as chemokine ligand 2 (CCL2)34. Up-regulation of these genes partially 
accounts for the enhanced microbial killing activity that is regarded as a typical 
characteristic of M1 macrophages. Thus, by augmenting the immediate resistance to 
bacteria, M1 polarization promotes immunity and serves a protective role in host 
defence during acute infectious disease. However, an extended period of M1 skewing 
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may lead to a deleterious outcome for the host if not kept in check. This is illustrated by 
the correlation between the amount of circulating M1-type cytokines and increased 
sepsis severity in a human population35. In their review, Benoit et al. further provide a 
detailed account of the approaches that several bacterial pathogens have developed to 
hamper the M1 polarization of macrophages in an attempt to endure in their 
surroundings. Different strategies include inhibition of the oxidative microbicidal 
capacity of macrophages (NO release), inhibition of the expression and secretion of M1-
type cytokines (primarily IL-12 and TNF), the release of virulence factors that interfere 
with M1-associated cellular signaling pathways and finally, direct promotion of M2 
polarization34. Skewing of macrophages towards an M2 phenotype is associated with 
the continual presence of bacteria in tissues and the conversion of some infectious 
diseases to a chronic state. For instance, replication of Coxiella burnetii, the causative 
agent of Q fever, was shown to be related to macrophages expressing a M2 signature 
that featured up-regulation of Arg-1, YM-1 and the mannose receptor (MR) and down-
regulation of iNOS and M1-type cytokines. Activation by IFN-ɶ however, inhibits 
replication of this pathogen and reprograms macrophages towards M136-38. 
Additionally, Whipple’s disease, which is caused by Trophyrema whipplei, has also been 
linked to M2 polarization. Whereas this pathogen is eradicated in an M1-driven 
immunological micro-environment, it actively replicates in a M2 setting39. Notably, 
these are only a few examples of the growing list of pathogens that take advantage of 
changes in macrophage activation profiles.  
Over the last few years, studies on macrophage function in parasite infections have also 
yielded great knowledge on the existence and function of different macrophage subsets 
in disease states40. In general, infection of a host organism with both intracellular and 
extracellular parasites triggers a specific inflammatory response. As a first line of 
defence preceding adaptive immunity, macrophages mediate both anti-parasitic 
immunity and parasite clearance by phagocytosis and immunosuppression. A pro-
inflammatory response by M1 macrophages, targeted at parasite elimination, is crucial 
for limiting parasite growth during the acute phase of the infection. After this initial 
immune reaction, a type II inflammatory response ensues aiming to resolve the 
inflammatory process. Any disturbance of the equilibrium between these two phases 
will consequently worsen the outcome of the infection. Whereas lack of the initial M1 
response would result in uncontrolled parasite colonisation, an insufficient M2 
response would lead to more efficient parasite killing that is however accompanied by 
excessive systemic inflammation. The subsequent anaemia and liver damage by ROS 
might eventually result in host death. The infection with Trypanosoma congolense, the 
African parasite responsible for sleeping sickness, exemplifies the influence this fragile 
balance of macrophage polarization has on parasite infection and even how this 
parasite can exploit these changes in the inflammatory response. Upon infection, this 
extracellular parasite will primarily settle in the liver, spleen and brain. It is covered by 
variant-specific surface glycoproteins (VSG) that are very immunogenic and cause a T-
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cell dependent B-cell response. However, by frequently transforming their molecular 
structure, these VSGs avoid targeting by the adaptive immune response and make 
vaccination against this parasite impossible41. Trypanosomes can be phagocytosed 
upon binding of antibodies to VSG, but this binding simultaneously releases these 
molecules to the circulation as soluble VSG (sVSG). Initially, sVSG modulate macrophage 
function towards systemic macrophage activation with M1 characteristics, which is 
sustained by T-cell-derived IFN-ɶ and characterized by production of the trypanotoxic 
agents  NO  and  TNF.  Following  this  early  response,  a  transition  towards  a  type  II  
response takes place that mainly involves M2a macrophages and is characterized by 
high plasma levels of IL-10, IL-4 and IL-13. The end result is tolerance towards the 
parasite with long host survival and limited tissue damage42-44. However, C57BL/6 mice 
lacking either TNF45 or IL-1046 signaling are both susceptible to trypanosomes and die 
upon infection, by excessive parasite growth or by an IFN-ɶ mediated shock syndrome 
respectively47. Concluding, fighting bacterial and parasitic infections necessitates an 
adequate regulation of the balance between M1 and M2 macrophages to ensure 
proper microbial killing. Increasing our knowledge on this part could eventually lead to 
more efficient ways to treat infections. Although selectively promoting or inhibiting M1 
or  M2  phenotypes  at  the  right  moment  is  likely  to  enhance  the  effectiveness  of  the  
inflammatory response, one should be aware of the risks involved with intervening in 
this delicate balance. Overstimulation of the M1 phenotype for a prolonged period will 
result in excessive tissue damage. Preventing an appropriate M2 macrophage response 
from counteracting M1-mediated inflammation might pose a similar hazard. Promotion 
of the M2 phenotype on the other hand will probably facilitate the survival and growth 
of pathogens. Additionally, the way in which the M1/M2 balance shifts during the 
course of different infections may prove another pitfall. Temporal variability in the 
macrophage response to distinct micro-organisms would hamper large-scale 
application of macrophage-based approaches. Furthermore, this would necessitate 
detailed knowledge of the macrophage kinetics in certain types of infection if successful 
timing of such a therapeutic approach were to be achieved. 
Tumour associated macrophages 
Another model illustrating the relevance of the macrophage M1/M2 paradigm in 
pathologic situations concerns the macrophages that are found within tumours48. A 
tumour micro-environment not only exists of malignant cells but also includes stroma 
and cells belonging to the immune system. The latter are part of a system of immune 
surveillance that aims to eliminate tumour cells through innate and adaptive 
responses49. Tumour cells evade this targeting through their genetic variability, active 
immune suppression and secretion of tolerogenic effectors. Because of their 
contribution to both the targeting and the protection of the tumour cells, tumour 
associated macrophages (TAMs) are a great example of the possible implications of 
macrophage heterogeneity in vivo8,50,51. Moreover, their ambivalent functional 
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characteristics clearly show the caveats to be dealt with when contemplating 
macrophage directed therapies52. 
Macrophages that are attracted to tumour sites by factors like M-CSF and CCL253,54, are 
initially cytotoxic through secretion of ROS and slow down tumour cell proliferation. 
This M1 phenotype induces an inflammatory environment that attracts and activates 
cells of the adaptive immune system55,56. However, with sustained activation, these 
cells increase the risk of DNA damage and tissue structure abnormalities, thus 
promoting carcinogenesis57.  However,  tumour  cells  that  are  lysed  by  these  M1  
macrophages release factors including TGF-ɴ and sphingosine-1-phosphate, which 
reprogram the macrophages towards an alternatively activated phenotype58. 
Subsequently, these M2 macrophages will temper the inflammatory response and 
create a more tolerogenic environment by secreting IL-10 and TGF-E58. Moreover, these 
cells mediate cell proliferation and tissue remodelling through arginase induction and 
tumour invasiveness through secretion of chitinase-like proteins, further contributing 
to tumour development. Another important feature of the alternatively activated TAMs 
is their role in the formation and remodeling of new blood vessels in the tumour area 
by releasing both pro-angiogenic factors such as vascular endothelial growth factor 
(VEGF), TNF, IL-8 and basic fibroblast growth factor (bFGF) as well as angiogenesis 
modulating enzymes such as matrixmetalloproteinase (MMP)-2, MMP-7, MMP-9, 
MMP-12 and cyclooxygenase (COX)-259. As the rapid tumour growth demands 
increasing perfusion to prevent hypoxia and subsequent necrosis, angiogenesis is 
essential for disease progression60. 
The formation of tumour promoting TAMs has been linked directly to the nuclear 
factor-ʃB (NF-ʃB) signal transduction pathway, which activates transcription factors 
that play an essential role in regulating inflammation and immunity61. Especially the NF-
ʃB subunit p50 has been identified as an important regulator of macrophage 
polarization in tumours. The observation that TAMs are defective in their production of 
the NF-ʃB target gene IL-12 but rather show higher levels of IL-10 indicated that a 
regulation at  the level  of  NF-ʃB could be expected62.  It  was shown that  p50 can form 
inhibitory homodimers that are able to bind the NF-ʃB consensus binding sites, thus 
repressing transcription of a subset of NF-ʃB-dependent inflammatory genes63. Indeed, 
TAMs show tolerance toward both LPS and other pro-inflammatory signals as indicated 
by a defective IL-12, IL-6 and TNF expression and relatively enhanced IL-10 expression64. 
Moreover, TAMs were characterized by massive nuclear overexpression of p50. 
Interestingly, the anti-inflammatory phenotype of TAMs was reversed in macrophages 
lacking p50 and both p50-deficient mice and wildtype mice that received p50-deficient 
bone marrow displayed a delayed tumour progression with increased survival64. Hence, 
activation of the NF-ʃB subunit p50 appears to induce an M2 phenotype in TAMs. 
Continuing on the role of NF-ʃB signaling in regulating TAM function, it was more 
recently shown that the main kinase mediating NF-ʃB activation, inhibitor of NF-ʃB 
kinase 2  (IKK2 or  IKKE), inhibits M1 differentiation of macrophages by affecting signal 
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transducer and activator of transcription-1 (STAT1) signaling. Consequently, 
macrophage-specific deletion of IKK2 led to a more pronounced M1 phenotype, 
characterized by high IL-12, iNOS and MHC-II expression and low levels of IL-1065,66. This 
phenotypic shift resulted in macrophages that were better capable of actively 
eliminating tumour cells, both directly by enhanced production of oxygen radicals and 
indirectly through IL-12-dependent natural killer (NK)-cell anti-tumour activity66. Thus, 
NF-ʃB activation is intricately involved in the induction of anti-inflammatory tumour 
repressive TAMs at different levels.  
Since high TAM density in tumours is correlated with a poor prognosis59,67, blocking the 
attraction of macrophages to the tumour might seem a promising therapeutic target. 
Indeed, in experimental models this approach showed to inhibit further tumour 
growth68-71. However, such a strategy would also rule out the potential of attracting 
more M1 polarized macrophages to engage in tumour cell lysis and promote an anti-
tumour immune reaction. Therefore, induction of macrophage polarization towards an 
M1 phenotype would be a more desirable treatment option than merely interfering 
with macrophage attraction to tumours. For now, the major challenge will be to find 
techniques that locally and specifically skew macrophages to the desired phenotype. 
Until such methods are developed, it remains unclear if any phenotype promoting or 
targeting treatment will suffice as a stand-alone therapy or will merely serve as an 
adjuvant therapeutic option. 
Macrophage heterogeneity in obesity and insulin resistance 
In recent years, mounting evidence suggests that low-grade inflammation contributes 
to the development of obesity and progression to insulin resistance72. More specifically, 
recent work has recognized adipose tissue macrophages (ATM) as the main source of 
pro-inflammatory mediators in adipose tissue and has correlated their function with 
the degree of insulin resistance73. Interestingly, in lean mice, resident ATMs exhibit 
characteristics of M2a macrophages with expression of Arg-1 and IL-1074. From a 
functional perspective, this IL-10 production was shown to protect adipocytes from 
TNF-induced insulin resistance74, advocating these M2 macrophages as being protective 
in obesity. Rather than altering macrophage activation state, the induction of obesity 
through a high fat diet superimposes a new population of macrophages to adipose 
tissue that possess an M1-polarized phenotype with expression of pro-inflammatory 
markers  such  as  iNOS  and  TNF75. With progressive obesity, these M1 macrophages 
accumulate in adipose tissue through recruitment by MCP-1 dependent mechanisms. 
Absence of MCP-1 or its receptor CCR2 abolishes migration of macrophages into 
adipose tissue, thereby preventing adipose tissue inflammation and improving insulin 
resistance76,77. 
The M2 phenotype of ATMs in lean mice was subsequently shown to be maintained by 
the nuclear receptor peroxisome proliferator-activated receptor ɶ (PPARɶ). Induction of 
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alternatively activated macrophages by IL-4 was reduced in the absence of PPARɶ and 
was accompanied by reduced Arg-1 activity, decreased suppression of IL-6 and 
inhibition of fatty acid oxidation in macrophages. Furthermore, macrophage-specific 
deletion of PPARɶ in vivo reduced the M2 phenotype of ATMs, impaired adipocyte 
function by reducing mitochondrial oxidation and ultimately resulted in enhanced 
obesity and insulin resistance78. In line with these findings, Hevener et al. showed that 
macrophage-specific PPARɶ deficiency propagates impaired insulin sensitivity in 
muscle, liver and adipose tissue and worsens insulin resistance upon high fat feeding of 
mice79. Thus, PPARɶ is necessary for sustaining the M2 phenotype in adipose tissue of 
lean individuals and thereby protects against obesity and insulin resistance. 
Remarkably, contrary to ATMs, disruption of PPARɶ does not affect Kupffer cells, the 
liver’s resident macrophages. In these cells, it is the transcriptional activation of 
another nuclear receptor known as PPARɷ by mono-unsaturated fatty acids that 
induces an alternative activation state. Analogous to PPARɶ deficiency, abrogation of 
PPARɷ impairs the alternative activation of Kupffer cells, thereby causing hepatic 
dysfunction, diet-induced insulin resistance and obesity80. Similar observations were 
described by Kang et al.81, demonstrating that myeloid-specific PPARɷ deficiency leads 
to insulin resistance and severe steatohepatitis. Hence, macrophage polarization in 
adipose tissue and liver is chiefly regulated by PPARɶ and PPARɷ respectively and 
provides an important incentive in the pathogenesis of metabolic diseases. Whereas 
the anti-inflammatory phenotype displayed by resident ATMs in healthy conditions 
appears to be protective, the obesity-induced recruitment of pro-inflammatory M1 
macrophages alters the macrophage polarization balance in adipose tissue and 
aggravates insulin resistance. 
The macrophage as central player in atherosclerosis initiation and progression 
From the above it is evident that macrophage polarization is a main determinant in the 
aetiology of many different diseases. In terms of atherosclerosis, this is no different. 
The major initiating events in atherosclerosis development encompass endothelial 
dysfunction and modification of low-density lipoprotein (LDL)82. Aberrant blood flow 
renders specific areas of the vessel wall more susceptible to atherogenesis, since the 
altered haemodynamics increase permeability of the endothelial barrier to 
macromolecules such as LDL1. These molecules subsequently accumulate in the 
subendothelial matrix, where they undergo modification through oxidative or 
enzymatic processes. Retention of these modified lipoproteins exerts a pro-
inflammatory stimulus on the micro-environment, thereby promoting expression of a 
range of adhesion molecules (e.g. vascular cell adhesion molecule 1; VCAM-1), 
chemotactic proteins (e.g. MCP-1) and growth factors (e.g. macrophage-colony 
stimulating factor; M-CSF) by the overlying endothelium83. This in turn mediates 
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leukocyte recruitment and monocyte migration into the intima at lesion prone sites 1. 
Upon M-CSF-induced differentiation, monocyte-derived macrophages will start to 
internalize substantial amounts of modified LDL (mLDL) via scavenger receptors 
(SR)1,83,84.  Although this  process  of  foam cell  formation may at  first  serve a  protective 
role in removing pro-inflammatory modified lipids and apoptotic cell debris from the 
vessel wall, the increasing build-up of these cells ultimately leads to the development of 
fatty streaks. The progression of a clinically insignificant fatty streak to a more complex 
lesion is hallmarked by the migration of smooth muscle cells (SMC) from the media to 
the subendothelial space of the vessel wall1,83. In conjunction with a continuous influx 
of immune cells, these SMCs can proliferate within the lesion, contribute to foam cell 
formation but primarily secrete extracellular matrix components. Concurrently, 
apoptotic foam cells that are improperly scavenged will contribute their lipid-filled 
contents to the growing necrotic core of the plaque82. Ultimately, an advanced lesion is 
formed, in which the lipid-rich necrotic core is shielded from the lumen by a fibrous cap 
of SMCs and extracellular matrix. In disease progression to clinical manifestation, 
rupture of this fibrous cap is generally thought to elicit thrombosis, as exposure of 
plaque lipids and tissue factor to blood components will consequently initiate the 
coagulation cascade1,85. The physical integrity of the fibrous cap therefore is vital for 
plaque stability. Interestingly, the balance between trophic and degenerative factors 
that determine fibrous cap thickness can be profoundly affected by both cellular and 
humoral factors of immunity. While IFN-ɶ, for instance, inhibits extracellular matrix 
production by SMCs, plaque macrophages enable the degradation of extracellular 
matrix proteins by the production of MMPs82,86. As such, the macrophage is 
acknowledged as a key player in atherosclerotic in the regulation of plaque 
development and stability (see Figure 5.1). 
 
Macrophage heterogeneity in atherosclerosis 
As detailed above, the functional characterization of macrophage heterogeneity in 
numerous different macrophage-related pathologies has been ongoing for several 
years now. Based on their inflammatory characteristics, M1 macrophages can be 
expected to promote atherosclerosis development, while M2 macrophages in general 
may  be  considered  to  be  protective  in  this  regard.  However,  to  this  point,  the  
functional contribution of individual macrophage subsets to atherosclerosis has barely 
been studied, despite the fact that macrophage heterogeneity in human atherosclerotic 
lesions was already demonstrated early on. Using differentiation markers and stainings 
for lipids and lysosomal phosphatase, van der Wal and co-workers reported that more 
centrally localized macrophages in lesions have more differentiated and matured 
characteristics, than their counterparts in the superficial layers of these plaques87. This  
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implied functional differences between macrophage populations within the same 
lesions. Similarly, using a set of macrophage specific monoclonal antibodies, it was 
shown  that  macrophages  in  murine  atherosclerotic  lesions  show  a  large  degree  of  
heterogeneity as well88. More recently, Waldo et al. confirmed the heterogeneity of 
human macrophages in atherosclerotic lesions yet again by using CD14 positivity to 
discriminate between subsets29. Thus, heterogeneity of macrophages has been well 
established in human and mouse atherosclerotic lesions. However, the amount of data 
that provide a direct functional link between the M1 and M2 subsets and 
atherosclerotic lesions is limited. 
Recently, Bouhlel et al.30 were the first to describe the expression of M1 and M2 
markers in atherosclerotic lesions. Concretely, they demonstrated M1-associated 
marker genes such as MCP-1, IL-6 and TNF and MR, CD163, IL-10 and CCL18, markers of 
M2 macrophages, to be expressed in human atherosclerotic lesions. Moreover, they 
Figure 5.1: Macrophages are paramount to plaque development:  
A schematic outline of the lumen and vessel wall is shown in which, from left to right, the development of an 
atherosclerotic plaque is depicted. Early phases of the disease involve the subendothelial retention and 
accumulation of LDL. These particles are subsequently modified and induce endothelial activation and 
chemokine secretion. In response, attracted monocytes migrate into the vessel wall where they differentiate 
into macrophages. These macrophages commence continual scavenging of these modified lipoproteins, 
which transforms them into foam cells that characteristically contain intracellular lipid droplets. Persisting 
foam cell accumulation eventually results in the formation of a fatty streak. Macrophages in atherosclerotic 
lesions also secrete lipid modifying enzymes, which promote further LDL oxidation, and chemokines and 
cytokines that control the inflammatory balance and regulate recruitment, activation and proliferation of 
cells. Upon further progression of atherogenesis, T-cells are attracted and activated which propagate the 
chronic inflammatory state of the lesion. When foam cells die through apoptosis, improper scavenging of 
these cells leads to secondary necrosis and the release of cellular debris (i.e. scavenged lipids) to the 
growing lipid-rich necrotic core of the lesion. As smooth muscle cells proliferate and migrate, they form a 
fibrotic cap that encloses the lesion and its necrotic core. In time, inflammatory factors compromise the 
integrity of this fibrous cap, resulting in thrombus formation when rupture of the fibrous cap exposes 
thrombogenic plaque contents to the blood. This process of rupture is promoted by the local recruitment of 
macrophages, producing matrix-degrading enzymes. Abbreviations: LDL, low density lipoproteins. 
 
Chapter 5 
 
 
102 
established a direct correlation between the expression of M2 markers and that of 
PPARJ, indicating a role for PPARJ in regulating M2 differentiation in atherosclerosis, 
similar to what was reported previously in murine diet-induced obesity (see above)78. 
Notably, through cell cultures they were able to confirm that PPARJ activation polarizes 
human macrophages towards an M2 phenotype. Interestingly, patients treated with 
PPARJ agonists showed a more pronounced M2 phenotype in their circulating 
mononuclear cells, whereas M2 marker expression in atherosclerotic lesions did not 
change. Although certain questions regarding the therapeutic benefit of this approach 
remain unanswered, this paper offers an interesting functional perspective by 
identifying the expression and localization of certain subset markers in atherosclerosis.  
More recently, Boyle et al. reported intraplaque haemorrhage, a main contributor to 
lesional development and instability, to induce a novel protective macrophage 
phenotype in atherosclerotic plaques of human coronary arteries89. Primarily defined 
by high levels of the scavenger receptor CD163, these macrophages use this surface 
molecule to bind and clear haemoglobin-haptoglobin complexes from the vessel wall. 
As a result, CD163high macrophages secrete a number of anti-oxidant and anti-
inflammatory mediators (e.g. IL-10 and haeme oxygenase-1) in an attempt to counter 
the atherogenic effects of plaque haemorrhage89. However, in spite of its beneficial 
qualities, this phenotype is by no means fully atheroprotective as is illustrated by the 
use of post-mortem specimens of culprit lesions in this study. This can be partly 
explained by the fact that even lesions with substantial haemorrhage predominantly 
featured pro-inflammatory macrophages, whereas plaques devoid of haemorrhage 
lacked CD163high macrophages altogether. As such, the relatively small size of the 
CD163high subpopulation seems to limit its impact on the surrounding tissue. Taken 
together, these data imply that CD163 might in fact be a suitable marker for high-risk 
atherosclerotic plaques. This notion is confirmed by Papaspyridonos et al.90, who found 
the expression of CD163 to be upregulated almost sevenfold in unstable plaque regions 
as compared to stable areas. Interestingly, the presence of neutralizing IL-10 antibodies 
prevented the development of CD163high macrophages in vitro, hereby showing a role 
for IL-10 in inducing this phenotype. Moreover, glucocorticosteroids have also been 
found to elicit CD163, be it to a lesser extent than haemoglobin-haptoglobin complexes 
or IL-10, which further enhances the analogy to the M2c subtype91. Unfortunately, to 
our knowledge, this is the only report to date that directly associates an M1/M2 subset 
marker with the functional phenotype (i.e. stability) of an atherosclerotic lesion.  
Macrophage subset effector function and atherosclerosis 
From a theoretical perspective and knowing the many specialized functions 
macrophages exert in all stages of atherogenesis, it can be expected that specific 
features of the M1 and M2 polarized macrophage subsets described before in this 
review contribute differently to plaque development. First of all, a range of cytokines 
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that has been associated to macrophage polarization (see table I) has been the subject 
of extensive atherosclerosis research (as reviewed by Tedgui and Mallat, Kleemann et 
al.)92,93. In general, cytokines that are specifically produced by M1 macrophages have a 
proatherogenic effect. Using knockout, transgenic, treatment or inhibitory approaches, 
it is firmly established that cytokines such as TNF, IL-1 and IL-12 promote disease 
progression in different animal models of atherosclerosis. In contrast, M2 associated 
cytokines are either anti-atherogenic (e.g. IL-10), or combine anti-atherogenic 
characteristics with profibrotic properties (e.g. TGF-E).  These cytokine data are in  line 
with the concept that M1 macrophages promote atherosclerosis, whilst M2 
macrophages inhibit plaque growth and mediate plaque stability.  
For chemokine patterns associated with macrophage polarization 4, the story is more 
complex. M1 inducers (e.g. IFN-ɶ and TLR-ligands) usually act through signal 
transduction pathways such as NF-ʃB and STAT-1 to evoke transcription of 
inflammatory chemokines (CCL2, 3, 4 and 5 amongst others)94,95. Moreover, both CCL5 
(RANTES) and CCL2 have been studied to some extent in atherosclerosis96. While CCL5 
blockade reduces atherosclerosis97, inhibition of its two receptors (i.e. CCR1 and CCR5) 
has opposing effects. CCR5 acts pro-atherogenic as genetic deletion of this receptor 
reduces atherogenesis and inhibits Th1 responses98-100, while in contrast CCR1-deficient 
mice show accelerated atherosclerosis, with IFN-J being an important mediator 101,102. 
CCL2  and  its  receptor  CCR2  seem  to  have  a  more  clear-cut  role  in  promoting  
atherosclerosis103-105 by regulating the specific recruitment of inflammatory monocytes 
to atherosclerotic lesions106. Interestingly, M2 stimuli (e.g. IL-4, IL-13 and IL-10) 
interfere with the general expression of M1-associated chemokines through inhibition 
of the same pathways that mediate M1 responses. Moreover, these signals elicit 
expression of a set of chemokines that is linked to type II immune responses4. As such, 
M2a macrophages display expression of CCL17, 18, 22 and 24 for instance107,108, 
whereas both the M2a and M2c subsets express CCL18109. Many other chemokines are 
currently still in need of better association with particular macrophage subsets or have 
yet to be investigated for their role in atherosclerosis development in general. 
In accordance with the atherogenic function of M1 macrophages and the putative 
atheroprotective effect of M2 macrophages, the ways in which these subtypes utilize 
the common substrate arginine also influence lesion fate. As mentioned before, M2 
skewing induces Arg-1 expression that enables the conversion of arginine to collagen 
precursors such as ornithine and subsequently proline and polyamines. In 
macrophages, this diverts arginine metabolism away from M1-associated iNOS-derived 
NO synthesis Hereby, M2 macrophages may contribute to enhancing the physical 
integrity of the fibrous cap, thus promoting plaque stability, and reduce atherogenesis. 
This was recently substantiated by genetic analysis of two rabbit strains with high and 
low susceptibility for atherosclerosis, showing that the rabbits which had reduced 
atherosclerosis development were characterized by elevated levels of Arg-1 activity, 
regulated through a polymorphism in the 3’-untranslated region110. 
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However, certain characteristics of M2 polarized macrophages, do not conform to the 
straightforward distinction between pro- and anti-inflammatory properties that has 
been put forth by the M1/M2 paradigm. Firstly, M2 macrophages are highly phagocytic 
and express increased levels of scavenging receptors such as scavenger receptor class A 
(SR-A) and CD36. Both these receptors have originally been described as major 
mediators of foam cell formation and promoters of atherosclerosis in general. 
However, recent studies have questioned the function of these scavenger receptors as 
being mere facilitators of lipid uptake and even advocated them as mediators of 
inflammation in atherogenesis111,112. Accordingly, M2 polarization may very well 
promote foam cell formation and thereby lesion growth, but may also add to a lesion’s 
inflammatory burden through changes in scavenger receptor activity. Secondly, as 
described above, through tumour biology research it is well known that M2 
macrophages promote angiogenesis113. Especially the so-called angiogenic switch, 
which concerns the induction of tumour vasculature that is conditional for tumour 
growth and disease progression, is considered to be at least partly mediated by 
TAMs113,114. Hypothetically, M2 macrophages in the vessel wall may similarly promote 
microvessel growth into atherosclerotic lesions. However, as these newly formed 
vessels often lack proper structural integrity, they can give rise to intraplaque 
haemorrhage that in turn promotes lesion development and compromises plaque 
stability115.  
Hence, despite the fact that the cytokine and chemokine repertoires raise high hopes 
for M2 macrophages as therapeutic targets in atherosclerosis, not all functional 
characteristics exerted by these cells are by definition beneficial. Even so, it is 
important to recognize that any undesirable effects need not necessarily concern all M2 
subtypes, since these factors might just as well be attributable to a single M2 
phenotype. Selecting an appropriate subset that promotes the desired properties will 
therefore be crucial for the development of diagnostic and treatment options. In this 
view, characterizing the temporal and spatial balance between macrophage subsets 
and its underlying mechanisms provides an interesting challenge that might open doors 
towards new methods of atherosclerosis diagnosis and therapy, namely by targeting, 
favouring or inhibiting specific cell types and functions. That said, one of the major 
obstacles that will have to be overcome when studying macrophage polarization in 
atherosclerosis is the current lack of a good readout system that uses markers to 
specifically distinguish the different phenotypes. Despite the existence of many 
accounts listing typical genes, proteins and metabolic products associated with the 
different subpopulations, these markers are usually more abundant in, but rarely 
specific for, a particular subset. To be able to recognize the different subsets within one 
tissue, a more clear-cut readout system would be advantageous. Moreover, most of the 
M1 and M2 associated markers have not been tested for their expression and 
intralesional localization in either human or experimental atherosclerosis models. 
Hence, to better understand the functions exerted by the different subsets, their 
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characteristics should be examined further on a molecular and phenotypic level. In 
addition, since atherosclerotic plaques contain a unique macrophage stimulus in mLDL, 
it will be of great interest to study if this at all alters the response of macrophages to 
the typical M1 and M2 inducing signals. Still, lipid-laden foam cells could possibly be 
seen as yet another phenotype with characteristics distinct from the current M1 and 
M2 phenotypes. Finally, since different subsets are present in the plaque and probably 
co-exist for extended periods within one tissue, it would also be valuable to study the 
interplay between macrophages with different phenotypes. An important feature to 
investigate here is the ability of macrophages to redifferentiate into another phenotype 
in response to stimuli from their environment10. 
Macrophage polarizing cytokines in atherosclerosis 
To actually study the role of the different macrophage subsets in atherogenesis, specific 
gene targeting in different murine models of atherosclerosis remains the method of 
choice. Up until now, a broad range of studies deleting or over-expressing cytokines 
with key functions in macrophage polarization have been performed in both ApoE-/- and 
LDLR-/- mice. However these investigations never focused directly on how a specific 
intervention affects macrophage phenotype in the plaque, but rather on 
atherosclerosis development in general93.  
In the setting of atherosclerosis, IL-10 is one of the best studied polarizing cytokines. As 
described earlier, IL-10 is involved in M2c polarization, but has also been shown in 
several studies to exert atheroprotective qualities, especially in early atherogenesis. 
Several knockout models for this cytokine describe a significant increase in lesion size 
and inflammation, which is accompanied by reduced plaque stability and an increased 
influx of T-cells116,117. In line with these findings, different transgenic models 
overexpressing IL-10 demonstrate a reduced lesion size118-120. However, since IL-10 also 
favours Th2 responses and has anti-inflammatory effects on most other cell types 
present in the atherosclerotic plaque, we are currently unable to appreciate exactly 
how much of its anti-atherogenic effects is mediated by macrophage phenotype 
skewing. For this reason, additional studies addressing IL-10 signaling specifically in 
macrophages should be performed that clearly dissect the inability of these 
macrophages to respond to or produce and secrete IL-10 from that of other immune 
cells. Moreover, such studies may provide novel insights into the expression of markers 
for macrophage subsets in atherosclerosis and their dependence on polarizing signals. 
Another polarizing cytokine, IL-4, rather induces an M2a phenotype in macrophages. 
Although these are potentially anti-atherogenic, IL-4 is also known to be involved in the 
up-regulation of VCAM-1121,122 and  MCP-1123,124 in endothelial cells, both important 
positive mediators of atherogenesis. This possibly blurs the effect of studies 
investigating the effects of IL-4 on atherosclerosis in mouse models and may be the 
reason why ApoE-/-IL-4-/- double KO mice or LDLR-/- mice transplanted with IL-4-/- bone 
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marrow initially rather showed an atherosclerosis promoting effect in a time and site 
specific manner125,126. However, an initial study on IL-4 deficiency in C57BL/6 mice 
showed no effect127 and more recently King et al. performed an extensive study with 
both ApoE-/- and LDLR-/- mice with IL-4 knockout or treatment approaches and also 
found no effect on atherosclerotic lesion formation128. These results raise questions 
concerning the contribution of M2a macrophages to atherogenesis, but may also be 
caused by the aforementioned opposing effects on different cellular populations in the 
plaques. Finally, contradicting evidence on IL-4 may even represent differences 
between mouse and man.  
Comparable to the difficulties that arise in distinguishing the M2 and Th2 promoting 
capacities of IL-10, the effect of macrophage polarization by IFN-ɶ on atherogenesis is 
also difficult to reveal, since this pro-inflammatory cytokine affects both M1 
macrophages and Th1 cells. Most experimental studies performed clearly show a 
reduction in lesion size upon absence of this cytokine or its receptor129-131 and report 
accelerated atherosclerosis upon intraperitoneal recombinant IFN-ɶ administration132. 
These data confirm the atherogenic effect of this M1 polarizing cytokine. However, as is 
the case with IL-10, it is still unclear which cell types mediate the observed effects and 
whether genetic modification or treatment with IFN-ɶ actually altered macrophage 
populations and functionality in the plaques of these mice.  
Last but not least, the pro-inflammatory TNF is probably one of the most difficult 
macrophage polarizing cytokines to study, due to its broad range of activities in 
atherosclerosis. Besides promoting an M1 phenotype, it also induces cell attraction 
through upregulation of intercellular adhesion molecule 1 (ICAM-1), VCAM-1 and MCP-
1 in endothelial cells and influences foam cell formation through regulation of 
scavenger receptor mediated LDL uptake133. This abundance in TNF’s possible 
interactions within several key stages of atherogenesis complicates the comparison of 
different experimental models, making it very difficult at this moment in time to distil a 
concrete theory on the effect of TNF-induced M1 macrophages on the atherosclerotic 
plaque. In general however, absence of TNF has been found to decrease atherosclerotic 
lesion size and progression133-136.  
In conclusion, the data above clearly shows association of polarizing cytokines with 
atherosclerosis development, as depicted in Figure 5.2 as well. However, studies on the 
direct effect of M1/M2 skewing on atherosclerosis in experimental models are lacking 
and more specifically, identification of subsets and their functional roles in vivo are 
scarce. To investigate this further, it may be important to realize that an approach of 
phenotypic switch should be preferred over the selective depletion of a specific subset. 
Targeting specific cell types with a cell death inducing method may lead to an 
accumulation of cell debris in the plaque, which causes plaque instability, especially in 
the more advanced lesions137. Another obstacle to keep in mind when further studying 
this matter is that both macrophage heterogeneity138 and atherogenesis139,140 are 
known to be differently regulated between species. Therefore, the major challenge in 
 the end will still be to translate novel findings from murine atherosclerosis models to 
the human situation.  
Figure 5.2: Macrophage polarization in atherosclerosis:  
Summary of macrophage properties that are altered by phenotype skewing and are known to play a role in 
the atherosclerotic plaque. The top part of the figure shows a list of cytokines and other 
typically associated with macrophage heterogeneity and have already been described to be relevant in 
terms of atherosclerosis development. Underneath (in bold) is a list of macrophage functions that are 
known to be involved in atherogenesis. The arrows indicate how macrophage polarization affects these 
processes. They are accompanied by the mechanism or effectors that are responsible for this altered 
function. 
Macrophage polarization: beneficial effects of therapeutics and future 
opportunities for imaging? 
Numerous studies provide an indication for therapeutic agents, of which the function 
can at least partly be ascribed to their immuno-modulatory properties. Hypothetically, 
distinct macrophage subsets might be involved in mediating the (
some of these drugs. In turn, these agents might drive macrophage polarization to a 
certain extent as well and may thereby present ways to manipulate macrophage 
reprogramming. Although a multitude of therapeutics may be worth consid
respect (e.g. type I interferons, corticosteroids), we opted to highlight just a selection of 
compounds that are readily prescribed in current cardiovascular medicine. 
Nevertheless, it would most certainly be interesting to pursue other drugs
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possible influence on macrophage phenotypes and even explore potential synergies 
between different immune-modulators. In addition, imaging of macrophages as a 
diagnostic tool has recently gained great interest. Since macrophage subsets are likely 
to be differentially involved in regulating plaque instability, future approaches based on 
the identification of certain detrimental macrophage subsets (or associated 
characteristics) may be of prognostic value in atherosclerosis. We focus on a number of 
studies reporting macrophage-based strategies for atherosclerosis imaging and 
speculate on potential methods for discriminating between macrophage 
subpopulations.   
Therapeutic interventions modulating macrophage polarization? 
Statins (3-hydroxy-3-methylglutaryl coenzyme A or HMG-coA reductase inhibitors), 
provide a proficient approach to achieve lowering of serum cholesterol in patients and 
have accordingly become one of the most commonly used drugs in the primary and 
secondary prevention of cardiovascular disease141. Over the last decade, several in vitro 
and in vivo studies have established that statins conduct at least part of their beneficial 
effects through a manner that is independent of their lipid-lowering properties 142,143. 
As a result, statins have gained strong interest in different fields of inflammatory 
disease, as several of their pleiotropic effects were demonstrated to be attributable to 
the modulation of inflammatory processes. First of all, these drugs have been 
demonstrated to inhibit inducible MHC-II expression by IFN-ɶ in monocyte-
macrophages and endothelial cells144. Moreover, in 2002, Youssef et al. showed that 
the HMG-coA reductase inhibitor atorvastatin significantly alters the inflammatory 
balance in a murine model of auto-immune encephalomyelitis145. Whilst inhibiting 
secretion of the pro-atherogenic Th1-cytokines IL-12, IFN-ɶ and TNF, atorvastatin 
promoted a shift towards a Th2-type immune response through the release of 
cytokines such as IL-4, IL-5, IL-10 and TGF-ɴ. Moreover, this study provides further 
confirmation that statins affect both T-cell and antigen-presenting cell (APC) 
compartments. Similarly, a decrease in Th1 bias was reported in human study 
populations146,147, providing additional in vivo evidence for the immunoregulatory 
potential of statins. With regard to macrophage polarization, these findings may be of 
particular interest, since changing the immune response through treatment with statins 
might shift the phenotype of macrophage populations. Apart from being acknowledged 
as anti-atherogenic factors, Th2 effector molecules are evidently engrossed in the 
skewing of macrophages towards M2 phenotypes13. For this reason, statin-mediated 
alterations in inflammatory processes might well offer an interesting mechanism for 
shaping macrophage polarization. Admittedly, as a therapeutic class, statins are 
comprised of many individual agents that may have varying degrees of immuno-
modulatory potential and thus may differently influence macrophage phenotype 
switching. However, to our knowledge, work on this subject is yet to be reported. 
Finally, rather than being limited to the development of atherosclerosis, differential 
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involvement of macrophage subsets may potentially be incorporated in other 
inflammatory disorders as well. As such, statins have been shown to exert anti-
inflammatory effects in rheumatoid arthritis148 and to inhibit the amount and size of 
brain lesions in multiple sclerosis (MS)149.  
Thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, are PPARɶ agonists 
that are used to increase insulin sensitivity in type 2 diabetes patients. In addition to 
their metabolic action, these compounds have also been shown to exhibit profound 
anti-atherosclerotic effects in several animal models150-152. These atheroprotective 
functions (e.g. reduced M1-cytokines and MMP-9 production153,154) are largely 
attributed to their immuno-modulatory properties, since PPARɶ can directly interfere 
with inflammatory signal transduction cascades such as NF-ʃB, STAT-1 and activating 
protein-1155. In line with this anti-inflammatory action, rosiglitazone treatment has 
been shown to reduce plasma levels of C-reactive protein in type 2 diabetes patients156. 
As discussed above, it was shown that PPARɶ agonists can directly drive macrophage 
polarization towards an M2 programme in both human and mouse cells30,78. Thus, an 
important part of the anti-atherosclerotic and perhaps even the anti-diabetic action of 
PPARɶ activation may be attributed to polarization of macrophages to an M2 
phenotype. In a recent randomized placebo-controlled trial in non-diabetic patients, 
rosiglitazone was indeed shown to reduce lesional inflammation and increased plaque 
collagen content and stability157. Interestingly, all of these effects are associated 
features of M2 macrophages. However, examination of macrophage gene expression 
identified certain M1 and M2-associated genes to be unresponsive to TZDs79,158, 
implying that activation of PPARɶ through agonists or ligands is influential, but not 
solely responsible for M2 polarization. More investigation into this area is needed to 
clarify the contribution of M1 and M2 macrophages and the role of PPARs in both 
atherosclerosis and diabetes. 
The macrophage as a diagnostic target 
As a large body of evidence has designated a lesion’s inflammatory burden, rather than 
the degree of stenosis, as the major determining factor for clinical outcome in 
atherosclerosis1,82, newly developed imaging strategies accordingly aim to assess the 
key inflammatory components that decide a plaque’s fate. Seeing that polarized 
macrophage subsets are hypothesized to highly affect plaque stability, supposedly with 
contrasting outcomes, imaging strategies that target specific macrophage populations 
or the polarization balance in general might prove valuable tools in the prevention of 
acute ischemic events.   
Above all, magnetic resonance imaging (MRI) is considered to be of great potential in 
terms of atherosclerosis imaging159.  Due to its  excellent  soft-tissue contrast,  this  non-
invasive imaging modality is recognized as being supremely adept for serially assessing 
atherosclerotic vessels160. Through application of MRI in experimental animal models 
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(i.e. rabbits and mice) and human research populations, adequate in and ex vivo 
imaging protocols for the assessment of atherosclerotic plaque composition have been 
defined161-163. By discriminating plaque constituents based on differences in magnetic 
relaxation properties, this technique is able to detect cellular elements, lipid core, 
fibrosis, and thrombus formation in atherosclerotic lesions with high sensitivity and 
specificity164. Interestingly, the use of contrast enhancement provides additional 
opportunities for depicting inflammatory mediators in atherosclerosis (e.g. 
macrophages). One such an approach utilizes ultrasmall superparamagnetic particles of 
iron oxide (USPIO) as a contrast agent for MRI. Once internalized by macrophages, 
these nanoparticles cause a focal loss of signal intensity on MRI and thus enable non-
invasive localization of macrophages in vivo165. At present, this technique has been 
used to assess atherosclerotic plaques in hyperlipidemic rabbits166,167, ApoE-/- mice168 
and was demonstrated to be a feasible strategy for macrophage detection in a human 
population169. Interestingly, the latter study reported accumulation of USPIO especially 
in macrophages in ruptured or rupture-prone atherosclerotic lesions. Hence, by 
appraising plaque macrophage content, USPIO-enhanced MRI might help distinguish 
between stable and vulnerable lesions. 
In a similar fashion, several studies evaluated alternative imaging modalities for their 
ability to portray macrophages in atherosclerosis. Recently, Hyafil et al. demonstrated 
that the iodinated contrast agent N1177 is readily taken up by macrophages and 
subsequently induces an increased density of macrophage-rich tissues on computed 
tomography (CT) imaging170. Upon histological examination this effect co-localized with 
macrophage infiltration. In addition, Fayad and colleagues reported a CT-based 
approach to be suitable for plaque characterization171. Finally, positron emission 
tomography (PET) imaging techniques can visualize macrophages by detecting uptake 
of 18F fluorodeoxyglucose (FDG). Macrophage-rich atherosclerotic lesions show 
augmented uptake of FDG due to the higher metabolic activity of activated 
macrophages. Interestingly, symptomatic lesions exhibit more FDG accumulation in 
comparison to their asymptomatic counterparts172, further implicating macrophages in 
plaque complication. 
Our growing insights into the molecular mechanisms that drive atherosclerosis 
emphasize the need for imaging techniques that are able to depict functional and 
biological processes (e.g. inflammation) as opposed to anatomical abnormalities (e.g. 
stenosis). Taken together, the accounts above use a myriad of ways to visualize 
macrophages in atherosclerotic lesions and thereby show these cells to be both 
promising and versatile targets for future imaging strategies. Although these methods 
need to be optimized before routine application in clinical practice can be realized, they 
may ultimately extend to the depiction of macrophage subsets in inflammatory disease. 
Striving to further unravel the involvement of distinct macrophage subsets in 
atherogenesis will surely propagate the development of novel imaging strategies that 
grant us information regarding the macrophage polarization balance in selected parts 
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of the vasculature. Attaining such data prior to the patient developing symptoms might 
revolutionize the ways by which we assess atherosclerotic arteries, stratify individual 
risk and might even allow us to intervene accordingly. For instance, selectively 
visualizing a lesion’s M1 macrophage content could point out plaques containing a 
relatively high inflammatory load that as such have a higher likelihood to experience 
rapid progression or even rupture. The role of different M2 macrophage subsets in 
atherosclerosis however is still somewhat controversial. As we mentioned before, 
specific features that are possibly attributable to a M2 subset (i.e. angiogenesis) may 
actually enhance atherogenesis, leaving that particular phenotype less desirable in 
atherosclerosis. Conversely, we certainly expect other M2 phenotypes to be beneficial 
for plaque stability. For this reason, reflecting on how imaging of M2 macrophages 
would likely be implemented in the diagnostic work-up of atherosclerosis is difficult. To 
illustrate this, we would like to refer to an earlier section of this review, in which we 
elaborately discuss that an M2 population of CD163high macrophages in atherosclerotic 
lesions could identify plaques that are predisposed to rupture through intraplaque 
haemorrhage. This particular example creates a remarkable controversy that shows the 
complexity of the M1/M2 paradigm, since an atheroprotective M2 subset may possibly 
also serve as a diagnostic tool for recognizing certain detrimental plaque 
characteristics. Therefore, depending on the M2 subset in question, a visual appraisal 
of lesional M2 content might provide additional, but diverging clues as to a plaque’s 
eventual outcome.  
However, at this time we can only speculate on possible diagnostic techniques that will 
allow for a dynamic application of macrophage heterogeneity in atherosclerosis. 
Ideally, continued efforts to characterize macrophage subsets will identify better (e.g. 
subset- but not species-specific) markers that could then be specifically targeted for 
imaging. In addition, differential affinity of polarized macrophage subtypes for the 
internalization of certain molecules and compounds might offer another window of 
opportunity for subset visualization.  
Conclusions 
Over the past few years, we gained considerable insight into the inflammatory 
processes that lie at the core of atherosclerosis development. Macrophages are 
progressively acknowledged as major determinants of atherosclerosis, joining both 
innate and adaptive immune responses in its pathogenesis. Currently, several polarized 
M1 and M2 macrophage subsets have been identified and both populations were 
demonstrated to be present in atherosclerotic lesions. Although the differential 
expression of effector phenotype implies macrophage function in atherosclerosis to be 
highly ambiguous (i.e. M1 and M2 macrophages as atherogenic and atheroprotective 
effectors respectively), evidence supporting their functional implications in vivo is 
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largely lacking. In this respect, several arising challenges complicate the 
implementation of macrophage polarization in our understanding of the atherosclerotic 
process. Firstly, additional markers are required that will allow us to better distinguish 
the current macrophage subsets and possibly help identify new ones. Preferably, these 
markers will be adept for characterizing both murine and human macrophage 
populations, as inter-species variability is becoming increasingly apparent. Any such 
markers might subsequently facilitate the exploration of means by which the 
inflammatory balance in atherogenesis can be affected (e.g. by pharmaceutical 
intervention). Additionally, we need direct functional studies in mice that lack a specific 
macrophage subset to clarify the in vivo relevance of that particular subtype and 
possibly increase our insight into the underlying mechanisms.  
Ultimately, the current M1/M2 paradigm offers a comprehensive take on the concept 
of macrophage heterogeneity. However, due to its simplified nature, it is highly unlikely 
that this digotomy represents the full scope of functional macrophage phenotypes. 
Instead, the current M1 and M2 states are better regarded as extremes of a continuum 
that remains to be explored. Hence, if we are to generate a classification that is a more 
accurate portrayal of in vivo atherosclerotic conditions, we should advance our 
knowledge on this phenomenon. Only by negotiating the aforementioned difficulties 
will we be able to develop strategies that allow us to skew macrophage polarization in 
such a manner that it serves our diagnostic and therapeutic goals, be it in the context of 
atherosclerosis or other macrophage-mediated disorders such as obesity and cancer. 
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Through its versatility, the macrophage is a key player in both innate and adaptive 
immune responses. Its broad range of functions is illustrated at its best in infectious 
diseases, where they participate in pathogen killing and engulfment, attract other 
leukocytes to the site of infection, and ultimately help in directing the response of 
these newly recruited cells1. But also the outcome of non-infectious diseases like 
tumorigenesis2 and insulin resistance3 depends on the inflammatory regulation and 
phagocytic capacity of the macrophage. 
In atherosclerosis, the multi-functionality of the macrophages is reflected in their 
different actions throughout the course of the disease4. After they initiate 
atherogenesis by taking up modified lipids in the vessel wall to a point where they are 
unable to leave the subendothelial space, they create a local inflammatory 
environment by producing and secreting chemokines, cytokines and growth factors. 
Hereby, they promote the attraction, activation and proliferation of new macrophages 
and other cells to the growing lesion. Their subsequent contribution to different 
processes can be either plaque stabilizing or destabilizing, a heterogeneity that is 
described in chapter 5. 
Atherosclerosis and its acute clinical complications are the number one cause for 
mortality in Western society. Although not a newly emerging disease, the combination 
of a sedentary life style, high-caloric diet pattern and several environmental factors has 
increased our morbidity and mortality to alarmingly high levels. Through our knowledge 
of risk factors contributing to this disease, a number of preventive, lifestyle changing 
actions can be advised in order to reduce the risk. However, our advancing 
understanding of the molecular and cellular mechanisms underlying the pathogenesis 
has yet resulted in a disappointingly limited array of pharmaceutical or therapeutical 
options. In addition to tackling the hyperlipidemia that is caused through lifestyle or 
genetic predisposition5 and surgically correcting the life-threatening clinical 
manifestations6,  therapeutics  that  can  alter  the  course  of  the  disease  would  be  more  
than welcome.  
Experiments in animal models have illustrated several strategies to interfere with 
molecular pathways and cellular interactions involved in atherogenesis that may 
present useful future treatment strategies but are still not readily applicable in the 
clinic. Because it is the most abundant cell type during plaque growth, the target of 
these therapies is often the macrophage and the several ways it contributes to the 
pathogenesis, from recruitment over foam cell formation to cell death and necrotic 
core formation. In this thesis, we further investigated the role of macrophages in 
atherogenesis, focusing on their recruitment to the plaque and inflammatory signaling 
pathways. 
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 Figure 6.1: The NF-ʃB and IRF3 signaling pathways that lead to the 
and type I interferons, followed by type I interferon signaling.
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Type I interferons promote atherosclerosis 
In Chapter 2,  the effect  of  type I  interferon (IFNɲ and IFNɴ)  treatment  as  well  as  the 
role of endogenous interferons on different mouse models of atherosclerosis was 
investigated. 
Interferons  were  described  more  than  50  years  ago  as  a  cytokine  family  that  is  
produced and secreted in response to virus infection and induces an antiviral state in 
the surrounding cells7. Exposure to specific viral or bacterial components activates Toll-
like receptor signaling which then leads to interferon production, parallel to the 
activation of the inflammation-regulating transcription factor NF-ʃB (Figure 6.1). Upon 
secretion, autocrine or paracrine binding of interferons to their heterodimeric receptor 
(IFNAR1 and IFNAR2) will induce a Jak/STAT pathway that ensures the expression of a 
set of interferon-stimulated genes (ISGs)8. This diverse group of more than 300 genes 
regulates the cell's defense against microbial threats, with multiple redundant actions 
including active elimination of pathogens, raising the cell's resistance to infection and 
slowing down the protein production in order to halt the de novo assembly of 
parasites9-11. Additional to these antiviral properties however, the ISGs were also found 
to be regulating other cell functions that can play a role in case of infection. They can 
facilitate cell death, presumably to kill infected cells before they can contribute to the 
microbial expansion, and they have immune-regulatory functions, simultaneously 
restricting a potentially exorbitant innate immune response to the infection and 
encouraging an adaptive immune response. 
Already since the early ‘80s, the therapeutic potency of these different type I interferon 
features is exploited in the clinic for the treatment of several diseases8, with side 
effects that are mainly limited to flu-like symptoms and injection site irritation12. While 
patients infected with certain viruses, e.g. hepatitis C virus, benefit from the antiviral 
effects of interferons13, some cancer patients have increased tumor cell necrosis upon 
interferon injections14,15. A more prolonged treatment is applied in patients suffering 
from relapsing-remitting multiple sclerosis (MS), a T cell-driven, chronic inflammatory 
disease that is characterized by episodic attacks of progressive neurological 
deterioration. Daily to weekly injections with interferons extends the period between 
the acute attacks through a yet largely unclear mechanism16. Both in these patients as 
well as in the experimental autoimmune encephalitis (EAE) mouse model for MS, 
treatment with interferons raised the plasma levels of IL-1017, suggesting that this anti-
inflammatory cytokine is playing a role in the therapeutic mechanism. 
The induction of plasma IL-10 levels appeared to be an interesting feature of these type 
I interferon injections, since this interleukin not only reduces inflammation but has also 
been described as one of the strongest anti-atherogenic cytokines18. It suggested that 
an existing therapy may be applied in the treatment of atherosclerosis. 
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While the role of other cytokines of the interleukin, TNF and type II interferon family 
was already well documented, with pro-inflammatory cytokines most often promoting 
atherogenesis and anti-inflammatory cytokines attenuating plaque growth19, the few 
studies on the effect of type I interferons showed conflicting results. In the earliest 
published study, Wilson et al. show how treatment of cholesterol-fed rabbits with type 
I interferons resulted in a further unexplained reduction in lesion size accompanied by a 
decreased plaque lipid content, while plasma lipids were unaffected20. However, the 
interferons used in this experiment were isolated from cell cultures without detailed 
identification or assessment of the purity of the isolate. Therefore, other factors 
influencing atherogenesis may have been administered along with the interferons, 
although in a previous study, treatment with two different interferon-inducing agents 
caused a similar effect on the rabbit plaques21.  In  a  second study,  a  low dose of  IFNɲ 
was given to hyperlipidemic LDLR-/- mice for five weeks. Here, the treatment 
accelerated atherogenesis, which is explained by the higher plasma levels of both 
cholesterol and triglycerides in treated compared to control mice22. A third and final 
experiment used a more aggressive, hypercholesterolemia-independent atherosclerosis 
model, surgically ligating the carotid artery in ApoE-/- mice and locally perfusing 
angiotensin II (AngII) through a mini-pump. Here, IFNɴ treatment attenuated 
atherogenesis as well as the AngII-induced but not the ligation-induced vascular 
remodeling. In their control ApoE-/- mice without AngII and on a normolipidemic diet, 
IFNɴ treatment did not affect plaque formation23.  
In our experiments24, daily injections with IFNɴ, in doses comparable to treatment 
studies in the EAE model, promoted atherogenesis in two different murine models, 
despite raised plasma IL-10 levels and without influencing plasma lipids. The 
mechanism involved a CCL5-dependent enhanced recruitment of leukocytes to the 
vessel wall at atherosclerosis-prone sites and a resulting sub-endothelial macrophage 
accumulation, as shown in both in vitro and in vivo experiments. Moreover, deleting 
the IFNAR1 gene specifically in lysozyme M-expressing cells and thereby inhibiting IFN 
signaling in myeloid cells resulted in smaller lesions, indicating that also endogenous 
IFN contributes to atherogenesis. 
Whereas  many  cell  types  can  produce  type  I  interferons  in  response  to  an  array  of  
specific stimuli, the endogenous IFNs in the plaque are believed to be predominantly 
produced by plasmacytoid dendritic cells (pDC). This subset represents about one third 
of all dendritic cells and has, compared to myeloid dendritic cells (mDC), a low presence 
of the CD11c membrane marker for DC’s, a high expression of IL-3 receptor CD123 and 
a less dendritic phenotype. They also express less extracellular but more intracellular 
Toll-like receptors and are therefore more specialized in the detection of viruses as well 
as nucleotides derived from dying cells. These viral- and autoantigens induce a massive 
production and secretion of type I interferons25.  
Since the presence of IFN-producing pDCs is demonstrated in human plaques25 and in 
vitro treatment of human macrophages with IFNɴ resulted in an upregulation of 
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chemokines and chemokine receptors24, similar to mice, it should be investigated if our 
findings in murine models can be translated to human atherogenesis. These novel 
findings may be of importance in the search for new diagnostic and therapeutic 
approaches. For obvious reasons of susceptibility to viral or bacterial infections26 
however, it will not be possible to inhibit interferon production, interfere with its 
signaling  or  deplete  pDCs  as  long  as  no  methods  are  developed  yet  to  target  these  
therapies specifically to the atherosclerotic plaque. Also the ability to upregulate the 
chemokine CCL5 may be essential in the reaction to other pathologies and can 
therefore not be inhibited systemically. One has to keep in mind as well that human 
lesions differ significantly from the murine models, being far more complex and 
especially developing over several years instead of a few weeks27. It is therefore still 
uncertain if the contribution of cell recruitment to human atherogenesis is equally 
important as in murine plaques. 
A  more  direct  consequence  of  our  results  is  the  awareness  that  type  I  interferon  
treatment may not be as harmless as previously reckoned. Perhaps short-time 
treatment, as applied in hepatitis or tumor patients, might not affect a slowly 
progressing disease that much, but care has to be taken when treating for extended 
periods. Therefore, a thorough assessment of the cardiovascular risks in IFN-treated MS 
patients and a comparison with patients receiving other treatment options should be 
made as soon as possible.  
Moreover, our findings may shed new light on the mechanisms that cause the 50-fold 
increased risk of developing atherosclerotic cardiovascular disease in patients suffering 
from systemic lupus erythematosus (SLE)28. This systemic autoimmune disease is 
characterized by elevated plasma levels of type I interferons29, which is thought to play 
a central role in its pathogenesis30 and is therefore targeted in experimental and clinical 
attempts to treat SLE31. Although the correlation between SLE and atherosclerosis in 
mice and patients was known before, it was until now explained by the combined 
contribution of different atherosclerosis-promoting factors, including traditional risk 
factors as well as a chronic inflammatory environment, elevated levels of auto-
antibodies, endothelial dysfunction, decreased vascular repair and increased levels of 
oxidized lipids28,32,33. We, and simultaneously with us also other groups, now postulate 
that the high plasma levels of type I interferons may be an additional and important risk 
factor24,34,35. 
Similarly to SLE, other autoimmune inflammatory diseases including psoriasis, psoriatic 
arthritis and rheumatoid arthritis combine an essential role for type I interferons in 
their pathogenesis with an increased cardiovascular risk36-40. Also in these diseases, 
interferon signaling may contribute to this risk, in combination with traditional risk 
factors and other immune mediators like IL-141 and TNF42. 
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A yet unpublished observation in our experiment in which ApoE-/- mice were treated 
with IFNɴ may potentially shed a light on the importance of macrophage recruitment 
during the course of atherogenesis. In our experimental approach, we initiated the 
daily IFN injections simultaneously with the surgical positioning of the collars around 
the carotid arteries, implicating that the elevation of plasma IFNɴ levels in these mice 
coincided with the initiation of carotid atherogenesis. At that moment however, these 
ApoE-/- mice were already fed a high-fat diet for more than three weeks and therefore, 
plaques had already started to form in other, more hyperlipidemia-dependent locations 
like the aortic root, the innominate artery and the aortic arch. While IFN injections 
promoted atherogenesis proximal of the collar,  as shown in Chapter 2,  plaques in the 
aortic arch and innominate artery were unaffected by this treatment (Figure 6.2). Since 
the plaque size in these locations was not assessed in our other models, there is no 
certainty that atherogenesis in these locations is similarly dependent on CCL5-mediated 
leukocyte recruitment as plaques in the aortic root. A more plausible and instinctive 
explanation however would be that this effect of IFN treatment on plaque growth is 
most outspoken in newly-formed plaques. Since early lesions are rapidly expanding 
through the recruitment of new cells, they may be more affected by CCL5 upregulation 
than the larger, more advanced lesions, in which plaque stability parameters become 
more relevant. More evidence is needed to support this theory, for example by 
assessing the number of newly-recruited macrophages in plaques of different stages 
and sizes with the ER-MP58 marker that was described in Chapter 3. The outcome will 
be of high importance when designing future experiments and therapies that target the 
cell recruitment to the lesions.  
It  is  therefore  also  possible  that  the  results  of  the  IFN  treatment  we  described  in  
Chapter 2 are highly dependent on the experimental setup we applied. In our models, 
daily IFN injections were initiated at the expected start of the high-fat diet-induced 
plaque formation (in the LDLR-/- model) or immediately after positioning the collars (in 
the ApoE-/- model) and therefore coincided with the earliest atherogenesis. In future 
experiments, it has to be verified if a similar atherosclerosis-promoting effect can still 
be observed when the treatment starts later in the disease progress. In the more 
advanced plaques, IFN treatment may affect the plaque stability, for example through 
TRAIL-mediated promotion of apoptosis43 or inhibition of smooth muscle cell 
proliferation44, rather than promote further plaque growth. 
Other future experiments should focus on the effect of type I interferons in other cell 
types within the atherosclerotic lesion. Repeating the studies of high-fat diet-induced 
atherosclerosis in LDLR-/- mice  that  have  a  cell  type-specific  deletion  of  IFNAR1  in  
smooth muscle cells (smooth muscle actin promoter45) or endothelial cells (Tie-2 
promoter46) may reveal additional mechanisms in which IFNs contribute to plaque 
growth or (in)stability. 
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Figure 6.2: IFNE treatment in ApoE-/- mice with a collar induced atherogenesis in the carotid artery (A) but 
did not affect plaque size in the innominate artery (B) nor in the transcersal aorta (C). 
Myeloid Iʃɲ deficiency promotes atherogenesis 
It has been shown extensively before that inflammation has a major effect on 
atherogenesis4,47. This is not only illustrated by the local presence of different 
inflammatory cell types48 but also the proven influence of inflammatory cytokines on 
the development of the plaque19. The transcription factor NF-ʃB plays a key role in 
many of the cellular responses that drive inflammation, including the production of 
many of these cytokines49. This homo- or heterodimer is kept inactive through binding 
of the inhibitor of NF-ʃB (IʃB). Phosphorylation of this inhibitor by the IʃB kinase (IKK) 
complex and subsequently ubiquitination and degradation releases NF-ʃB and enables 
it to translocate to the nucleus, resulting in a specific gene expression pattern. This IKK 
complex can be activated through many different converging signaling pathways that 
respond to a wide range of stimuli, including microbial molecules, cytokines50 and, 
notably in the atherosclerotic plaque, oxidized LDL particles51 (Figure 6.1). 
Because of its role in the initiation of inflammation and because atherosclerosis is an 
inflammatory disease, NF-ʃB activation was thought to contribute to the pathogenesis 
of this disease. In experiments targeting upstream signaling molecules that were 
previously published by our group and other groups however, it was shown that the 
role of NF-ʃB is far more complex and yet to be thoroughly investigated52-54. 
A 
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In Chapter 3, we aimed at further clarifying the effect of NF-ʃB activation in 
macrophages on murine atherogenesis by genetically and myeloid-specifically deleting 
its main inhibitor of the IʃB family, Iʃɲ. Contrary to the full Iʃɲ-/- mice, these 
conditional LysMCre-Iʃɲfl/fl mice have no dysregulation of myelopoiesis55. Instinctively, 
they should result in a continuous NF-ʃB activation and a sustained NF-ʃB-dependent 
gene expression pattern in macrophages and neutrophils. However, both in vitro and in 
vivo experiments revealed disappointingly little increase in macrophage NF-ʃB 
translocation to the nucleus or upregulation of some typically NF-ʃB-dependent genes. 
Without clear experimental evidence for compensatory mechanisms, functional 
redundancy56 or interference with other transcription factors57 in this complicated and 
tightly regulated pathway, we still don’t know yet why Iʃɲ deletion cannot be used as 
a model for NF-ʃB hyper-activation. Knowing that the deletion of a directly binding 
inhibitor is still insufficient to deregulate this pathway, it can be questioned if it will 
even be possible to design genetic models of sustained NF-ʃB activation. Perhaps the 
closest useful approach would involve mice with a myeloid-specific deletion of the de-
ubiquitinating enzyme A2058, but one has to bear in mind that these mice also display a 
continuous IRF3 activation and thus produce elevated levels of the atherosclerosis-
promoting type I interferons. 
Remarkably, even without demonstrable effect on NF-ʃB activity, the chemokine CCL5 
was upregulated in Iʃɲdel macrophages, promoting their adhesion to endothelial cells 
in a similar way as we described for IFNɴ in Chapter 2. Although considered an NF-ʃB-
dependent gene59, we and others demonstrated the importance of IFNs in macrophage 
CCL5 expression24,60. This raises the question whether the observed upregulation is a 
consequence of the NF-ʃB or IFN signaling. As we have not detected an induced 
production  of  IFNs  in  the  Iʃɲdel cells, future experiments may investigate whether 
these cells perhaps have an increased sensitivity to IFNs. In order to completely 
understand the effect of Iʃɲ deletion on the gene expression pattern, a full micro-
array should be performed on these macrophages, instead of the confined list of some 
typical NF-ʃB-dependent or atherosclerosis-influencing genes we assessed. 
The introduction of ER-MP58 as a marker for newly-recruited macrophages in the 
plaque may offer new possibilities for further research. As mentioned above, 
quantification of the ER-MP58+ macrophages throughout the course of plaque 
development will bring valuable insights in the role of cell recruitment in different 
stages  of  the  disease.  It  can  also  serve  as  a  tool  for  assessing  the  effect  of  future  
therapeutic strategies and dietary changes in murine atherogenesis models. 
A lentiviral vaccination targeting survivin potently reduces plaque size 
In Chapter 4, a novel vaccination strategy for murine atherosclerosis was 
demonstrated. After confirming the presence of the mostly tumor-specific protein 
General discussion 
 
133 
survivin in newly-recruited macrophages of murine plaques, similarly to the human 
lesions61, the evocation of a targeted immunity by injections with survivin-expressing 
lentiviral vectors successfully reduced diet-induced atherogenesis.  
Despite the wide range of survivin-targeting therapeutic strategies that have been 
developed in tumor models and are already applied in the clinic62,  most  of  these  
approaches are aimed at a one-time elimination of survivin-positive cells and are 
therefore not applicable in the treatment of a chronic disease. Moreover, as discussed 
above, the recruitment of new macrophages to the lesion may contribute more to early 
pathogenesis and gradually reduce in importance when the plaques become more 
advanced. Survivin-targeting interventions would therefore be at their most effective 
against newly-forming plaques and thus should be prophylactic rather than 
therapeutic. This makes immune therapy the desired option for treating 
atherosclerosis, over the short-lived small-molecule antagonists, siRNA, anti-sense 
oligonucleotides and other survivin-targeting methods.  
But although this vaccination strategy has been applied before in mice as well as in the 
clinic to combat survivin-expressing tumors with limited side effects and now appears 
to successfully target murine atherosclerosis as well, this therapy is not yet ready for 
application in atherosclerosis patients. First of all, one may question the ethics of 
vaccinating against a disease that affects a whole population but is, when well 
managed, invisible and non-terminal. On the other hand, vaccinating only the people 
that are proven to be at risk may come too late for optimal efficacy. Moreover, 
survivin-targeting vaccinations already were shown to be strongly varying in efficiency 
between  different  types  of  tumor  cells,  ranging  from  phase  I  trials  that  achieved  a  
decrease in tumor markers in less than half of the treated patients63 to patients that 
have temporary or even complete remission after vaccination64. Thence, the efficiency 
against plaque macrophages remains uncertain. 
Also, the long-term effects of this vaccination should be assessed thoroughly first. 
Other than in cancer, where short-term and aggressive immunity against survivin 
should suffice to eliminate as many tumor cells as possible, usually in addition to other 
tumor-targeting therapies, inhibiting atherogenesis requires a life-long, latent 
immunity. Before this can be attempted, the role of survivin in non-tumoric, healthy 
cells should be investigated more exhaustively. However survivin is thought to be 
predominantly tumor cell specific and expressed only shortly and in low levels in 
healthy tissues65,66, there may still be yet unknown cell type-specific and situation-
specific requirements for survivin-expression67,  similar  to  the expression that  was just  
recently discovered in plaque-infiltrating macrophages61. Certitude of the specificity is 
required before long-term immunity can be induced safely.  
Before the above mentioned requirements can be met, a survivin-targeting immune 
therapy for atherosclerosis will not be ready for clinical application. Meanwhile, these 
results should rather be regarded as an illustration of the possibility to specifically 
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target cells in the atherosclerotic plaque, not only for vaccinations but potentially for 
plaque-specific delivery of other future therapeutics as well. Furthermore, immune 
histochemistry for survivin could be used in a similar way as described above for ER-
MP58 to monitor macrophage recruitment to the plaques. 
Future Perspectives 
Other than a change in lifestyle and cholesterol-lowering drugs, no pharmaceuticals or 
therapies are yet available for intervening with the disease progression of 
atherosclerosis. Similarly to the difficulties in finding cancer treatments, the main 
problem may be that the cells  we would wish to target are not differing enough from 
the healthy cells, while their functions we hope to block are still necessary in other, 
physiological processes. Therefore, it will be very important to focus further research 
on finding the properties that make the cells in the atherosclerotic plaque significantly 
different from healthy cells, enabling targeted therapies. 
The abundance and the central role of macrophages in the plaque make this cell type 
the desired target for different therapeutic strategies68.  From the  very  first  phases  of  
atherogenesis up until plaque rupture, macrophages drive the disease progression and 
influence the attraction and function of the surrounding cell types. Unlike the earliest 
proposed models of macrophage heterogeneity, with pro-inflammatory M1’s and anti-
inflammatory  M2’s,  we  now  know  that  there  is  a  wide  range  of  macrophage  
phenotypes in between these two extremes and that each of these phenotypes is 
induced by their specific environment during differentiation, priming and activation69. 
Most likely, even the plaque macrophages are a collection of different phenotypes, 
depending on the cells’ exposures to growth factors, cytokines, lipids etc. Therefore, 
macrophage markers related to the uptake and storage of lipids may be more attractive 
as a target than the classic M1 and M2 markers. Only a few genes are already described 
to be more or less specifically upregulated in (subsets of the) plaque macrophages, 
including the genes for the fatty acid binding protein aP270, the reverse cholesterol 
transporter ABCA171,72 and the nuclear receptor PPARɶ73,74. Also the survivin gene is, as 
discussed earlier, upregulated in newly recruited plaque macrophages. Knowledge of 
these specific genes and pathways may allow therapeutic interventions but may also be 
useful for targeting vaccinations, like we and others demonstrated before75,76, and as a 
target in other directed therapies. A recent publication from the oncology field for 
example illustrates the possibility of generating cytolytic viruses that specifically 
replicate in cells where a certain gene is expressed or pathway is induced77. 
As we explained in chapter 5, macrophage phenotype skewing in vivo through exposure 
to the right cytokines or other skewing stimuli may become a future therapeutic option 
for atherosclerosis78. A thorough knowledge of the phenotypes present in the lesion, 
their contribution to atherogenesis and the triggers needed to generate the desired 
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phenotype would be required, as well as a method to specifically affect the plaque 
macrophages while retaining the full functionality of macrophages in other tissues. This 
may be achieved by exploiting the above mentioned lesion-specific genes. For example, 
viral delivery of constructs that provide the aP2 or ABCA1 promoter regulating the IL-10 
gene could trigger the expression of this anti-inflammatory cytokine specifically in the 
plaque macrophages and thereby induce an auto- and paracrine macrophage 
phenotype skewing and an anti-atherogenic effect79. While aP2 expression is 
independent of IL-1080, ABCA1 expression is upregulated upon IL-10 signaling81 and will 
therefore further amplify the cytokine’s expression. Experimental evidence should 
clarify which of these options would be most successful, or if self-limiting mechanisms 
should rather be pursued.  
 
In this thesis, the importance of leukocyte (and predominantly macrophage) 
recruitment to the plaque is an often recurring theme. Its modulation largely affects 
plaque growth, presumably most in newly forming lesions and to a lesser extent in 
more advanced stages of the disease. Reducing this recruitment by inhibiting 
chemokine secretion or blocking adhesion molecules slows down plaque growth82-84 
but it is important to remember that this recruitment is still essential in other functions 
of the macrophage, like infiltrating tissues upon the local detection of infectious agents. 
Therefore, general inhibition of recruitment is no option and more targeted solutions 
should be found85.  
Instead of interfering with the function of adhesion molecules and chemokines, it might 
be more useful to focus on the stimuli that induce their production instead, for example 
by skewing the plaque macrophages towards a phenotype that has a significantly 
reduced chemokine production. The endothelial cells’ adhesion molecule production on 
the other hand could be reduced by targeting the source of the activation of these cells. 
As shown by Duewell et al86, cholesterol crystals activate the NLRP3 inflammasome in 
plaque macrophages, leading to the activation and secretion of IL-1. Although the 
influence of this IL-1 on the surrounding cell types is still to be investigated, endothelial 
cells do express its receptor IL-1R and can, at least in vitro,  be  activated  by  IL-187. 
Indeed, plaque size was reduced in mouse models with IL-1 deletion88, IL-1R antagonist 
overexpression89,90 or injections with this IL-1Ra91. The IL-1 production is rather specific 
for sterile inflammatory stimuli like cholesterol crystals, necrotic cells, asbestos and 
silica crystals but not for the microorganism-stimulated inflammatory response and 
subsequent cell recruitment92. It may therefore be an interesting target in future 
therapies aiming at the reduction of endothelial activation as a result of these stimuli 
while maintaining a proper response to the detection of microorganisms. Conveniently, 
IL-1 targeting therapies (e.g. anakinra) are already available in the clinic93. 
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In conclusion, this thesis further illustrates the importance of macrophage recruitment 
in  the  pathogenesis  of  atherosclerosis.  We show how an  increase  in  the  attraction  of  
new macrophages to the lesion deteriorates the disease while specifically targeting 
these cells through vaccination reduces plaque size. These data may result in new 
therapeutic strategies for (early) atherogenesis. Also a thorough knowledge of the 
macrophages’ inflammatory signaling and their intra-plaque heterogeneity will reveal 
new possibilities for the treatment of this disease, as described in this thesis. 
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Figure S2.1: Expression of chemotactic factors after treatment with IFNɲ. 
Indicated is the fold-induction in bone marrow macrophages after 24h treatment with IFNɲ compared to 
untreated cells. Bars represent average of triplicate wells. (** p<0.01) 
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Figure S2.2: Expression of type I IFN signature genes in arches of atherosclerotic ldlr-/- mice and cytokine 
levels in IFNAR1WT and IFNAR1del mice after 8 weeks of high fat diet. 
(A) Expression of OAS1, OAS2, IRF9 and MX2 was detected in arches of ldlr-/- mice that had been fed a high 
fat diet for 6 (6W) or 9 (9W) weeks. (B) IL-6 levels are reduced in IFNAR1del mice compared to IFNAR1WT 
mice, while IL-12, TNF and MCP-1 show a non-significant trend towards a reduction. N=10 animals per 
group, P values are indicated. 
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Figure S2.3: Secretion of CCL5 after treatment with IFNɴ. 
Human primary macrophages were untreated (ctrl) or treated with IFNɴ for 24h (IFNɴ) and CCL5 was 
measured in the supernatant. Bars indicate average of triplicate wells. (** P<0.01) 
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Table ST2.1: Differential gene expression of Type I IFN signaling pathway and chemokines in human carotid 
plaques: Ruptured vs. Stable. 
The Type I IFN signaling pathway is upregulated in unstable regions of human atherosclerotic lesions. Both 
genes involved in the Type I IFN signaling pathway as well as its target genes are mostly upregulated in 
ruptured human carotid plaques compared to stable regions. Fifty percent of the investigated chemokines 
are also upregulated in ruptured plaque regions. 
* CCR5 was not detected on the array for unknown reasons, values presented are qPCR values relative to 
18s rRNA of cDNA from 4 stable vs. 8 ruptured plaque lysates. 
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Figure S3.1: Deficiency of Iʃɲ does not lead te increased NF-ʃB activity and subsequent gene expression. 
(A) Western blotting for Iʃɲ on lysates of bone marrow derived IʃɲWT or Iʃɲdel macrophages confirmed 
a reduction in Iʃɲ production, both before and after LPS activation. (B-C) A western blot for 
phosphorylated NF-ʃB subunit p65 showed that NF-ʃB is not continuously activated in Iʃɲdel 
macrophages, (D) resulting in a lack of differential expression patterns for NF-ʃB dependent genes. 
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Figure S4.1: Schematic overview of the experimental setup used in the atherosclerosis vaccination study
Each bar represents one week and indicates the age of the mice. Three immunizations with lentivirus were 
administered and the mice were fed a high-fat diet for 11 weeks. At the end of the experiment, mic
sacrificed and their atherosclerotic plaques were analyzed. 
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Figure S4.2: Body weight, plasma lipids and atherosclerosis parameters of vaccinated mice. 
(A) Body weight of the mice after 11 weeks of high-fat diet. (B-C) At the end of the experiment, blood was 
drawn from the mice and plasma cholesterol (B) and triglyceride (C) levels were measured enzymatically. 
None of these parameters showed significant differences. (D-E) Histochemical analysis of the lesions 
revealed no difference in plaque collagen content (D) and necrotic area (E). 
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Cardiovascular events are the number one cause of death in western society and even 
gain quickly in importance since a disease-promoting lifestyle becomes more common. 
Obesity,  high blood pressure,  smoking and a lack of exercise are just some of the risk 
factors that contribute to atherosclerosis, the underlying pathogenesis of most of these 
cardiovascular diseases. While we have a fair idea of the cellular and molecular 
mechanisms that contribute to atherogenesis, treatment options are still mainly 
focused on reducing the risk factors. 
The disease initiates when macrophages migrate to the vessel wall of an artery, where 
they take up modified lipids. This turns them into large, lipid-laden foam cells that 
cannot re-enter the blood stream but instead secrete factors that create a local 
inflammation, attracting even more macrophages and other immune cells. This 
accumulation of lipids and cells in the vessel wall is called an atherosclerotic plaque. In 
the chronic disease phase, the plaque will further grow until it ruptures and thereby 
forms a blood clot that can occlude downstream blood vessels. Depending on the 
location of the affected blood vessel, this results in acute manifestations such as 
ischemia, stroke or heart attack.  
The macrophages are the most abundant cell type within the plaques and play a key 
role in all disease phases, from early atherogenesis to plaque rupture. This makes them 
potentially interesting targets for future therapies. Consequently, the experiments 
presented in this thesis mainly focus on the macrophages and their signaling pathways 
that are involved in the creation of an inflammatory environment as well as the 
recruitment of other cells to the plaque. 
In Chapter 2, we investigated the effect of type I interferons (IFN) on the plaque 
macrophages. Although classically seen as antiviral mediators, it is becoming 
increasingly clear that these cytokines also play a major role in normal physiology and 
can act both as pro- or anti-inflammatory mediators in a variety of non-pathogen 
associated diseases. Using both treatment with IFNɴ and myeloid specific knockouts for 
the type I interferon (IFN) receptor (IFNAR1) we have investigated the functional role of 
type I IFN in atherosclerosis in experimental models. We show that IFNɴ enhances 
atherogenesis in two well established mouse models of atherosclerosis by upregulating 
chemokines and chemokine receptors that are necessary for atherosclerotic lesion 
development.  In  addition,  we  show  that  major  targets  for  endogenous  type  I  IFNs  in  
atherosclerosis are myeloid cells, since mice with a myeloid specific deletion of IFNAR1 
show reduced accumulation of myeloid cells in atherosclerotic lesions and thereby have 
reduced disease development. Moreover, we show that type I IFN signaling pathways 
are also activated in human atherosclerotic lesions and are associated with plaque 
rupture, making them potentially relevant for clinical outcome of disease.  
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It has been shown before that both the level of inflammation and the balance between 
pro- and anti-inflammatory mechanisms tremendously regulate the growth and 
composition of the atherosclerotic plaque. An important transcription factor involved in 
this regulation is NF-ʃB, which has indeed been described, by our group and others, to 
affect the process of atherogenesis. Its precise role(s) in the different cell types present 
in the plaque however remains unclear. In Chapter 3, the role of the NF-ʃB pathway in 
atherogenesis is further assessed by deletion of NF-ʃB’s main inhibitor, Iʃɲ, in the 
myeloid cells of a murine atherosclerosis model. It resulted in a two-fold increase in the 
size of the plaques. Further analysis suggests that myeloid Iʃɲ deletion promotes 
atherogenesis by an enhanced recruitment of myeloid cells to plaques. This was 
supported by an immunohistochemical staining of the plaques with the ER-MP58 
antibody, a novel method to quantify myeloid cell recruitment to the atherosclerotic 
plaque that we introduce in this chapter. This effect of myeloid Iʃɲ deletion on murine 
atherogenesis is of high relevance in the further assessment of the role of inflammatory 
signaling pathways in the atherosclerotic plaque.  
 
Chapter 4 features a new vaccination strategy in the treatment of experimental 
atherosclerosis, using a lentiviral vaccination approach to specifically target newly 
recruited macrophages in the atherosclerotic plaque. Evoking an immune reactivity 
against the antigen ‘survivin’ indeed resulted in a reduction of the plaque size and a 
local accumulation of cytotoxic T cells without causing adverse side effects.  
Survivin is mainly known as a tumor-specific antigen since its expression in healthy cells 
is low but it is upregulated in virtually all tumors. Several survivin-based (gene) 
therapies targeting tumor cells have been developed in experimental models and some 
of them have already been applied in the clinic. Next to its tumor-specificity however, 
an article published a few years ago described that newly recruited macrophages in 
human atherosclerotic plaques also express survivin under the influence of local growth 
factors.  
We confirm survivin expression in the newly recruited macrophages of murine plaques, 
target them using a vaccination strategy with a survivin-expressing lentivirus and 
demonstrate that this results in a significant reduction in lesion growth accompanied by 
an induction of recruitment of CD3+ T cells and CD8+ cytotoxic T cells to the plaque. This 
completely novel approach in experimental atherosclerosis may open up the potential 
of new therapies for this disease. 
 
In Chapter 5, we describe the characteristics of different macrophage subsets and their 
specialized functions. While this wide range of phenotypes is already well described in 
other diseases with a key role for macrophages, like infection diseases and cancer, it 
most probably also affects atherogenesis. In this chapter we give an overview of the 
current relevant knowledge on macrophage heterogeneity and its putative roles in 
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disease progression, but also speculate on diagnostic and therapeutic possibilities that 
may benefit from it. 
In conclusion, this thesis illustrates through different KO and treatment models the 
importance of macrophages and their inflammatory and chemotactic signaling 
pathways in the pathogenesis of atherosclerosis. Next to showing the disease 
promoting effect of enhanced recruitment of macrophages to the plaque, we also 
demonstrate that the specific targeting of these newly recruited cells may present a 
new strategy for plaque reducing therapies. 
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Cerebrovasculaire accidenten zijn de voornaamste doodsoorzaak in de westerse 
samenleving en winnen nog steeds aan belang wegens het groeiend aantal mensen met 
een levensstijl die deze aandoeningen in de hand werkt. Obesitas, een verhoogde 
bloeddruk, roken en een gebrek aan lichaamsbeweging zijn slechts enkele van de 
risicofactoren die bijdragen tot atherosclerose, in de volksmond ook wel aderverkalking 
genoemd, de ziekte die de meeste van die accidenten veroorzaakt. En hoewel we al vrij 
goed op de hoogte zijn van de cellulaire en moleculaire mechanismen die 
verantwoordelijk zijn voor het ziekteverloop van atherosclerose, blijven de 
therapeutische opties voorlopig beperkt en wordt er vooral gefocust op het elimineren 
van de risicofactoren. 
Atherogenese begint wanneer macrofagen vanuit het bloed naar de vaatwand van een 
slagader migreren, waar ze chemisch gemodificeerde lipiden opnemen. Hierdoor 
veranderen ze in zogenaamde schuimcellen. Deze grote, met vet gevulde cellen kunnen 
niet meer terug migreren naar de bloedbaan en zitten dus vast in de vaatwand. Van 
daar secreteren ze specifieke ontstekingseiwitten die nog meer macrofagen en andere 
immuuncellen rekruteren. Deze lokale ontstekingshaard en de opeenstapeling van 
cellen in de vaatwand wordt een atherosclerotische plaque genoemd. Gedurende de 
chronische fase van de ziekte zal deze plaque steeds verder groeien tot ze uiteindelijk 
openscheurt, waarbij zich een bloedklonter vormt die stroomafwaarts kleinere 
slagaders kan verstoppen. Afhankelijk van de slagader waarin de bloedstroom wordt 
afgesloten veroorzaakt dit acute problemen zoals lokaal zuurstoftekort, een beroerte of 
een hartaanval. 
Een  plaque  bestaat  voor  een  groot  deel  uit  macrofagen  en  zij  spelen  dan  ook  een  
hoofdrol in elke fase van de ziekte, van de vroegste atherogenese tot het scheuren van 
de plaque. Dit maakt ze interessante doelwitten in de zoektocht naar nieuwe 
therapieën. De experimenten die in deze thesis worden beschreven focussen daarom 
voornamelijk op de rol van macrofaag signaaltransductie in het creëren van een 
inflammatoire omgeving en het aantrekken van nieuwe cellen naar de plaque. 
In Hoofdstuk 2 gaan  we  dieper  in  op  het  effect  van  type  I  interferonen  (IFN)  op  
plaquemacrofagen. Hoewel deze cytokines vooral zijn bestudeerd omwille van hun 
antivirale effecten, krijgen hun fysiologische functies steeds meer aandacht en is het 
duidelijk dat ze ook in andere, niet-infectieuze ziektes een rol spelen die zowel pro- als 
anti-inflammatoir kan zijn. Onze studie van deze type I interferonen in atherosclerose 
bestond zowel uit KO- als behandelingsexperimenten: in twee verschillende 
muismodellen voor atherosclerose konden we aantonen dat een dagelijkse 
behandeling met IFNɴ de atherosclerotische plaquegroei stimuleert via een verhoogde 
productie van enkele chemokines en chemokinereceptoren die essentieel zijn in de 
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plaquevorming. Daarnaast beschrijven we hoe, binnen de plaque, myeloïde cellen het 
belangrijkste doelwit zijn van endogene interferonen, aangezien muizen waarin de 
receptor voor IFN (IFNAR) specifiek ontbreekt in de beenmerg afgeleide cellen minder 
accumulatie van cellen in de vaatwand vertonen en daardoor een vertraagd 
ziekteverloop hebben. Ten slotte bekijken we ook atherosclerotische plaques uit 
patiënten, waarin de IFN-signalering ook is geactiveerd en kan worden geassocieerd 
met het scheuren van de plaque. Dit wijst op een mogelijke klinische relevantie die 
verder onderzoek vereist. 
Het is reeds vaak beschreven dat de groei en samenstelling van de atherosclerotische 
plaque zeer afhankelijk is van de mate van ontsteking alsook van de balans tussen pro- 
en anti-inflammatoire mechanismen. Bij de regulatie hiervan is een centrale rol 
weggelegd voor de transcriptiefactor NF-ʃB, waarvan inderdaad eerder al door zowel 
onze groep als andere groepen een invloed op het atherogeneseproces is beschreven. 
Desondanks blijft het precieze mechanisme in de verschillende celtypes van een plaque 
voorlopig onduidelijk. In Hoofdstuk 3 wordt deze rol van NF-ʃB verder onderzocht door 
middel van een muismodel waarin Iʃɲ, de belangrijkste inhibitor van NF-ʃB, ontbreekt 
in de beenmergafgeleide cellen. Het resultaat is een verdubbeling van de plaquegrootte 
in de muizen met Iʃɲ-deletie. Verdere analyse van deze plaques suggereert dat dit kan 
worden verklaard door een verhoogde rekrutering van myeloïde cellen naar de 
plaques. Dit wordt bevestigd door immunohistochemische kleuringen van de plaques 
met het antilichaam ER-MP58, een in dit hoofdstuk geïntroduceerde methode voor het 
bepalen van de hoeveelheid nieuw-gerekruteerde macrofagen in een plaque. Dit effect 
van myeloïde Iʃɲ-deletie kan van groot belang zijn in de verdere studies naar de rol 
van inflammatoire signalering in plaque-ontwikkeling. 
In Hoofdstuk 4 introduceren we vaccinatie met lentivirussen die een immuunreactie 
tegen het antigen ‘survivin’ induceren als een nieuwe strategie in de behandeling van 
experimentele atherosclerose. Door zo specifiek de nieuw-gerekruteerde macrofagen 
in de plaque te viseren konden we inderdaad de plaquegrootte reduceren zonder 
belangrijke neveneffecten te induceren. Survivin is vooral bekend als tumorspecifiek 
antigen aangezien het nauwelijks detecteerbaar is in gezonde cellen maar sterk tot 
expressie komt in zowat alle tumoren. Bij onderzoek in experimentele tumormodellen 
werd van deze eigenschap reeds gebruik gemaakt voor het ontwikkelen van 
verschillende survivin-gebaseerde (gen)therapieën, waarvan sommige intussen zelfs al 
succesvol in de kliniek worden toegepast. Een publicatie van enkele jaren geleden 
beschreef echter dat, naast deze tumorspecificiteit, nieuw-gerekruteerde macrofagen 
van humane plaques ook survivin tot expressie brengen onder invloed van lokale 
groeifactoren. Wij bevestigden de aanwezigheid van deze survivin-positieve, nieuw-
gerekruteerde macrofagen in atherosclerotische plaques van de muis. Wanneer we 
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deze cellen gericht viseerden door middel van een vaccinatie met survivin-
producerende lentivirussen, resulteerde dit in een significante vermindering van de 
plaquegroei en een verhoogde aanwezigheid van CD3+ T-cellen en CD8+ cytotoxische T-
cellen in de plaques. Deze nieuwe behandelingsstrategie in experimentele 
atherosclerose zou het pad kunnen effenen voor nieuwe therapiemogelijkheden. 
In Hoofdstuk 5 beschrijven we de eigenschappen en specifieke functies van de 
verschillende macrofaagsubsets. Hoewel het bestaan van een brede waaier aan 
macrofaagfenotypes reeds uitvoerig is beschreven bij ziektes met een hoofdrol voor 
macrofagen, zoals infectieziektes en kanker, is dit concept hoogstwaarschijnlijk ook 
relevant voor de macrofagen in een atherosclerotische plaque. We geven daarom eerst 
een overzicht van de relevante kennis die over deze verschillende macrofagen bestaat, 
relateren dit aan de gekende macrofaagfuncties in een plaque en beschrijven tot slot 
enkele mogelijke diagnostische en therapeutische toepassingen.  
 
Samenvattend illustreert deze thesis in verschillende KO- en behandelingsmodellen het 
belang van macrofagen en hun inflammatoire en chemotactische signalering in de 
pathogenese van atherosclerose. Behalve een sneller ziekteverloop ten gevolge van een 
verhoogde rekrutering van macrofagen naar de plaque, tonen we ook dat een 
specifieke targeting van deze nieuw-gerekruteerde cellen een nieuwe strategie voor 
atherosclerose-therapieën kan zijn. 
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ACE  Angiotensin-converting enzyme 
acLDL   Acetylated LDL 
ANOVA  Analysis of variance 
APC  Antigen-presenting cell 
ApoE  Apolipoprotein E 
Arg1  Arginase-1 
ATM  Adipose tissue macrophage 
Bcl  B-cell lymphoma-encoded protein 
bFGF  Basic fibroblast growth factor 
BMM  Bone marrow-derived macrophage 
CCL  CC chemokine ligand 
CCR  CC chemokine receptor 
CD  Cluster of differentiation 
cDNA   Complementary DNA 
COX  Cyclooxygenase 
Cre  Cre recombinase 
CT  Computed tomography 
CTL  Cytotoxic T cell 
Ctrl  Control mice/cells 
CVD  Cardiovascular disease 
CXCL  CXC chemokine ligand 
CXCR  CXC chemokine receptor 
DAG  Diacylglycerol 
DAMP  Damage-associated molecular pattern 
DC  Dendritic cell 
ELISA  Enzyme-linked immunosorbent assay 
ER  Endoplasmic reticulum 
FDG  Fluorodeoxyglucose 
Flox  Flanked by loxP 
GFP  Green fluorescent protein 
GM-CSF  Granulocyte/macrophage colony stimulating factor 
HDL  high-density lipoprotein 
HSP  Heat-shock protein 
IAP  Inhibitor of apoptosis protein 
ICAM   Intercellular adhesion molecule 
IFN  Interferon 
IFNAR  Interferon-ɲͬɴ receptor 
IFNGR  Interferon-ɶ receptor 
/ʃB  Inhibitor of NF-ʃB 
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IKK  /ʃB kinase 
IL  Interleukin 
IL-1R  Interleukin-1 receptor 
iNOS   Inducible nitric oxide synthase (=NOS2) 
IP3  Inositol triphosphate 
IRF  Interferon regulatory factor 
ISG  Interferon-stimulated gene 
JAK  Janus kinase 
KO  Knock-out 
LDL  low-density lipoprotein 
LDLR  LDL receptor 
LFA-1  Lymphocyte function-associated antigen 1 
LPS   Lipopolysaccharide 
LysM   Lysozyme M 
MAP   Mitogen-activated protein 
MAPK   MAP kinase 
MCP-1  Monocyte chemotactic protein-1  
M-CSF  Macrophage colony stimulating factor 
mDC  Myeloid dendritic cell 
MHC   Major histocompatibility complex 
mLDL   Modified low-density lipoprotein 
MMP  Matrix metalloproteinase 
MPO   Myeloperoxidase 
MR  Mannose receptor 
MRI  Magnetic resonance imaging 
MS  Multiple sclerosis 
Mx  Myxovirus resistance 
NEMO   NF-ʃB essential modulator 
NF-NB   Nuclear factor-NB 
NK  Natural killer cell 
NKT  Natural killer T cell 
NLRP3   NOD-like receptor family, pyrin domain containing 3 (=NALP3) 
NO  Nitric oxide 
OAS  2'-5'-oligoadenylate synthetase 
oxLDL  Oxidized LDL 
PAMP   Pathogen-associated molecular pattern 
pDC  Plasmacytoid dendritic cell 
PET  Positron emission tomography 
PKC  Protein kinase C 
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PLC  Phospholipase C 
PPAR  Peroxisome proliferator-activated receptor 
PRR  Pattern recognition receptor 
PSGL-1  P-selectin glycoprotein ligand 1 
RANTES  Regulated upon activation, normal T cell expressed and secreted 
RNI  Reactive nitrogen intermediates 
RNS  Reactive nitrogen species 
ROI  Reactive oxygen intermediates 
ROS  Reactive oxygen species 
RPMI  Roswell Park Memorial Institute medium 
SEM  Standard error of the mean 
SLE  Systemic lupus erythematosus 
SMC  Smooth muscle cell 
SPECT   Single-photon emission computed tomography 
SR-A  Class A scavenger receptor 
STAT  Signal transducer and activator of transcription 
SURV   Survivin 
sVSG   Soluble variant-specific surface glycoprotein 
TAM  Tumour associated macrophage 
TF  Tissue factor 
TGF-ɴ  Transforming growth factor ɴ 
Th1/2  T helper 1 or 2 cell 
TLR  Toll-like receptor 
TNF  Tumor necrosis factor 
TNFR   TNF receptor 
TRAIL   TNF-related apoptosis-inducing ligand 
Treg  Regulatory T cell 
TUNEL   Terminal deoxynucleotidyl transferase dUTP nick end labeling assay 
TZD  Thiazolidinediones 
UPR  Unfolded protein response 
USPIO   Ultrasmall superparamagnetic particles of iron oxide 
VCAM   Vascular cell adhesion molecule 
VEGF   Vascular endothelial growth factor 
VLA-4  Very late antigen 4 
VSG  Variant-specific surface glycoprotein 
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Betrapt! Dit zullen voor de meesten onder jullie de eerste pagina’s van dit boekje zijn 
die ze ook werkelijk lezen (en laat ons eerlijk zijn, voor velen ook meteen de enige). De 
andere pagina’s zijn volgens mij nochtans ook interessant hoor, kijk maar eens! Maar 
goed, aan mij nu dus de lastige opdracht om niemand van jullie die bijgedragen heeft 
aan al dit werk of de aangename tijd waarin het uitgevoerd is te vergeten vermelden! 
Nu ja, de perfectie bestaat niet dus ik excuseer mij nu alvast bij de arme stakker die net 
even aan mijn aandacht wist te ontsnappen: als je van jezelf vindt dat ik je dankbaar 
hoor  te  zijn,  dan  bén  ik  dat  ongetwijfeld  ook  en  moet  je  er  maar  vanuit  gaan  dat  dit  
voor mij zó vanzelfsprekend was dat ik er uiteindelijk niet meer aan gedacht heb. Voila, 
een betere uitvlucht kon ik niet bedenken, maar dus nogmaals mijn excuses alvorens ik 
aan de moeilijke taak begin om zo veel mensen te bedanken in ‘n stukje dat voldoende 
mijn appreciatie duidelijk maakt maar tegelijk ook op een paar bladzijden past… 
 
En allereerst wil ik uiteraard mijn co-promotor bedanken voor de geweldige tijd die ik 
mocht beleven in zijn lab! Menno, in de aangename en stimulerende werkomgeving 
van jouw groep heb ik niet alleen heel veel geleerd maar blijkbaar ook de toch wel zeer 
besmettelijke macrofaag-microbe te pakken gekregen… Ik heb nooit een drempel 
gevoeld om even bij jou binnen te springen en heb bovendien heel veel vrijheid 
gekregen in mijn onderzoek, je gaf wel aanwijzingen maar je corrigeerde me enkel 
wanneer dat echt nodig was. Zoals achteraan, in mijn CV, te lezen valt heb ik van jou 
ook de kans gekregen om regelmatig mijn data op congressen te gaan presenteren en 
daar heb ik gretig gebruik van gemaakt! Bedankt voor alles en heel veel succes met je 
nieuwe avontuur in Amsterdam! 
 
Daarnaast wil ik uiteraard ook mijn promotor Dr. Glatz bedanken. Jan, bedankt voor het 
vertrouwen en alle hulp die ik kreeg bij het beëindigen van mijn promotie. Meteen 
daarbij wil ik ook Petra zeker niet vergeten, een groot deel van het papierwerk is (zeer 
efficiënt) over haar bureau gepasseerd! In diezelfde twee bureaus maar een paar jaar 
eerder ben ik trouwens ook dank verschuldigd aan Dr. Marten Hofker en Wilma! 
Marten, ik zal me vooral je wijze opmerkingen na mijn werkbesprekingen blijven 
herinneren, eerlijk en to the point maar tegelijk ook altijd zeer gemoedelijk. Een betere 
presentatie-coaching kan ik me niet voorstellen! En Wilma, toen ik net in Maastricht 
aankwam heb ik heel veel aan je gehad voor alle praktische zaken. Later pas ontdekten 
we een gemeenschappelijke passie voor reizen. Wel, als je ooit richting Marseille komt 
dan bied ik je bij deze alvast een gratis gids aan. 
 
Marion, onze eerste ontmoeting bij mijn sollicitatiegesprek was een teleurstelling! Voor 
jou  dan  toch,  ik  leek  helemaal  niet  op  de  stoere  foto  die  je  van  mij  op  het  internet  
gevonden had…! Voor mij was het ook meteen een eerste kennismaking met de 
Nederlandse directheid en vooral met je legendarische gezelligheid (“We gaan het hier 
nu toch niet over wetenschap hebben zeker, wat zijn je hobby’s?”). Orgaantjes 
Dankwoord 
  
174 
verzamelen, samen achter de microscoop zitten of koffiepauze nemen, het was 
allemaal goed voor jou zolang het maar gepaard ging met een leuke babbel. Bedankt 
voor al  je hulp,  je bijdrage aan de sfeer op het lab en ook voor de gastvrijheid bij  jou 
thuis! En tot binnenkort in Marseille! 
Tijdens mijn eerste maanden in Maastricht heb ik enorm veel nieuwe technieken 
moeten aanleren en daarbij was de hulp van Inge van onschatbare waarde. Je kon er 
nooit iets teveel aan vragen, bij elke techniek kende ze de tips and tricks en zelfs 
wanneer iedereen al naar huis vertrokken was bleef ze om te helpen. Inge, ik mag er 
niet aan denken hoeveel experimenten fout zouden afgelopen zijn als jij er niet bij was 
geweest... Los daarvan heb ik enorm genoten van onze momenten samen op het lab, 
met of zonder toppertje en een breezer ananas - Ik weet dat ik het al lang zeg maar 
ooit kom ik Malou en jou nog wel eens bezoeken in Amsterdam, echt waar!  
Monique, het was niet altijd eenvoudig om onze manieren van werken en onze 
dagindelingen op elkaar af te stemmen, maar we zijn er toch maar mooi in geslaagd het 
/ʃɲ-verhaal af te ronden. Dat verdient op z’n minst een paar honderd stickertjes! De 
organisatie en precisie in je werk zullen altijd een voorbeeld blijven voor mij.  
Patrick, volgens mij bestaat er geen enkel probleem op het lab waar jij geen (al dan niet 
creatieve) oplossing voor weet. Met je gevatte antwoorden en plagerijen kon je zelfs de 
intelligentste vraag oerdom doen lijken, om ons dan meteen daarna toch gewoon te 
hulp te schieten.  
Chantal, er zijn weinig mensen die met zo veel enthousiasme “Ik wil daar wel bij 
helpen…” roepen om daarna pas te vragen “… en wat moet ik precies doen?”. Zelfs bij 
het saaiste werk heb ik je nooit horen klagen! En je haar en je afvalemmertje brachten 
bovendien wat meer kleur in het lab - 
 
Danielle, je was een model-postdoc: vrolijk en uitbundig wanneer het kon maar serieus 
en gedreven wanneer het nodig was. Voor minder dan de perfectie deed je het niet en 
je stond ook anderen bij met raad en daad om ze richting hetzelfde doel te leiden. Een 
bezoekje bij jou en Koen thuis duurde ook altijd veel langer dan vooraf gepland, dat 
zegt denk ik wel genoeg over hoe gezellig ik het vond bij jullie! Geniet van jullie 
weekendjes samen (ik weet hoe dat is…) en heel veel plezier met Anna!  
So when you’re working late and the lab is quiet and dark, you’d think you’re all alone 
because everybody left hours ago. Well, you’re usually wrong! Sofia, thanks a lot for 
keeping me company during the late shift, ɸʐʖɲʌɿʍʏʙ!  
Marjo, met het vertrek van Menno is er voor jou waarschijnlijk heel wat veranderd. 
Heel veel succes op’t werk en veel plezier thuis, en stuur nog regelmatig maar eens een 
mailtje, da’s altijd leuk! 
 
Toen ik in Maastricht begon te werken kreeg ik een tafeltje in een overvolle kamer 
toegewezen. Daar zat ik onder andere bij Jana, Daphna,en Petra, die alle drie heel veel 
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van mijn praktische vragen beantwoord hebben. Verder zat daar ook nog Stijn (ik heb 
jaren later nog slakken van jou teruggevonden, ik moet zeggen dat ik eerder fan ben 
van de foto’s die je maakt…) en Mathijs. Van die laatste leerde ik al meteen in de eerste 
week hoe ik beenmerg en LDL kon isoleren, later respectievelijk mijn meest en minst 
favoriete bezigheden op het lab. En als je mijn bureau zag dan leek het wel alsof ik ook 
de organisatie ervan bij jou geleerd heb! Ook aan de activiteiten met je scoutsgroep 
heb ik erg veel plezier beleefd! En last but not least, in deze kamer zat ook nog een 
zekere Kristiaan, flauwe plezanten van beroep en tussendoor nog wetenschapper als 
hobby erbij, maar uitblinkend in beide disciplines! Ik ben dan ook heel blij dat je mijn 
paranymf wou zijn! Great minds think alike zeggen de Engelsen en ze zullen wel gelijk 
hebben aangezien wij intussen niet eens meer iets moeten zeggen om te weten wat de 
andere denkt… Ik ben blij dat Ellen en jij ook buiten het lab goede vrienden zijn 
gebleven  (en  zelfs  familie  zijn  geworden!)  en  ik  hoop  dat  de  afstand  ons  niet  zal  
tegenhouden om elkaar nog af en toe eens te zien!  
Voor een tijdje ben ik dan naar een andere kamertje verhuisd, bij Veerle (C.) en Remco, 
die beiden jammer genoeg maar even collega zijn geweest. Daarna keerde ik terug naar 
de grote AIO-kamer en zat ik uiteindelijk bij “de 5 blondjes”. Nadine en Lauran, 
Nederlandse afgevaardigden in een kamer vol Belgen, ik wens jullie heel veel succes 
met de experimenten, publicaties en voorbereidingen voor jullie promotie! Ellen, mijn 
buurmeisje, tussen al dat Limburgs en Hollands kon ik met jou nog wat Vlaams klappen. 
Ik moet je verdediging missen maar ik twijfel er niet aan dat’t een groot succes zal zijn! 
Ine, een jaartje heb ik je stagebegeleider mogen zijn. Inderdaad, mogen, want zo’n 
vlijtige en gemotiveerde student is echt een luxe! Nu je ook muizen kan injecteren staat 
er je niets meer in de weg om nog mooie dingen te verwezenlijken. Jammer genoeg 
komt uit een experiment niet altijd het gewenste resultaat, maar laat wat pech je nooit 
ontmoedigen en blijf er voor gaan! Veerle, als vervangster van Kristiaan lag de lat vanaf 
het begin al hoog maar dat is duidelijk nooit een probleem geweest voor jou, getuige 
daarvan je snelle en zeer succesvolle promotie! Uiteindelijk had je me al zo veel 
geholpen met mijn boekje en promotie-voorbereidingen dat het voor de hand lag dat ik 
je als paranymf zou vragen, en ik ben dan ook heel blij dat je dat wou doen. Het was 
trouwens pas later dat ik me realiseerde dat mijn paranymfen beiden “lever-mensen” 
zijn én op dezelfde plaats gezeten hebben… Maar naast al die praktische hulp ook heel 
erg bedankt voor de leuke babbels, ik twijfel er niet aan dat wij tweeën het best op de 
hoogte waren van alles wat zich in het lab afspeelde - 
In de andere AIO-kamer, bij de buren, zaten ook veel leuke mensen, maar het was er 
natuurlijk lang niet zo gezellig als bij ons…! Marten, mij was geleerd dat de bedoeling 
van een stage is dat je op’t einde beter op de hoogte bent van je onderwerp dan je 
begeleider.  Gelukkig is  dit  geen officiële regel  want anders had je stage niet echt lang 
geduurd!  Bovendien  ben  je  ook  nog  eens  een  geweldig  toffe  gast  om  mee  samen  te  
werken. Hou me maar op de hoogte van je resultaten daar in Amsterdam, dat worden 
toppublicaties! En aangezien we tegenwoordig op een gelijkaardig onderwerp werken 
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hoop ik je nog wel eens te zien op congressen of misschien zelfs hier in Marseille, wie 
weet… Frank (de Ajacied en Radiohead-liefhebber), Hanneke, Peggy (feestbeest in hart 
en nieren), Guus, Yeliz, (“somewhere only”) Wino, Laura (he kijk, we zijn in dezelfde 
richting vertrokken),…: allemaal bedankt voor de aangename sfeer! 
Naast Ine en Marten zijn er natuurlijk nog veel andere studenten in het lab gepasseerd, 
ik ga ze dus niet allemaal opsommen maar ik zal vooral Bram, Evi, An, Tim, Emiel, Hilde, 
Robin en Nadine niet snel vergeten. 
Ook bedankt aan al de rest van Moleculaire Genetica: Ronit (bedankt voor je geloof in 
mij), Willem (heel veel beterschap!!), Joost, Guillaume (de kwieke twintiger die zichzelf 
vermomt als oude wijze man), Robert, Nicole (we hebben er een leuk labuitje van 
gemaakt!), Will (de roodste flamingant), Vivian, Claudia, Raymond, Mo, Celine,… 
Ook bij andere groepen, binnen en buiten de universiteit van Maastricht, heb ik leuke 
en vaak ook productieve tijden beleefd. Bij Pathologie waren dat vooral Dr. Esther 
Lutgens, Dr. Erik Biessen, Dr. Mat Daemen, Linda, Dirk, Wouter, Mat, Judith, Isabelle, 
David,… Ook Richard en Rik van het CPV, Liselotte en Koen van Biofysica, Dr. Wim 
Buurman van Algemene Heelkunde en Wilfried en Joris van Immunologie zijn bij deze 
heel erg bedankt! 
Uit Leiden bedank ik Dr. Johan Kuiper, Gijs, Ilze, Silvia,… In Aachen I did some very 
interesting experiments in the lab of Prof. Dr. Christian Weber, with a lot of help from 
Alma, Oliver, Rory, Kathryn, Maik and Jolanta. I also want to thank Dr. Rudolph Rupec, 
Dr. Ulrich Kalinke and Dorothea Kreuz for the mice they gave me. 
 
A few weeks ago I started working at the Centre d’Immunologie de Marseille-Luminy in 
sunny Marseille and I want to thank Dr. Toby Lawrence for this great opportunity. Il me 
faut encore beaucoup de pratique en français mais merci à Magali, Juan, Caroline, 
Sylvie et toutes les personnes du laboratoire pour leur accueil chaleureux ! 
 
En  dan  ga  ik  wat  verder  terug  in  de  tijd  want  ik  zou  ook  nog  graag  wat  mensen  
bedanken die me tot in Maastricht gekregen hebben. En allereerst denk ik aan Hans 
Kinders, die me met zijn interessante lessen op het Heilige-Maagdcollege heeft doen 
inzien dat mijn roeping toch eigenlijk in de wetenschappen lag. Het was een leuke tijd, 
daar in het kleine gezellige klasje van de Latijn-Wetenschappen! Toen ik daarna een 
studierichting moest kiezen zocht ik iets medisch maar zonder patiënten, iets biologisch 
maar zonder plantjes, iets farmaceutisch maar zonder winkelier te worden. Zo ben ik 
terecht gekomen in de Biomedische Wetenschappen aan de VUB, waar ik veel 
fantastische mensen heb leren kennen. En dan denk ik in de eerste plaats aan Luc (we 
gingen zowaar 2 keer naar dezelfde les omdat’t gewoon té plezant was om niet te 
gaan), Isabelle (samen fietsend langs de fontuin), de bende van “de zetelkes” (Gunter, 
Tessa, Tineke, Miguel, Glucon, Dimitri, Liesbeth,…) en andere sfeermakers als Drietand 
en Abdelghani. Dankzij mijn geweldige kotgenoten heb ik me daar ook jaren thuis 
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gevoeld, merci Tom & Seffie, Iris, Nalliiieeee, Wim, Sofieke,… En ook andere studenten, 
al dan niet van de Geneeskundige Kring, hebben het leven voor mij daar zeer 
aangenaam gemaakt. Het zijn er zeer veel maar ik zou graag zeker nog Katia, Sas, 
Steven, Floris, Hans, Siddharta, Nancy, Kristof & Ann, Ivyn, Tom en de Jette Hegging 
Club willen vernoemen! 
Na drie jaar Biomedische Wetenschappen mochten we dan een stageplaats kiezen voor 
ons  laatste  jaar.  Hoewel  er  voor  het  labo  van  Prof.  Kris  Thielemans  véél  meer  
kandidaten dan beschikbare plaatsen waren heb ik het been stijf gehouden (en ben ik 
zelfs meerdere malen aan het leukaferese-toestel gaan hangen) en daar ben ik nog 
steeds blij om. Of het wederzijds is durf ik nog wel te betwijfelen, ik besefte jaren later 
pas dat ik allerminst een voorbeeld-stagair was (sorry!), maar ik heb er op korte tijd 
heel veel geleerd. Niet alleen een enorme diversiteit aan technieken (wie kan er zeggen 
dat ze tijdens hun stage leren werken hebben met virussen én bacteriën én cellijnen én 
primaire cellen én proefdieren?) maar ook bijvoorbeeld het besef dat schrijven nu 
eenmaal niet mijn sterkste kant is. Bedankt Kris voor deze kans, bedankt Lieven en 
Karine voor alle tijd die jullie in mij geïnvesteerd hebben (laat dit boekje een bewijs zijn 
dat het niet nutteloos was!), bedankt Catherine voor de wijze raad zo nu en dan, 
bedankt Carlo voor alle hulp (ook nog lang na mijn stage!) en bedankt Peggy, Elsy, 
Petra, Yasmina, Roger, Jurgen, Sonja, Tomas, Maja, Aude, Melissa,…! 
Op het einde van mijn studies Biomedische Wetenschappen heb ik lang moeten zagen 
om nog een jaartje wat vakken van de Bio-Ingenieurs te mogen volgen. Maar de 
aanhouder wint en zo kwam ik terecht in een zeer leuke groep: Lien, Frédéric, Sigrid, 
Jan, Katty, Jorn, Sophie, Tom, Ann, Pieter,… Het was elke keer weer een plezier om bij 
jullie in de les of het zelfstudiecentrum te zitten! 
Immediately thereafter I had the opportunity to start working in the group of Dr. 
Michael Kalai at the Pasteur Institute of Brussels. Miki, I really appreciate your trust in 
me! And although our (too) short collaboration didn’t result in publications, it sparked 
my passion for innate immunity. Dankzij onze samenwerking met het DMBR in Gent 
heb ik veel interessante mensen leren kennen, zoals Dr. Rudi Beyaert, Dr. Peter 
Vandenabeele, Dr. Mohamed Lamkanfi en de mensen in hun groepen.  
 
Al van mijn negende was ik elke zondagmiddag te vinden bij Chiro Ommekaar. 
Zeventien jaar lang heb ik mij met jullie geamuseerd in de Vlassenbroekse polders! 
Bedankt aan alle leiding, oud-leiding en leden voor deze fantastische tijd! 
In de weekends waarin ik Maastricht ontvluchtte en naar Dendermonde ging heb ik mij 
nooit verveeld dankzij de Ridders van de Vettige Tafel, merci mederidders Maarten, 
Timo en Roel! En ook bedankt aan het Ardennenoffensief-team (Ewoud, Timmie, 
Steven & Blonde Nele,  enniroC, Tine,  Dompie,  Benji  & Nele,  Yves & Liesbeth, Merel  & 
Collin, Lijne, …) voor de leuke tijden samen. En laat ik natuurlijk ook Kurt & Linda, Staaf 
& Marie-Antoinette, Jan, Zanne, Billy, Bram & Griet, Piet, die Mädchen,… niet vergeten! 
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En dan wordt het hoog tijd om mijn familie te bedanken. Hoewel, ik zou eerst even 
willen beginnen bij Guy en Liliane, die eigenlijk geen familie zijn maar waar ik me 
intussen al lang een kleinzoon van voel! Guy, ik voel me zeer vereerd dat je zo veel tijd 
gespendeerd hebt aan de unieke cover van dit boekje. Ik hoop dat je er even tevreden 
over bent als ik zelf. De originele tekening is intussen ingekaderd en krijgt een ereplaats 
in ons appartement in Marseille. Liliane, ik wens je al het beste met je gezondheid! 
Hopelijk gaan we jullie nog af en toe eens kunnen zien nu we zo ver wonen… 
Heel veel dank ben ik natuurlijk verschuldigd aan mijn ouders! Al van zeer jonge leeftijd 
werd leergierigheid erg gestimuleerd. Zo kon ik namen van componisten opsommen 
voor  ik  zelfs  nog maar  deftig  kon spreken,  kon ik  lezen (en zelfs  al  wat  schrijven,  ook 
dankzij meter natuurlijk) voor ik dat op school zou leren, ging ik in de bibliotheek enkel 
bij de boeken van een hogere leeftijdscategorie zoeken en was ik in een opstel zelden 
of nooit op een taalfout te betrappen. Toen ik in het zesde studiejaar de vraag kreeg 
wat ik in het secundair zou gaan studeren antwoordde ik dan ook met de vraag “Wat is 
het moeilijkste?”, en ook zes jaar later heb ik me niet neergelegd bij het studieadvies 
maar koppig hoger gemikt (bedankt dat jullie mij toen ook het vertrouwen gegeven 
hebben). Ongetwijfeld pluk ik nu nog steeds de vruchten van die onverzadigbare 
nieuwsgierigheid, en in tijden waarin alles wat al gekend is eenvoudig op te zoeken valt 
ga ik dan maar op zoek naar dingen die nog niet ontdekt zijn. Die zoektocht leidde mij 
ook  steeds  verder  weg  van  huis:  van  het  schooltje  op  ’t  Keur  naar  het  college  in  
Dendermonde, van daar naar Brussel en dan via Maastricht nu naar Marseille. Gelukkig 
(voor ons moederke) is dit nog steeds te overbruggen met de auto, al zullen jullie mij nu 
ongetwijfeld nóg minder zien. Maar ooit kom ik wel weer wat dichter wonen hoor… 
Zus,  amuseer  u  met  de  Sisters  maar  vooral  ook  met  Björn.  En  vergeet  niet  om  
regelmatig eens op bezoek te komen, kies u maar al eens een match van l’OM uit waar 
we samen naar toe kunnen! 
Ook de rest van mijn familie is heel erg bedankt voor alle hulp en interesse! Sinds een 
paar jaar hoort daar ook mijn schoonfamilie bij, ik ben blij dat ik me zo welkom mag 
voelen bij jullie! 
 
En zoals het hoort eindig ik dit dankwoord met de allerbelangrijkste persoon, diegene 
aan wie ik het allermeest gehad heb: Gudrun, mijn schatteke, ik zou gemakkelijk nog ne 
keer zo’n boekske kunnen vullen als ik zou moeten beschrijven wat gij voor mij 
betekent, maar ik weet dat ge liever niet te veel in the picture staat. Toch zou ik u 
enorm willen bedanken voor alle hulp, plezier, steun, verdraagzaamheid en vooral 
liefde die’k van u gekregen heb! We hebben op de nauwelijks 3 jaar waarin we elkaar 
kennen al  zoveel meegemaakt en nu ik je meesleur naar Frankrijk,  op avontuur in het 
onbekende, zal dat waarschijnlijk nog niet meteen veranderen… Bedankt da ge dat ziet 
zitten. En hopelijk mag ik nog voor de rest van mijn leven van u genieten! 
 
  
179 
 
 
 
 
 
 
 
Curriculum vitae 
 
 
 
 
 
 
 
  
 
Curriculum vitae Pieter Goossens 
 
180 
 
 
 
 
 
 
  
Curriculum vitae Pieter Goossens 
 
181 
Pieter Goossens was born on September 11, 1981, in Dendermonde (Belgium). In 1999 
he acquired his secondary school diploma in Latin – Sciences at the Heilige 
Maagdcollege (Dendermonde, Belgium). In September of the same year, he started to 
study Biomedical Sciences at the VUB (dutch-speaking Free University of Brussels) in 
Jette, Belgium, obtaining his Bachelor (candidate) diploma in 2001. In 2003, he got his 
Master (licentiate) degree cum laude after performing an internship of 10 months in 
the Laboratory for Molecular and Cellular Therapy at the Department of Immunology 
and  Physiology  of  the  VUB  (Jette,  Belgium).  Under  the  supervision  of  Dr.  Karine  
Breckpot, Lieven Straetman and Prof. Dr. Kris Thielemans he investigated the then 
newly-discovered protein survivin as a target in dendritic cell-based cancer immune 
therapy and as a potential tool for cell immortalization. In agreement with the 
university, this Master’s degree was further complemented with a one-year custom 
made program, combining selected courses from the curriculum of the 2nd and 3rd year 
of the Bio-Engineer studies (specialization Cell and Gene Biotechnology) of the VUB in 
Etterbeek, Belgium. These courses included Microbiology, Virology, Parasitology, 
Immunology and Molecular Biotechnology. 
In 2004, Pieter started working as a research fellow at the Laboratory of Cellular 
Microbiology of the Pasteur Institute Brussels (Belgium), under the supervision of Dr. 
Michael Kalai (Pasteur Institute Brussels) and Dr. Rudi Beyaert (Department for 
Molecular Biomedical Research, VIB Gent, Belgium). Supported by grants of Les Amis de 
l’Institut Pasteur and the Jean et Rose Hoguet Foundation, he assisted in organizing this 
newly-established lab and started investigating the interaction of the hepatitis G virus 
with the antiviral and ER stress pathways of its host cells. Less than two years later 
however, this project was discontinued prematurely due to a lack of funding. 
In 2006, Pieter joined the Macrophage Group Maastricht of Dr. Menno de Winther in 
the Molecular Genetics department of the Maastricht University and the Cardiovascular 
Research Institute Maastricht (CARIM). His research on the role of macrophages and 
their inflammatory signaling in mouse models of atherosclerosis led to the findings 
described in this thesis. These experiments were supported by a Marie Curie Research 
Training Fellowship and the Netherlands Heart Foundation. Next to his own research, 
Pieter also mentored several students during their internships in the lab. His results 
were published in high-impact journals and presented on conferences and in labs in the 
Netherlands as well as the USA, Canada, Germany, Denmark, France and Greece. 
Currently, Pieter is working in Marseille (France), in the Inflammation Biology Group of 
Dr. Toby Lawrence at the Centre d’Immunologie de Marseille-Luminy (CIML). Here, he is 
studying the phenotype of tumour-associated macrophages and the regulation of their 
inflammatory signaling pathways. 
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List of publications 
Goossens P*, Stöger JL*, De Winther MPJ (*equally contributing) 
Macrophage heterogeneity: relevance and functional implications in atherosclerosis  
Current Vascular Pharmacology 2010, Mar; 8(2): 233-48 (Review) 
 
Goossens P, Gijbels MJJ, Zernecke A, Eijgelaar W, Vergouwe MN, Van der Made I, Beckers L, 
Buurman WA, Daemen MJAP, Kalinke U, Weber C, Lutghens E, De Winther MPJ 
Myeloid type I interferon signaling promotes atherosclerosis by accelerating macrophage 
recruitment to lesions 
Cell Metabolism 2010, Aug; 12(2): 142-53 
 
Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix I, Wijnands E, Goossens P, Van 
Kruchten R, Thevissen L, Boon L, Flavell RA, Noelle RJ, Gerdes N, Biessen EA, Daemen MJAP, 
Heemskerk JWM, Weber C, Lutgens E 
Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis 
Blood 2010, Nov; 116(20): 4317-27 
  
Goossens P, Vergouwe MN, Curfs D, Van Woezik JHG, Van der Made I, Rupec RA, Hofker M, 
Gijbels MJJ, De Winther MPJ 
Myeloid Iʃɲ deficiency induces macrophage accumulation in atherosclerotic lesions 
PLoS ONE 2011, 6(7):e22327 
 
Submitted publications 
Goossens P, Van  Puijvelde  GH,  Wolfs  IMJ,  Gijbels  MJJ,  Breckpot  K,  Straetman  L,  Heirman  C,  
Donners MPC, Bot I, Thielemans K, Kuiper J, De Winther MPJ 
A lentiviral vaccination strategy targeting the tumor antigen survivin reduces murine 
atherogenesis 
 
Highlighted publications 
Bird L 
Macrophages: Interferons promote artery lesions  
(Highlighting Goossens et al., Cell Met 2010) 
Nature Reviews Immunology 2010 Sep; 10, 616-617 
 
Published abstracts 
Goossens P, Gijbels MJJ, Zernecke A, van der Made I, Beckers L, Buurman WA, Weber C, Kalinke 
U, Lutgens E, de Winther MPJ 
Type I interferons promote atherosclerosis by affecting chemotaxis and cell death 
Circulation 2008, 118: S 308 
 
Goossens P, Vergouwe MN, Curfs D, Rupec RA, Gijbels MJJ, de Winther MPJ 
Myeloid specific absence of Iʃɲ aggravates atherosclerosis without altering plaque stability 
European Journal of Immunology 2009 Sep; 39-S1 
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Fellowships & awards 
 
Poster prize - Maastricht Medical Student Research Conference  (2003, Maastricht, NL) 
Les Amis de l’Institut Pasteur Fellowship    (2004-2005, Brussels, BE) 
Jean et Rose Hoguet Foundation Fellowship   (2005-2006, Brussels, BE) 
Marie Curie Research Training Fellowship    (2006, European Commission) 
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